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SUMMARY
Injections using hypodermic needles cause pain, discomfort, localised trauma 
and apprehension. As an alternative, microneedles facilitate drug delivery without 
significantly impacting on pain receptors or blood vessels that reside within the 
dermis. In this study we aimed to investigate, for the first time, whether two 
silicon microneedle arrays (36 equally spaced 180pm or 280pm length 
microneedles) elicit pain and sensory response when applied to human 
volunteers. In addition to in-vivo clinical testing of silicon microneedles, 
alternative polymer microneedle designs were characterised and tested ex-vivo.
Prior to applying silicon microneedles clinically, ethically approved testing of 
applicator devices determined that inverted-syringe plungers caused minimum 
discomfort when applied to human volunteers. Microneedle arrays mounted onto 
inverted-syringe plungers reproducibly created microconduits through the stratum 
corneum of ex-vivo skin. Following ethical approval, 12 subjects received single­
blinded insertions of a 25G hypodermic needle and both microneedle arrays. A 
visual analogue scale (VAS), perception questionnaire and audio-recording 
collected descriptions of the pain intensity and sensory perception following each 
application. The creation and temporal retention of skin microchannels was 
assessed over 24 hours by external dye staining and measurement of 
transepidermal water loss (TEWL). Characterisation of wound healing markers, 
including keratin K16, was carried out by immunohistochemistry.
Mean VAS scores, verbal descriptions and questionnaire responses showed that 
the 180pm and 280pm silicon microneedles caused significantly less pain and 
discomfort than the hypodermic needle. Dye staining and TEWL analysis 
confirmed that microchannels were formed in the skin following microneedle 
application with repair and resealing apparent at 8-24 hours post-application. A 
spring-loaded applicator device was developed to reproducibly accelerate 
polymer microneedles into the skin along a trajectory perpendicular to the skin 
surface.
Microneedles provide a less discomforting method of skin penetration than 
hypodermic needles. Future work should optimise the design of microneedle 
devices for clinical delivery of active molecules.
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Chapter 1 
General Introduction
1
1.1 Introduction
Hypodermic needles have been used for the therapeutic delivery of 
medicaments and drugs since Francis Rynd invented the hollow needle in 1845 
(Schorr 1966). The delivery method was further developed over the 19th century 
and became commonly used in clinical practice. A child in the UK will receive at 
least 15 injections from birth to adulthood in an effort to vaccinate against 
infectious disease (NHS 2008). However, hypodermic needle use is not 
exclusive to vaccinations and their use is set to increase further with the rising 
prevalence of diabetes (Katz et al. 2009; Knip 2008; Turner et al. 2009), the 
emergence of biotechnology derived medications that are not orally active (Jin 
et al. 2008; Nandedkar 2009) and for use in the delivery of cosmetic agents, 
such as botulinum toxin type A (Botox) (Carruthers and Carruthers 2007; 
Frankel and Markarian 2007; Sepehr et al. 2010). Whilst the use of hypodermic 
needles is clearly commonplace in healthcare, their use poses a variety of 
issues such as difficult storage and disposal, possibility of cross-contamination, 
intentional or accidental reuse and patient phobia to needle injection (Hogan 
2006; Kleinknecht 1994; Nir et al. 2003; Pandit and Choudhary 2008).
The main focus of this study was to determine, in a pilot clinical study, the pain 
and sensations caused by the use of a hypodermic needle and compare those 
responses against a less invasive alternative to conventional injection 
(microneedles). The study will explore the wound healing responses to skin 
injury caused by these devices and learn more about appropriate application 
techniques for microneedles in human skin. This introductory chapter considers 
the structure of human skin, the major methods of facilitating transdermal drug
2
delivery (including the use of microneedles), the measurement of pain and 
changes to skin barrier function and processes of wound healing.
1.1.1 The anatomy of the skin
The skin is considered the largest organ of the body and forms a multifaceted 
barrier between the internal and external environments of the body. The skin 
varies in thickness, sensitivity and metabolic activity depending on its location, 
age, and exposure to its environment (Fenske and Lober 1986; Levi et al. 2009; 
Mancini 2004). Skin provides physical protection from harmful ultraviolet (UV) 
rays and regulates body temperature by altering blood flow and sweat excretion 
(Stocks et al. 2004; Tadokoro et al. 2005). There are two main areas of skin. 
The non-hairy smooth (or glabrous) skin, such as found on the soles of the feet 
and palms of the hands, is characterised by thicker epidermis and a 
dermatoglyphic configuration of troughs and ridges (El Gammal et al. 1999; 
Moore and Munger 1989). The other skin areas consist of both follicular ducts 
and sebaceous glands. The surface hairs provide insulation whilst intra- 
epidermal, intradermal and subcutaneous immunological defences react to 
pathogens (Proksch et al. 2008). In all types of skin, the presence of nerves 
enables individuals to feel sensations of touch, heat and cold, and pain. This 
enables the body to respond to the external environment through regulating the 
internal environment, for example, vasodilatation of blood vessels under skin in 
times of heat or vasoconstriction when cold, or the regulation of hair follicles 
and sweat glands (Stocks et al. 2004).
All healthy skin can be divided into two main layers, the epidermis and dermis,
each with a distinct role in the function of the skin (Goldsmith 1991; Montagna
and Parakkal 1974). The dermis is further attached to the underlying
hypodermis or panniculus adiposus, which comprises mostly of adipose tissue
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for fat storage (Figure 1.1) and is separated from the striated muscle by the 
panniculus carnosus (Goldsmith 1991; Montagna and Parakkal 1974).
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Figure 1.1. Schematic showing the various layers of the skin.
1.1.1.1 The viable epidermis
The viable epidermis is approximately 50 to 100pm thick and forms the primary 
barrier of the skin. This layer is histologically sub-divided into 5 strata (layers): 
starting from the outermost surface with the stratum corneum (SC), stratum 
lucidum (SL), stratum granulosum (SGR), stratum spinosum, and stratum 
germinativum (SG), which is separated from the dermis by a thin basement 
membrane (Ko and Marinkovich 2010; Montagna et al. 1992; Rook and Burns 
2004; Schellander and Headington 1974). The cells in the SG undergo mitotic 
division to provide cells which constantly regenerate the epidermis (Montagna 
et al. 1992; Rook and Burns 2004). Subsequently cells from the SG 
progressively mature and keratinise as they migrate through the strata (Rook 
and Burns 2004). Keratinocytes slowly migrate through the strata whilst
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undergoing histological changes. For example, in the SGR, keratinocytes 
accumulate dense basophilic keratohyalin granules which contain lipids (Gray 
and Williams 1974).
The SG also hosts the majority of melanocytes, which are the pigment- 
producing cells in the skin (Blair 1968; Sulaimon and Kitchell 2003). 
Melanocytes contain melanin pigment throughout their dendritic structure 
(Busam et al. 2001; Lin and Fisher 2007; Sulaimon and Kitchell 2003). These 
reside in the SG in an approximate ratio of 1 melanocyte to 10 keratinocytes 
(Baxter et al. 2009; Lin and Fisher 2007). Another important cell population of 
the epidermis are the Langerhans cells, which as part of the immune system, 
act as a primary defence against pathogens, regulating reactions to foreign 
substances (Elias 2005; Harding 2004; Rook and Burns 2004).
Epidermal thickness varies depending on age, the regional function, exposure 
and frictional forces on the surface (Batisse et al. 2002; Giangreco et al. 2008; 
Holbrook and Odland 1974; Montagna and Carlisle 1979). For example, the 
eyelids have the thinnest epidermis, on average about 0.05mm, whilst the 
palms of the hands and soles of the feet have the thickest on average 1.5mm 
(Dutton et al. 2007). As keratinocytes migrate towards to the SC, they are filled 
with keratin filaments aligned into disulphide cross-linked fibres (Fuchs 2007; 
Jensen and Proksch 2009; Proksch et al. 2008). These keratinocytes lose their 
nuclei and cytoplasmic organelles to form corneocytes. At the SC the 
desmosomal junctions degrade and corneocytes are bound together by 
intracellular lipids.
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The SC is an average of 10-20pm thick across the main torso and limbs of an 
adult, consisting of 10 to 20 layers of flattened, closely packed corneocytes 
(Jensen and Proksch 2009; Nouveau-Richard et al. 2004; Proksch et al. 2008; 
Welzel et al. 2004). In healthy skin, keratinocytes proliferate and migrate 
through the layers of the epidermis in homeostatic balance to the constantly 
shedding SC (Brysk and Rajaraman 1992). Corneocytes break away from the 
SC by desquamination when the intracellular lipids are degraded by mechanical 
or biochemical insult from the environment (Brysk and Rajaraman 1992; 
Madison 2003; Pierard et al. 2000). The usual life cycle of skin cells is 
approximately 28 days, thereby enabling efficient healing and repair of the skin 
(Blanpain and Fuchs 2006; Madison 2003).
1.1.1.2 The dermis
The dermis is separated from the epidermis by the continuous basement 
membrane which is usually one cell thick (Gruson and Cohen 2004; Ko and 
Marinkovich 2010; Uitto and Pulkkinen 1996). The dermis is approximately 2- 
3mm thick and maintains thermoregulation of the body and vascular supply for 
nutrient exchange to the skin tissue (Briggaman 1982; Briggaman and Wheeler 
1968). The dermis can be subdivided into two areas, the papillary dermis and 
the reticular layer. The dermis forms from mesenchymal cells that differentiate 
into vasculature and connective tissue cells (Fuchs and Horsley 2008; 
Sellheyer and Krahl 2009; Smith and Holbrook 1982), whilst, fibroblasts in the 
dermis secrete elastins and collagens to assist in providing elasticity of the skin 
(Fuchs 2007; Fuchs 2008; Rook and Burns 2004).
The dermis also contains populations of immune cells. The dermal dentritic 
cells (DDCs), act as antigen-presenting cells and represent a population of
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immunoresponsive cells that recognise and process foreign antigens (Brand et 
al. 1992; Cerio et al. 1989; Meunier et al. 1995; Zaba et al. 2007). DDCs can 
associate to T lymphocytes and migrate through the dermis to the lymph 
vessels where they are transported to the lymph nodes to generate a whole- 
body response to an antigen. Other immune cells, such as macrophages, act 
by engulfing foreign cells by phagocytosis. Therefore macrophages prevent 
foreign cells invading through the dermis (Akimoto et al. 1998; Cameron et al. 
2002; Groneberg et al. 2005; Gruschwitz et al. 1991; Gupta et al. 1989; 
McLellan et al. 1998).
The papillary dermis contains blood vessels and provides the avascular 
epidermis with nutrients, whilst also functioning as a major thermoregulatory 
system of the body (Abdel-Naser et al. 2007; Branzan et al. 2007; Braverman 
1983). The papillary dermis also contains free nerve endings and Meissner’s 
corpuscles, which are highly sensitive areas for sensory recognition (Holbrook 
et al. 1982; Holbrook and Odland 1975). The reticular layer consists of dense 
connective tissues to increase skin strength and elasticity whilst protecting the 
epithelial derived structures such as hair follicles, sweat and sebaceous glands 
(Caspers et al. 2003; Hristakieva et al. 2000; Hwang and Baik 1997; Lazarova 
et al. 2000; Lindberger et al. 1989).
1.1.2 Wound healing in the skin
The various strata of skin provide humans with a protective barrier that can
systematically respond to trauma. Generally wound healing proceeds, after
trauma or microbial insult, via imbrications of inflammation, epithelialisation,
granulation, and matrix and tissue remodelling (Epstein et al. 1999; Midwood et
al. 2004; Werner and Grose 2003). These processes are mediated on a
molecular level with interactions from interstitial and intracellular cytokines
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being released through keratinocyte damage (Barrientos et al. 2008; Li et al. 
2007). These cytokines initiate and orchestrate the inflammation and healing 
responses in the wounded skin (Gillitzer and Goebeler 2001; Hackam and Ford 
2002; Pradhan et al. 2009).
Response to cutaneous injury has been modelled in the skin of patients 
suffering from chronic disease related wounds (Usui et al. 2008) or wounds 
caused by injury (Evers et al. 2010; Merz et al. 2010; Miller and Nanchahal
2005). Such wounds tend to cause damage to multiple blood capillaries from 
which the coagulation factors and platelets are released as a rapid-fire 
response to prevent blood loss (Evers et al. 2010; Meijer-Jorna et al. 2002; 
Schiech 2002). When intradermal lesions damage blood vessels, the 
aggregation and degranulation of platelets within fibrin clots induces the 
plethora of cytokines and growth factors to be released from surrounding skin 
cells (Epstein et al. 1999; Falanga 2005; Servold 1991). It is these factors, for 
example cytokines from the transforming growth factor (TGF) and tumour 
necrosis factors (TNF) super-families, and platelet derived growth factor 
(PDGF) that initiate and influence inflammation (Schmid et al. 1993; Yonei et al.
2007). However, for minor insults to the skin, the response is expected to be 
less as fewer or no blood vessels are damaged (Diegelmann and Evans 2004; 
Li et al. 2007). Therefore, when compared to larger wounds, minor wounds 
initiate smaller quantities of cytokines to be released from damaged cells 
causing reduced inflammation, proliferation and healing (Diegelmann and 
Evans 2004; Li et al. 2007).
1.1.2.1 Inflammatory response during wound healing
Acute cutaneous injury incites a combination of different cytokine signalling
pathways which progresses skin healing causing inflammatory responses;
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therefore, several cytokine pathways have been researched to understand their 
roles in wound healing (Barrientos et al. 2008; Gillitzer and Goebeler 2001). 
Fibroblasts are pivotal in wound healing as they undergo various phenotypic 
transitions to become myofibroblastic, thus contracting skin tissue to close and 
form scars (Sorrell et al. 2007, 2008; Werner et al. 2007).
Fibroblasts express TGF-(31, which is a 112 amino acid polypeptide member of 
the TGF family of cytokines (Lawrence 1996). TGF-p1 is released by 
degranulating platelets and is activated by proteolytic and non-proteolytic 
mechanisms and influences the formation of clots, deposition of matrix and 
remodelling of the tissue (Gabrielli et al. 1993; Martinez-Ferrer et al. 2009; 
Myers et al. 2007). TGF-p1 induces the release of additional cytokines 
including tumour necrosis factor alpha (TNF-a) and interleukin 1 beta (IL-1P). 
These cytokines drive inflammation, whilst also mediating the maturation and 
activation of dendritic monocytes and macrophages (Abe et al. 2000; Amento 
and Beck 1991; Amjad et al. 2007). TG F-pi has been investigated thoroughly 
and appears to instrumental in all types of wound healing. However other 
cytokines such as TNF-a are released from multiple cellular sources (Arnett et 
al. 2001; Grimstad et al. 2011). TNF-a is a 157 amino acid length protein of 
17kDa which drives transcription of inflammatory proteins (Barrientos et al. 
2008; LaDuca and Gaspari 2001).
1.1.2.2 Secondary responses during wound healing
Monocyte populations increase as neutrophil recruitment peaks at around 24 to
48 hours post-wounding (Kim et al. 2008; Weber-Matthiesen and Sterry 1990).
Wounding causes activation of monocytes to release chemokines, which recruit
more monocytes leading to amplified release of cytokines (Barrientos et al.
2008; Gillitzer and Goebeler 2001; Werner and Grose 2003). Antigen
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stimulation drives lymphocytic recruitment and activation. In conjunction with 
neutrophil, monocytes, macrophage and lymphocytes, mast cells also 
propagate at the site of injury (Bulat et al. 2009; Groneberg et al. 2005; 
Jarvikallio et al. 2003). Macrophage assist in clearing cell debris and foreign 
agents, whilst re-epithelialisation restores functional integrity of the skin (Raja et 
al. 2007; Rodero and Khosrotehrani 2010; Spiekstra et al. 2007).
1.1.2.3 Re-epithelialisation of the skin during wound healing
Re-epithelialisation is an important stage for optimal wound healing to ensure 
wound contraction and reformation of the cutaneous barrier (Steffensen et al. 
2001). Chemokines released by keratinocytes instigate the dissociation of 
matrix metalloproteases (MMPs) from the basement membrane and the 
migration of keratinocytes across the wound bed (Strodtbeck 2001).
As keratinocytes proliferate from the basal, stratum germinativum cell layer, 
they release various growth factors including TGF-p1, EGF, IL-1 p and TNF-a  
(Barrientos et al. 2008; Choi and Fuchs 1990; Suter et al. 2009). Upregulation 
of TNF-a and IL-1 p are also mediated by macrophages in a paracrine fashion 
and influences fibroblast development (Epstein et al. 1999; Rodero and 
Khosrotehrani 2010; Strodtbeck 2001).
Re-epithelisation begins 8 to 12 hours after the injury (Li et al. 2005; Raja et al.
2007; Spiekstra et al. 2007). Keratinocytes detach from the underlying basal
lamina and progenitor cells proliferate and migrate into the clot matrix (Garlick
and Taichman 1994b; Martin and Leibovich 2005). Keratinocytes at the wound
edges react to chemical signals, such as, keratinocyte growth factor, TGF-a,
TGF-pi and EGF, which are produced by the clot, inflammatory cells, and
neighbouring keratinocytes and fibroblasts (Garlick and Taichman 1994b;
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Martin 1997; Werner and Grose 2003). As a result, keratinocytes begin to 
produce new integrin and keratin subtypes, which reorganise the actin 
cytoskeleton and produce MMPs, which dissolve the matrix to make space for 
the migrating cells (Larjava et al. 1993; Martinez-Ferrer et al. 2009). 
Subsequently, as keratinocytes cover the wound surface and stop migrating, 
the basal lamina and epidermis structures are re-established (Ahn et al. 2009; 
Bae et al. 2002; Chen et al. 1993; Martin 1997). Nedlec and Ghahary et al. 
(2000) discussed how at 3 or 4 days post-wounding, the dermal fibroblasts 
adjacent to the lesion begin to proliferate causing underlying connective tissues 
to contract, closing the wound during re-epithelisation.
1.1.3 Delivering medicaments through the skin barrier
Transcutaneous drug delivery (TDD) can be defined as the delivery of drugs 
through the skin into the systemic circulation. TDD differs from topical delivery 
as molecules permeate through the skin for systemic affect (Naik et al. 2000). 
TDD may provide several advantages over the oral delivery route for certain 
molecules in both safety and efficacy. For example TDD avoids the risk of first 
pass elimination by the liver (Chien 1984). Furthermore, TDD offers increased 
control, whereby removal of the TDD device allows rapid termination of 
treatment to prevent overdosing (Karande et al. 2005; Panchagnula et al. 2005; 
Varvel et al. 1989; Yang and Zahn 2004). Disadvantages of this approach when 
compared with intravenous administration may arise due to slower therapeutic 
effect or reduced bioavailability as the molecule has to diffuse through 
hydrophilic and lipophilic domains for systemic effect (Barry 1999; Knepp et al. 
1987). TDD patch-based methods are used for various drugs including nicotine 
for smoking cessation (McNeil et al. 2010; Schnoll et al. 2009; Shiftman et al.
2008), oestradiol for hormone replacement, testosterone for hypogonadism
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(Busse and Maibach 2011; Mazer et al. 2005; Rutledge et al. 2006) and nitrates 
for angina and ischemic chest pain (Abrams 1984; Berner and John 1994; Todd 
et al. 1990).
The rate of transcutaneous transport follows Fick’s law, such that molecules 
passively diffuse through the skin across a concentration gradient (Hadgraft 
2001b; Hadgraft and Valenta 2000; Knepp et al. 1987). Therefore, transport of 
molecules through the skin depends on drug concentrations, the thickness of 
the SC and the diffusion constants of the molecule in the skin. If the molecule is 
applied to a greater surface area of skin, the amount of molecule permeating 
the skin will increase, whilst thicker skin will reduce the permeation of the 
molecule through the skin (Ansari et al. 2006; Henning et al. 2008; Sloan et al. 
2006). Furthermore, owing to the free fatty acids composing the SC, the skin 
has a pH of 4.5-6 (Hadgraft and Valenta 2000). This weak acidic environment 
could change the degree of ionisation of a molecule, as inonised molecules do 
not permeate the SC as rapidly as nonionised molecules. In particular weak 
bases such as fentanyl which ionise more as the pH decreases (Grond et al. 
2000; Guy and Hadgraft 2003; Hadgraft and Valenta 2000)
However TDDs can employ topical preparations containing permeation
enhancers to improve systemic drug delivery through the skin (Hadgraft and
Lane 2005). For example, gels or solutions can contain alcohol, which can
increase permeation of hydrophilic molecules by reducing the hydration of the
SC (Sugibayashi et al. 1992); whilst ointments are occlusive and hydrate the
skin (Gabbanini et al. 2009; Sloan et al. 2006). Water hydrates the skin and
disrupts the lipid structure of the SC, thereby improving the solubility of
hydrophilic molecules (Alonso et al. 1996; Bjorklund et al. 2010; Michaels et al.
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1975). Once a molecule diffuses through the SC and permeates the dermis, it is 
absorbed by the capillary plexus and transferred into the system circulation, 
though some molecules may pass through the dermis into underlying 
subcutaneous tissue (Bos and Meinardi 2000; Busse and Maibach 2011; Knepp 
et al. 1987; Varvel et al. 1989).
The skin surface presents a formidable barrier consisting on average of 10-15 
layers of corneocytes (Anderson and Cassidy 1973; Holbrook and Odland 
1974). The skin is often described as a ‘brick and mortar’ structure, whereby the 
keratinocytes are connected by desmosomes and comprise the ‘bricks’ which 
are stacked in a ‘mortar’ of intercellular lipid matrix composed of free fatty acids, 
long chain ceramides and cholesterols (Guy et al. 1987; Hadgraft 2001a; Heisig 
et al. 1996). The corneocytes form polygonal flat structures from 0.2-1.5pm 
thick, 34-46pm in diameter (Anderson and Cassidy 1973; Mathur et al. 2010; 
Scheuplein 1967). The intercellular matrix is formed by lamellar content 
released from keratinocytes as they migrate from the middle to upper SG 
(Brody 1989; Elias et al. 1977). The lamellae associate into lipid bilayers, thus 
forming a lipid rich out skin surface (Madison 2003; Pierard et al. 2000; Van Hal 
et al. 1996).
Transport through skin can potentially occur via three main routes:
transappendageal, transcellular and paracellular. The percutaneous diffusion of
therapeutic moieties through the skin is considerably limited by the lipid rich SC
as well other factors, such as the release of sebum and sweat, skin pH, fluidic
pressures and the small cross-section of sweat ducts (Barbero and Frasch
2005; Degim 2006; Lademann et al. 2005; Moser et al. 2001). Early
transdermal studies investigated transport through the skin’s appendages
13
(sweat ducts and hair follicles). However, skin appendages comprise less than 
0.1% of the skin surface area, thus the transappendageal pathway has been 
determined to have minimal contribution to the steady state flux of most 
molecules (Bronaugh and Maibach 1999, 2002; Johnson et al. 1997; Schaefer 
and Lademann 2001).
Alternatively, molecules can undergo transcellular transport, whereby 
molecules enter the cytoplasm thought the cellular membrane, travel though the 
cytoplasm and cellular membrane of neighbouring cells (Barbero and Frasch
2006). Therefore, molecules would have to diffuse through lipophilic and 
hydrophilic phases as they transition the cell membrane and cytoplasm of 
keratinocytes. Furthermore, molecules would need to transfer to adjacent 
keratinocytes through intercellular spaces consisting of lipid lamellae (Bonte et 
al. 1997; Corcuff et al. 2001; Elias et al. 1977; Potts and Francoeur 1991).. 
Additionally, transcellular transport through keratinocytes in the epidermis 
requires molecules to be stable to avoid degradation by intracellular enzymes 
such as the cytochrome P-450 family and reductases, or be metabolised as 
they pass through multiple cells (Devine et al. 2009; Gibaldi et al. 2007; Khan et 
al. 1989; Vyas et al. 2006).
Paracellular transport, whereby small molecules administered topically may
passively diffuse through the tight junctions in between skin cells for systemic
effect (Hadgraft 2001b). Paracellular transport requires molecules to pass
through virtually impermeable intercellular apical tight junctions. Apical regions
contain claudins and occludins, which are proteins that associate with other
proteins in the intracellular side of the cellular membranes of neighbouring cells
(Kirschner et al. 2010; Morita and Miyachi 2003). Tight junctions contain several
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strands of associated proteins that maintain cellular polarity and prevent ion 
transport through the intracellular fluid.
Given the aforementioned challenges, it is unsurprising that only a few 
molecules can traverse the skin barrier. These molecules, such as nicotine, 
should have low molecular weight (<500Da), low melting points for better 
solubility and high lipophilicity (Bos and Meinardi 2000; Donnelly et al. 2010; 
Kligman 1984). Extending the range of candidates that can be delivered across 
the skin requires reduction of skin barrier properties to enable more efficient 
permeation or penetration (Sugino et al. 2009; Wille 2006; Xing et al. 2009). 
Reduction of the skin barrier can be physically and chemically aided by various 
techniques: skin ablation and abrasion to remove the SC (Birchall et al. 2006; 
Moser et al. 2001; Sasaki et al. 2009); biolistics using high velocity propulsion 
to penetrate skin (Lee et al. 2008b; Liu 2006; Yang et al. 2001); sonication to 
vibrate and disrupt the plasma membrane (Escobar-Chavez et al. 2009b; Lee at 
al. 2009); electrical modulation to alter the isoelectric point or charge of the skin 
(Escobar-Chavez et al. 2009a; Wong et al. 2005); and perforation to make 
artificial conduits through the skin (Badran et al. 2009; Kim and Colton 2005). 
These methods however, have yet to make significant clinical impact and 
require complex and expensive equipment making their use cumbersome and 
often impractical for clinical use (Asbill et al. 2000; Prausnitz and Langer 2008). 
Furthermore they can cause skin irritations and discomfort due to prolonged 
exposure (Brown et al. 2006; Huang et al. 2004; Karande et al. 2005).
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1.1.3.1 Drug delivery by injection
Hypodermic injections represent the standard established method for delivering 
many different types of therapeutics and vaccines. There are currently over 15 
billion injections administered globally each year, of which at least 40 million are 
curative or therapeutic injections being administered worldwide daily. Only 5% 
of injections are used for vaccinations, whilst the vast majority including opioids, 
atropine and adrenaline, are prescribed for other medical requirements. 
Injections using hypodermic needles are essential for many forms of treatment 
as they provide reliable and effective interventions (WHO 1999, 2004).
There are many incidences of injection abuse or improper use, especially in the 
developing world (Reeler 1990; WHO 2004). Patients can be misdiagnosed or 
wrongly prescribed an injected therapeutic, whilst others may have the injection 
administered by someone with poor injection technique (Flaskerud and 
Nyamathi 1996; Foege and Eddins 1973; Hutin et al. 2003; Janjua et al. 2005; 
Kermode 2004; Marilyn 2002; Meit et al. 2004; Simonsen et al. 1999). Poor 
injection practices have been a major factor in the spread of acquired immune 
deficiency syndrome (AIDS) across Africa, where over a million cases of human 
immunodeficiency virus (HIV) and viral Hepatitis B and C have been associated 
to the lack of proper sterilisation of injection equipment and the reuse of 
needles (Apetrei et al. 2006; Kane et al. 1999; Newman et al. 2004; Reid 2009; 
Ross et al. 2008; Simonsen et al. 1999; Whitworth et al. 2007). Reuse of 
needles has been shown to increase transmission of blood borne pathogens 
from patient to patient, or to health care workers (Kermode 2004; Ndinya- 
achola et al. 1986; Priddy et al. 2005). The World Health Organisation (WHO) 
bulletin (October 1999) shows there to be only 30% regulated recycling of the 
needles and syringes used throughout the world, whereby plastics and metals
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are melted down and recycled for other use. Thus, inappropriate disposal of 
injections also causes an unnecessary waste of resources and an increase in 
dangerous sharps. In addition to these administration and disposal issues, 
vaccine safety, storage, transport and handling, all form key challenges of 
immunisation programmes in developing countries.
Regulations published by the WHO and national health bodies aim to control 
the safe production, storage, administration and disposal of hypodermic 
needles and provide trained clinicians to administer injections (Dodoo et al. 
2007; Gisselquist 2009; W HO 2004). The chances of needle-stick injuries 
increases with the number of personnel handling hypodermic needles. For 
example, healthcare workers may place used needles on a surface prior to 
disposal and either forgets or a second person removes these, they may prick 
themselves if not taking suitable precaution, such as being double-gloved 
(Bolyard et al. 1998; Clever and Omenn 1988; Jagger et al. 1988). Thus 
needle-stick can be attributed to the accidental spread of diseases from patient 
to patient or clinician, particularly in developing countries, such as in African 
nations, where needle disposal is improperly managed (Delobelle et al. 2009; 
Pandit and Choudhary 2008). The Centers for Disease Control and Prevention’ 
(CDC) (USA) estimate that in the US alone during 1994 nearly one thousand 
healthcare workers contracted work-related Hepatitis B infection, and each year 
between 100-200 healthcare workers die from Hepatitis B (Bolyard et al. 1998; 
Clever and Omenn 1988; Jagger et al 1988).
There are also many psychological issues to consider with regard to injections.
Whilst the use of various needles in a variety of devices has led to a culture of
acceptability in their application, equally many patients experience needle-
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phobia or ‘belonephobia’ that can inhibit patients from seeking medical and 
dental help due to fear of pain and injury (Deacon and Abramowitz 2006; 
Fredrikson et al. 1996; Hart and Yanny 1998; Kettwich et al. 2007; Kleinknecht 
1994; Marks 1988; Milgrom et al. 1997; Nir et al. 2003; Ost 1992). In relation to 
needle-phobia, the psychological affects of needle insertion can cause 
physiological responses such as vasovagal shock or transient cardiac asystole 
(Catanzaro et al. 2006; Deacon and Abramowitz 2006; Hart and Yanny 1998; 
Sprung et al. 1998). Physiological problems with injections also exist in relation 
to the actual injury by the needle. These include local hypersensitivity with 
regular users such as insulin users or illegal substance abusers; 
lipohypertrophy in children, where fats and fibrous tissues accumulate at 
injections sites; pain and discomfort caused by the force and pressure of 
administering several millilitres of therapeutic agent or vaccine into muscle or 
veins; and bruising and bleeding after intramuscular injections (Ipp et al. 2007; 
Montgomery et al. 2005; Okawa et al. 2005; Yomtoob et al. 2009).
Injections of therapeutics and many immunisations given daily have saved 
numerous lives, however, the cost of producing, administering and disposing of 
these injections is prohibitively high in the developing world (Bridges et al. 
2000; Cutts et al. 1990; Taddio et al. 2009). Therefore, it is important to develop 
a safer, cheaper and easily administrable needle device, to potential increase 
the use of drugs and vaccines (Hutin et al. 2003).
1.1.3.2 Drug delivery using microneedles
Recently, microneedles have been explored as a simple alternative method to
deliver molecules and macromolecules into the skin epidermis* (Ding et al.
2009; Henry et al. 1998; McAllister et al. 2003). In the last 20 years silicon-
based microchip technology has rapidly developed through great advances in
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microelectromechanical systems (MEMS) and microfabrication techniques 
(McAllister et al. 2000; Park et al. 2005; Teo et al. 2005; Wang et al. 2009; 
Wilke et al. 2005a). These advances have helped progress the development of 
microfluidic and microneedle device technologies for healthcare applications. 
Microneedles are needles with a length of less than one millimetre that can 
pierce the skin in a minimally invasive manner to increase the repertoire of 
drugs deliverable transcutaneously in a less painful manner than hypodermic 
needles (Kaushik et al. 2001; Sivamani et al. 2009; So et al. 2009). Upon 
applying microneedle arrays to the skin, each microneedle on the array pierces 
the skin to create micro-conduits across the stratum corneum and into the 
epidermis. Therefore, larger arrays with more microneedles have the capacity 
to produce multiple micro-conduits to enhance skin permeation. Microneedles 
provide a direct route for transport of drugs and vaccines into the skin.
Microneedles can benefit patients and clinicians alike by providing a method of 
controlled and targeted drug delivery, causing negligible pain, no bleeding and 
potentially at reduced cost of production, storage and transport (Prausnitz et al. 
2009; Wermeling et al. 2008). Currently, a search of the U.S. National Institutes 
of Health clinical trial database highlights there are 9 microneedle-based clinical 
trials, 2 of which are completed, 2 are active, 3 are recruiting and 2 are not 
recruiting (Health 2011). These studies are varied, looking at the delivery of 
different molecules for different purposes. For example, a study in Hong Kong 
evaluated the safety of a low-dose H1N1 influenza vaccine (Trial Identifier 
NCT01049490) (ClinicalTrials.gov 2010a), whilst a Phase I study by 3M is 
aiming to investigate the tolerability of the application of microneedle structures 
(Trial Identifier NCT01257763) (ClinicalTrials.gov 2010b).
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1.1.3.2.1 Types of microneedles
Microneedles can be manufactured from silicon, glass, metal, and 
biodegradable polymers (Donnelly et al. 2010). The needles are either solid or 
hollow with bevelled or tapered tips of various sizes and shapes (Prausnitz
2004). In the case of silicon, chemical and electronic engineers use MEMS 
techniques to fabricate microneedles. Dry-etch and wet-etch microfabrication 
techniques have both been used to manufacture microneedles. Dry-etching 
refers to a process, such as deep reactive ion etching, whereby a material is 
bombarded through a masked pattern with a plasma of gas contain various ions 
of fluorocarbon, fluorine, chlorine and oxygen (Bessel et al. 2003; Cakmak 
2002; Chekurov et al. 2009; Wilkinson and Rahman 2004). Deep reactive ion 
etching has been used to create microneedles on silicon wafers (Ashraf et al. 
2010; Coulman et al. 2010; Hafeli et al. 2009; Mikolajewska et al. 2010; Yan et 
al. 2010; Yeshurun 2010). Dry-etching is limited to only certain materials and 
process scale-up is difficult due to expensive equipment costs, which require 
specialist training due to many operating parameters and slow etch rate (Madou 
2001).
Wet-etch microfabrication methods utilise the anisotropic characteristics of 
silicon in potassium hydroxide (KOH) solution (Pearton et al. 2007; Wilke et al. 
2005b). Wet-etch techniques are not as expensive as dry-etching and are 
therefore more amenable to mass production of microneedles (McAllister et al. 
2000). Wet-etching of silicon relies on aligning the crystal planes of the silicon 
structure and the lithographically patterned mask prior to exposing the silicon 
wafer to KOH solution. The design of the square mask causes the silicon at the 
edges to etch very slowly, whilst the corners are under-etched and thus form 
the octagonal shape of the microneedle. When the corners meet, the point of
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the microneedle is formed and the etching is stopped. This technique is limited 
by the planes within the silicon structure and thus alterations in geometry or 
density are significantly harder to make when compared to dry-etching 
techniques (Wilke et al. 2005a). Once the silicon wafers are etched to form 
microneedles, these are then coated by platinum to provide rigidity and though 
this is an expensive treatment (Park et al. 2005). Platinum-coated silicon 
microneedles have been shown to be of appropriate dimensions to create 
microconduits, approximately 50pm in diameter, extending through the SC and 
viable epidermis (Birchall et al. 2005).
Stainless steel microneedles are easily and cheaply manufactured using laser-
etching techniques to cut thin stainless steel sheets, after which the etched
needle is folded out of the plane of the sheet (Davis et al. 2004; Gill et al. 2008;
Kim et al. 2009b; Martanto et al. 2004; McAllister et al. 2000; Song et al. 2010).
Initially steel microneedles were used to perforate the skin to enable topically
applied solutions, for example insulin, to diffuse through the microconduits
(Martanto et al. 2004). However, increasingly the focus is on coating steel
microneedles to deliver a dosage upon application to the skin (Cormier et al.
2004; Gill and Prausnitz 2007; Prausnitz et al. 2009; Quan et al. 2009). Glass
microneedles have also been produced using conventional drawn-glass
micropipette techniques. Such microneedles may offer advantages, as these
techniques can be adapted for large-scale manufacture (Lee et al. 2003;
Martanto et al. 2006; McAllister et al. 2003; Wang et al. 2005b). However, glass
microneedles may be limited in their distribution and use due to fragility and
physical stability of the glass structure (Martanto et al. 2006). Polymers, such
as polyvinylpyrrolidone (PVP) (Sullivan et al. 2010) and sugars including
maltose and galactose (Donnelly et al. 2009; Kolli and Banga 2007) have been
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used to produce dissolving microneedles. Dissolving microneedles offer the 
advantages of reducing bio-hazardous waste as they dissolve and are 
completely absorbed into the skin (Ito et al. 2006b; Lee et al. 2011; Sullivan et 
al. 2010). However, dissolving microneedles remain unstable at changing 
temperature and humidity, thus causing global logistic and distribution related 
issues (Donnelly et al. 2009; Ito et al. 2006a; Lee et al. 2008a). Meanwhile 
other polymers, such as the photoreactive acrylate-based polymer eShell 200 
(Gittard et al. 2009) and the mucoadhesive copolymer Gantrez® AN-139 
(Donnelly et al. 2011) are commonly used in the pharmaceutical industry, and 
when combined with two-photon polymerization (2PP) microfabrication or laser 
engineering method, produce structurally stable and functional microneedles.
1.1.3.2.2 Transcutaneous drug/vaccine delivery by microneedles
Solid microneedles can be used for drug and vaccine delivery by coating the 
therapeutic onto the microneedle surface and inserting into the skin whereby 
the coated drug then dissolves upon contact with interstitial and cellular fluids 
(Cormier et al. 2004; Gill and Prausnitz 2007; Kim et al. 2009b; Pearton et al. 
2010; Shirkhanzadeh 2005; Teo et al. 2005; Widera et al. 2006a; Zhu et al. 
2009). Microneedles have been shown to be robust enough to penetrate skin 
and dramatically increase skin permeability to macromolecules and 
nanoparticles (Coulman et al. 2009; Donnelly et al. 2010; McAllister et al. 2000; 
McAllister et al. 2003). Microneedle devices have been used to successfully 
administer a variety of model compounds, including lower-weight compounds 
such as methylene blue (Li et al. 2010), cascade blue (Verbaan et al. 2007), 
calcein (Oh et al. 2008), as well as, macromolecular model compounds such as 
fluorescein isothiocyanate (FITC)-dextrans (Verbaan et al. 2007; Wonglertnirant 
et al. 2010), bovine serum albumin (BSA) (Henry et al. 1998; Park et al. 2006)
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and fluorescent polystyrene nanoparticles (Chabri et al. 2004; Coulman et al. 
2009; McAllister et al. 2003),
Low-molecular weight drugs including diclofenac (Banks et al. 2011), 
naltrexone hydrochloride (Banks et al. 2008) and methyl nicotinate (Sivamani et 
al. 2005) have been successfully administered through microneedle-punctured 
skin. Furthermore, macromolecules such as insulin (Martanto et al. 2004; 
McAllister et al. 2003) human immunoglobulin G (IgG) (Li et al. 2010) and 
desmopressin (Cormier et al. 2004). Coulman et al (2006) investigated the 
ability of microneedles to create microconduits through the stratum corneum of 
ex-vivo skin which could facilitate the delivery of charged macromolecules and 
plasmid DNA. Macromolecules such as (3-galactosidase and fluorescent 
nanoparticles were delivered to the viable epidermis. It was concluded that 
further research into applicator morphology, application technique and 
therapeutic formulation are essential to optimise delivery through 
microchannels.
Microneedles have been widely investigated as a means for facilitating
minimally invasive immunisation. Microneedle vaccines may confer stability,
storage, transport and administration advantages to improve vaccine
distribution for mass-vaccinations (Koutsonanos et al. 2009; Li et al. 2009;
Quan et al. 2009; Van Damme et al. 2009; Zhu et al. 2009). Zhu et al. (2009)
investigated the different coating capabilities of solid microneedles, showing
that up to 10pg of viral protein could be coated onto their array of 5
microneedles. Quan et al. (2009) demonstrated that microneedles can be
coated with stabilized vaccine to produce superior protective immune response
to conventional intramuscular vaccination. Van Damme et al. (2009) conducted
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a randomised trial in 180 healthy adults to evaluate the safety and 
immunogenicity of low-dose influenza vaccines delivered intradermally by 
microneedle devices. The resultant data showed that the intradermal 
microneedle vaccination caused significant local reactions, though these 
remained transient and mild in their nature, whilst the immunogenic responses 
were similar to those of a full-dose intramuscular vaccination.
As microneedle technology continues to develop, microneedles of different 
dimensions, varying array designs and material composition are being 
produced for clinical use. Therefore, the way microneedles interface with 
patients is becoming an essential consideration. It is hoped that in the future 
microneedles will be valuable alternative to current vaccine and drug delivery 
methods.
1.1.4 Pain
1.1.4.1 Defining pain
The Oxford English Dictionary (2009) defines pain to be “a strongly unpleasant 
bodily sensation such as is caused by illness or injury” and as “mental suffering 
or distress”. Pain has also been defined by the International Association for the 
Study of Pain (2009) as “An unpleasant sensory and emotional experience 
usually associated with actual or potential tissue damage, or described in terms 
of such damage”. Whilst sensation is defined in the Oxford English Dictionary 
(2009) as a “a feeling that one gets when something affects your body” or “the 
ability to feel through your sense of touch” or “a general feeling or impression 
that is difficult to explain”.
Pain can be comprised of various sensations though not all of a negative nature
(Chambers et al. 2009; Grob and Mannion 2009; Jeba et al. 2009). Pain can be
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constant, sporadic, regular or random and can be felt as either sharp or dull 
sensations (Chen et al. 2009b; Hanley et al. 2009; Leppert 2009). Pain can 
exist in several or single anatomical locations which may represent the area of 
physical injury or damage (Ivanusic et al. 2009; Kobayashi et al. 2009; Lane et 
al. 2005; Quevedo and Coghill 2009). Pain provides a vital clue to the location 
of any injury or external forces that might be acting on the body. This enables 
treatment of the primary cause of pain or at least alleviation of the pain by 
means of medical treatment. Therefore the physiological and psychological 
triggers and receptors of pain form the patients’ perception of interventions 
such as injections (Bergh et al. 2008; Cox et al. 1996; Dunwoody et al. 2008; 
Harvima et al. 1993; Jamison 1996; Uman et al. 2006; Uthaikhup et al. 2009). 
However, extensive literature searches highlights that the severity and intensity 
of the overall sensations and pain specifically felt during an injection have not 
been measured or quantified.
1.1.4.2 Measuring pain
There are many different pain intensity and pain measuring devices discussed
in the literature (Barakatt et al. 2009; Grob and Mannion 2009; Ho et al. 1996;
Holtan and Kongsgaard 2009; Katz and Melzack 1999; Snow et al. 2009). It is
important to take certain key attributes into account before choosing a
measuring instrument: The instrument must have been used in the clinical
setting previously and it must be valid and reliable in measuring that particular
type or aspect of pain for which it is intended. In this context validity is the
extent to which a measuring instrument actually measures what it is designed
to measure and reliability is the extent to which a measuring instrument remains
consistent regardless of minor changes in conditions. The instrument of pain
measurement must also be efficient and able to collect maximum information
for the type of pain it is measuring. Most pain assessment instruments can be
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combined to give maximum data, though to remain efficient it is advisable to 
use an instrument from each dimension (pain description, responses to pain 
and impact of pain) (Carnes 2006; Grotle et al. 2004; Guyatt et al. 1987; Vierck 
et al. 2008).
1.1.4.3 Reliability and validity of pain measuring instruments
A reliable device will be able to measure pain consistently without being 
effected by minor changes in environment, administration or circumstances, yet 
would register a change if the pain was to change. Guyatt et al (1987) 
discussed the importance of responsiveness to change and how a reliable pain 
measuring instrument will provide similar information in between readings 
unless the pain changes. This is known as ‘intrarater reliability’. The instrument 
will also measure very similarly, if not identically, for a given situation even if the 
administrator changes. This is known as ‘interater reliability’.
However, the data collected are often context specific, such as, specific to a 
certain pain condition, population, ethnicity or demographic, and this limits the 
instrument’s range of uses in general populations or all pain conditions. Thus it 
is important for the administrator to determine which measurement instrument 
is appropriate for the specifics of the given situation in which it will be used (Al 
Jarad et al. 1999; Bimstein et al. 2009; Blomkalns et al. 2005; Greenwald 1991; 
McCrary and Fitzgerald 2004; Melzack 2005; Vierck et al. 2008).
Certain instruments may be more reliable but time consuming to administer
thereby making them impractical in a clinical setting. Thus in many clinical
settings it is important to account for the complexity and duration of the
pain/perception-measuring instrument. A valid instrument is one that is
designed for that situation and will measure that type of pain and not another.
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However, deciding which pain measurement instrument is valid for a given 
situation is a contentious issue (Caraceni et al. 2009; Carnes 2006; Clark et al. 
2003; Margolis et al. 1986; Voorhies et al. 2007).
1.1.4.4 Different types of pain measuring instruments
There are three main types of pain measurements: self-reporting, physiological 
and observational. Self-reporting requires the individual pain sufferer to 
complete various key items of information and/or maintain a diary to monitor the 
pain experienced. Such instruments often consist of a variety of rating scales to 
rate, for example, from ‘the least pain felt’ to ‘worst pain imaginable’ (Alves et 
al. 2009; Balbierz et al. 2006; Bartell et al. 2008; Choiniere and Amsel 1996). 
Dairies and long term self-report forms can assist in classifying the pain as 
sporadic or persistent, and acute or chronic. Dairies also provide insight into 
how the sufferer copes with the pain and its impact on the sufferer’s life 
(Jamison et al. 2009; Lewandowski et al. 2009).
Physiological measures are often used to assess the biological responses in 
relation to pain. Pain can cause muscular tension, increased blood pressure, 
and alterations in heart rate, sweating, breathing and other stress responses. 
Such changes in physiology can be used to indirectly measure acute pain, but 
are prone to stabilising as the body becomes accustomed to the pain stimuli. 
Therefore, even if the pain remains, the biological characteristics may have 
returned to normal (Jamison 1996; Jensen et al. 1989; Sim and Waterfield 
1997; Tunks et al. 2008).
Observational measurements usually rely on a person close to the sufferer
completing a measurement, for example their perception of the sufferer’s mood,
expression, physical mobility or activity (Apolone et al. 2009; Nijrolder et al.
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2009; Veresciagina et al. 2009). These can often be used with the self-reporting 
and physiological measures to determine any missing features of the pain or its 
cause.
It is clear that no single method or measuring instrument is totally accurate or 
encompassing. Each provides perception and description that can be used in 
varying degrees to determine the cause, site and impact of pain on the 
sufferer’s life.
1.1.4.5 Different techniques for measuring pain in a clinical setting
Most measuring instruments rely on self-reporting as that is regarded as the 
best standard for understanding and assessing pain. This requires the sufferer 
to describe their pain through a variety of measurement instruments, which can 
either be questionnaires, rating scales, visual analogue scale (VAS), drawings 
or a combination of some or all. Pain can be described by its intensity, 
descriptive words and location on the body (Dias et al. 2008; Huskisson et al. 
1976; Ipp et al. 2009; Katz and Melzack 1999; Melzack R 1994; Okawa et al. 
2005; Rokyta et al. 2009). Self-reporting is a very commonly used instrument as 
it provides subjective descriptions consistent with the objective nature of pain 
and measures the sufferer’s personal perception to pain. However, due to the 
variations in individual perception, self-reported inter-individual data cannot be 
easily compared, but can provide details for intra-individual comparisons 
(Bringuier et al. 2009; Cohen et al. 2009b; Jensen et al. 1989; Serpell 2002; 
Spielberg et al. 2003). Research by Jamison (1996) shows that self-reporting of 
pain intensity is a very valid and reliable method.
The VAS is a simple quantifying tool consisting of a 10cm line marked at one
end with “no pain” and the other with “worst pain imaginable”. The sufferer is
28
asked to mark the intensity of pain felt on the 10cm scale. The VAS has been 
shown to be reproducible, sensitive and universally simple to understand and 
administer (de Boer et al. 2004; Harding et al. 2009; Vieira et al. 2005). 
Numeric rating scales are commonly used alongside a VAS (Choiniere and 
Amsel 1996; Fauconnier et al. 2009; Hirsh et al. 2009; Jennings et al. 2009; 
Katz and Melzack 1999). Jensen et al (1989) suggests that acute pain is best 
measured by the 11-point box, whilst linear numerical rating is better for chronic 
pain.
Pain drawings are a useful method of gauging pain and sensation by marking 
on a picture of the anatomy (Parker et al. 1995). Sometimes these can be 
scored or used to indicate the type of pain felt in different regions of the body. 
The scoring and marking of these pictures can differ considerably depending on 
use, though they essentially consist of outlines drawings of the human body, 
front and back, onto which the patient either marks using defined symbols or 
shading, the type or location of pains (Margolis et al. 1986). Attempts to rate 
such drawings as physical manifestations of psychological distress have been 
unreliable, though pain drawings are still a clinically useful method of 
understanding the location and distribution of pain (Carnes 2006; Giske et al. 
2009; Parker et al. 1995; Voorhies et al. 2007; Wenngren and Stalnacke 2009).
The McGill pain questionnaire (MPQ), developed by Melzack et al. (1975),
measures dimensions of pain quality by including a VAS, a set of descriptor
adjectives, an intensity scale and pain drawing. Patients are asked to rate 20
adjectives that describe various pain sensations. These descriptors are divided
into 4 categories: sensory (categories 1-10), affective (categories 11-15) and
evaluative (category 16) and miscellaneous (categories 17- 20). Thus the MPQ
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provides multidimensional evaluation of pain (Melzack 2001). It can be 
quantitatively evaluated using the pain intensity (VAS), individual rating indexes 
for each descriptor category and an evaluative overall pain index (EOPI). This 
makes it one of the most widely used of all pain measurement tools. In 1987, 
Melzack developed the short-form version of the MPQ (MPQ-SF), which uses 
key adjectives from the longer MPQ (Melzack 1987). As shown by Melzack 
(1994), the MPQ and MPQ-SF provide a reliable and valid method of assessing 
the qualitative nature of an individual’s pain experience, thereby differentiating 
between subtle and dramatic clinical changes, as well as recording any 
unexpected features.
Audio recordings are used in the social sciences to collect data from focus 
groups and interviews. Everything said by the participants is potentially 
important to improve understanding and further develop the topic being 
discussed (Arber 2007; de Salis et al. 2008; Maikler 1991). In the case of a 
clinical study, literature searches provide no evidence of audio-recordings being 
used as a data source in the clinical assessment of drugs or medical 
technologies, though Van Tilburg et al. (2009) used audio and video recording 
to assess a home-based, guided imagery treatment protocol. However, when 
assessing pain, especially transient pain, audio recording may add another 
dimension to the details of the pain and sensation felt.
1.1.4.6 Measuring pain caused by microneedle applications
To better understand the complex nature of pain and sensation during needle-
based injections it is important to appreciate the various layers of skin through
which a needle may penetrate. For example, the epidermal layer of the skin
contains multitudes of nerves that enable us to feel sensations of touch, heat
and cold and regulate pain sensing. These physiological details are covered in
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Section 1.1.1 but their implications will always present as intra-and inter­
individual differences in the intensity of each sensation felt.
Microneedles have been tested to determine their potential benefits in the 
delivery of vaccines and other medicaments. Whilst it has been purported that 
microneedles can facilitate delivery of insulin, nicotine and therapeutic 
antibodies into humans without stimulating underlying pain receptors or blood 
vessels, only a few studies have measured qualitatively or quantitatively the 
pain related to microneedle insertion into human volunteers (Gupta et al. 2009; 
Kaushik et al. 2001; Li et al. 2009; Prausnitz et al. 2009; Sivamani et al. 2009). 
Bal et al. (2008) investigated the penetration and pain of solid microneedle 
arrays of 400pm and 200pm lengths on human volunteers. Microneedle 
penetration of skin was confirmed by significant increase in transepidermal 
water loss (TEWL) upon application. The microneedle devices caused minimal 
pain when measured on a 10-point measuring index, though little information is 
provided on how pain was measured.
Other assessments of pain caused by microneedle insertion use the VAS,
which is an efficient, reliable and validated measure of ‘pain intensity’, but
provides limited information on sensation or an overall assessment of the
human perception of microneedle application. Gill et al. (2008) tested single
microneedles 480pm to 1450pm length with varying base widths, as well as,
microneedle arrays containing 5 to 50 microneedles. The microneedles were
inserted into the volar forearms. Gill et al. (2008) demonstrated that
microneedle length had the greatest effect on pain, whilst the number of
microneedles applied on an array had less influence on pain. Microneedle
morphology, for example the thickness, base width and tip angle, did not
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significantly influence pain. However, all microneedles tested caused 
significantly less pain than 26-gauge hypodermic needles.
Kaushik et al (2001) measured pain response using VAS to the application of 
an array of 400 microneedles, each approximately 150pm in length. The pain 
responses were statistically insignificant when compared to the application of a 
smooth surface, and statistically insignificant to the pain responses following 
the insertion of a 26G hypodermic needle. However, Kaushik et al. (2001) did 
not attempt to simultaneously demonstrate both microneedle functionality and 
pain response, as there was no in-vivo assessment during the study to verify 
skin puncture due to microneedles in relation to level of sensations.
Sivamani et al. (2005) compared in-vivo human injections of 1pl methyl 
nicotinate, using 200pm length hollow needle arrays, to topical application. The 
data revealed increased blood flux post-application of microneedles whilst 
comments from the volunteers describe the application of microneedles as a 
feeling of “pressure but no pain”. Miyano et al. (2005) described that 500pm 
length detachable and biodegradable microneedles manufactured from maltose 
do not cause any pain on skin insertion. Shirkhanzadeh (2005) reported that 
volunteers tolerated microneedles coated with porous calcium phosphate, 
although pain scoring was not performed. Further reports suggest that 
microneedles do not cause any significant pain when used for extraction of 
interstitial fluid or blood for glucose monitoring (Smart and Subramanian 2000; 
Wang et al. 2005).
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These aforementioned studies did not use instruments such as the MPQ or 
either real-time or reflective audio commentary of the participants to clearly 
define the extent and type of pain felt during microneedle insertion.
1.1.5 Transepidermal Water Loss (TEWL) as a measure of skin 
penetration
The non-aqueous SC restricts water loss from the deep, water-rich layers of the 
skin. This creates a water gradient that increases gradually from the dermis to 
higher strata of the epidermis. Water vapour diffuses continuously through the 
skin through pores and hair follicles because vapour pressure is higher in the 
dermis than in the external environment (Morgan et al. 2003; Richards et al. 
2003; Rodrigues et al. 2004; Schwindt et al. 1998; Singh et al. 2001). The 
amount of water diffusion through skin is not only regulated by environmental 
humidity but also by regulatory responses from the skin.
TEWL measurement is a standardised method of determining water loss in the 
skin and is frequently used in the cosmetics and dermatology industry to test 
safety and irritancy of topical creams (Berardesca and Distante 1994; Loden 
2003; Robinson and Perkins 2002). As TEWL is a process of passive diffusion, 
the rate of water vapour diffusion across the SC depends not only on the 
ambient relative humidity and temperature but also on the thickness and 
integrity of the SC (Pinnagoda et al. 1990; Roskos and Guy 1989; Shah et al.
2005). Therefore, the measurement of TEWL provides an assessment of skin 
barrier function. The skin surface is surrounded by a microenvironment formed 
by a vapour boundary. This forms a physical barrier against the environment 
and enables transition of moisture and heat from the body to the ambient 
surrounding. This transition can be expressed in terms of the vapour pressure 
gradient (Grove et al. 1999; Pinnagoda et al. 1990). High TEWL values
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correspond to dry or damaged skin whilst low TEWL correlate to healthy 
undamaged skin (Bashir et al. 2001; Bornkessel et al. 2005). The measurement 
of TEWL in this study will provide information concerning the compromised 
integrity of the epidermis following application of microneedles.
There are, however, limitations with TEWL measurement. TEWL apparatus are 
very sensitive and subject to disturbances by ambient airflow due to physical 
moment, windows, breathing or opening doors near the probe whilst taking 
measurements (De Paepe et al. 2005; Miteva et al. 2006; Pinnagoda et al. 
1990; Rosado et al. 2005a). It is also acknowledged that TEWL varies 
considerably with anatomical locations and differences in skin physiology 
(Aramaki et al. 2002; Atrux-Tallau et al. 2009; Fluhr et al. 2006; Garcia Bartels 
et al. 2009; Rosado et al. 2005b; Schwindt et al. 1998; Singh et al. 2001).
1.1.6 Aims and objectives
This thesis aims to determine pain response, sensory perception and skin 
barrier damage, following hypodermic and microneedle applications in human 
volunteers and inform the development of a reliable application method for 
microneedle administration.
Objectives:
•  To assess the ability of microneedles to puncture ex-vivo and in-vivo 
human skin.
• To use appropriate pain measurement instruments to characterise pain 
post-application of microneedle devices and hypodermic needles in 
human volunteers.
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• To determine the degree and breadth of sensations felt during 
microneedle and hypodermic needle applications.
•  To investigate the wound healing responses within the first 24 hours 
following clinical applications of hypodermic and microneedle devices.
• To develop a suitable application method that allows for efficient and 
reproducible application of polycarbonate microneedles to human skin.
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Chapter 2
Pre-clinical testing of potential microneedle 
applicators and characterisation of silicon
microneedles
2.1 Introduction
This chapter will aim to characterise the microfabricated silicon microneedle 
arrays, as well as test simple applicators for administering the microneedles to 
human skin ex-vivo and in-vivo. The results of this chapter will thereafter assist 
in defining the appropriate methods for applying microneedles, and assessing 
microneedle penetration, in Chapter 3.
2.1.1 Defining Pain
Pain has been defined in Section 1.1.4. as “a strongly unpleasant bodily 
sensation such as is caused by illness or injury” and as “mental suffering or 
distress” (Waters and Bull 2006). It has been reported that physiological and 
psychological aspects of pain are apparent in patients when they are subjected 
to injections (Arendt-Nielsen et al. 2006; Chambers et al. 2009; Ipp et al. 2009; 
Lane et al. 2005; Lawes et al. 2008; Price et al. 2009; Shah et al. 2009; Taddio 
et al. 2009; Uman et al. 2006). However, as outlined in Section 1.1.4, few 
research groups have conducted detailed studies into the intensity and nature 
of pain and other sensations, specifically experienced during microneedle 
injections (Gill et al. 2008; Kaushik et al. 2001; Sivamani et al. 2005).
2.1.2 Measuring Pain
The various techniques of assessing and quantifying pain and sensory 
perception are described in Section 1.1.4. Each technique aims to collect 
multidimensional data on the perception of pain. Thus the measurement and 
manifestations of pain and associated perceptions, and the complexities in 
describing pain (Benoliel et al. 2009; Fabbri et al. 2009; Lundqvist et al. 2009; 
Melzack 1987; Snow et al. 2009; Strand et al. 2008; van Tilburg et al. 2009)
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were carefully considered when developing the instruments for data collection 
during the clinical study.
2.1.3 Imaging to characterise microneedles to be used in the clinical 
study
As discussed in Chapter 1, microneedles come in many different shapes and 
sizes as a result of different material composition and manufacturing process 
(Ayittey et al. 2009; Badran et al. 2009; Coulman et al. 2009; Kolli and Banga 
2008; Ramasubramanian et al. 2008; Wang et al. 2009). To assess 
microneedle morphology, magnified imaging techniques such as scanning 
electron microscopy (SEM) are used. SEM provides greater surface detail than 
simple light stereomicroscopy by using electrons instead of light to form an 
image (Moore 2009; Xiong et al. 2009). The advantage of SEM compared with 
light microscopy is that the former has a larger depth of field which improves 
focus over a greater surface, also the ability to use higher resolutions allows for 
greater magnification. Using the magnetic field to control electrons, the user is 
able to minutely alter magnification and resolution. SEM requires vacuum 
conditions, thus sample preparation is important. For example, all samples 
must be dehydrated and as the electron beams will only give a clear image off 
an electron dense surface, non-metal surfaces usually have to be sputter- 
coated with gold (Goodhew et al. 1997; Lopes et al. 2009; Risnes 2003; Xiong 
et al. 2009).
2.1.4 Measuring transepidermal water loss (TEWL) to establish skin 
penetration
The measurement of TEWL provides an assessment of the integrity of the 
epidermis under normal and various disease situations, for example dermatitis 
and eczema (Shimada et al. 2009; Wynne et al. 2002). TEWL is a measure of 
the degree of evaporation of water immediately above the stratum corneum
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(Faurschou et al. 2007; Rosado et al. 2005b; Schmid et al. 2005). Evaporation 
from the skin surface is measured using a TEWL probe and meter, which relies 
on two hygrosensors and thermistors placed in a chamber (De Paepe et al. 
2005; Miteva et al. 2006; Rosado et al. 2005a). When placed on the skin the 
open chamber forms a seal on one end to the skin whilst remaining open at the 
other end. The resulting vapour flow from the skin surface to the ambient air is 
measured by specific electro-sensors in the chamber. The degree of 
evaporation is determined by measuring the vapour pressure at one point of the 
chamber. Another sensor measures the humidity levels in the chamber close to 
the skin surface. As water vapour builds in proximity to the skin surface, the 
humidity in the chamber increases in comparison to the humidity in the ambient 
air. This creates a humidity gradient in the chamber that is measured by the two 
measuring sensors inside the open chamber. The vapour flow evaporating from 
the surface of the skin can be calculated by diffusion equations from the 
measured humidity gradient (Cohen et al. 2009a; Miteva et al. 2006). The 
humidity and vapour pressure gradient is approximately constant in the 
absence of external airflow. Thus under steady-state condition it is proportional 
to the amount of water vapour passing through the transition layer per unit of 
time multiplied by the area over which evaporation from the skin surface occurs. 
The proportionality constant is a measure of the permeability of the skin to 
water. TEWL meters measure at two different fixed heights perpendicularly 
above the skin surface and within the transition zone and calculate TEWL on 
the basis that the difference between the vapour pressures at the two points is 
approximately proportional to the vapour pressure immediately above the skin 
(Cohen et al. 2009a; Fluhr et al. 2006; Miteva et al. 2006; Nuutinen et al. 2003; 
Shah et al. 2005; Tagami et al. 2002).
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2.1.5 Aims and objectives
The method of application of microneedles is important to achieve successful 
penetration through the skin. The use of an applicator will help to ensure that 
the microneedles will penetrate efficiently. Thus, prior to the clinical study 
detailed in Chapter 3, it was necessary to perform a preliminary study to assess 
the puncturing efficacy of microneedles when mounted onto different applicator 
designs and ensure that the applicator itself did not cause pain upon 
application.
Objectives:
•  To characterise the morphology of silicon microneedle arrays.
•  To determine whether silicon microneedles penetrate ex-vivo 
human skin and create microconduits.
•  To design and test a simple, clinically acceptable, method of 
applying the microneedles to human volunteers.
•  To assess pain and sensation induced by different applicator 
devices when applied to human volunteers.
2.2 Materials and Methods
2.2.1 Materials
Araldite epoxy resin (Huntsman International LLC, Basel, Switzerland); TEWL 
probe and DERMALAB data unit (Cortex Technology, Handsund, Denmark); 
Sanyo TRC-525M dictaphone (Sanyo, Japan); methylene blue dye powder 
(Sigma-Aldrich Ltd, Dorset, UK); Olympus DP-10 Camera (Olympus Optical, 
London, UK); Olympus TH3 Power unit (Olympus Optical, London, UK); Philips 
XL-20 Scanning Electron Microscope (Philips, Eindhoven, Netherlands); Schott 
KL1500 fibre optic light source (Schott UK Ltd, Stafford, UK)
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The 180pm and 280pm wet-etched silicon microneedle arrays used in this 
study were provided by Anthony Morrissey at The Tyndall National Institute, 
Cork, Ireland. These microneedles were manufactured from silicon wafers that 
were coated with silicon nitride on a silicon oxide layer and wet-etched using 
potassium hydroxide (KOH). Square shape patterns were transferred into the 
masking double layer by standard photolithography, after which, the patterned 
silicon wafer was etched using a 29% KOH solution at a temperature of 79°C. 
The needle formation was based on convex-corner under cut. Each 
microneedle array was comprised of 36 equally spaced pyramidal shaped 
microneedles of either 280pm or 180pm length with a base diameter of 
approximately 180pm and microneedle tip of 1pm wide. The silicon arrays were 
then coated in 0.3pm platinum. These microneedle arrays have been used ex- 
vivo in a number of previous studies (Birchall et al. 2005; Coulman et al. 2006; 
Pearton et al. 2008; Wilke et al. 2005a).
Outline designs for the aluminium applicator rods, onto which the microneedle 
arrays were mounted, were provided to Professor David Barrow at the Cardiff 
School of Engineering who kindly agreed to machine the applicator rods. The 
addition of foam and rubber was undertaken in the laboratory.
2.2.2 Selecting a suitable applicator and application method for the 
clinical study
Before applying microneedles to humans, it was important to establish a 
suitable method of application to the skin. Initially 9 potential applicator devices 
were designed and tested.
41
2.2.2.1 Designing various applicator rods for the application of 
microneedle arrays
Applicators for the clinical application of silicon microneedles were designed
with the aim of increasing skin penetration of microneedles whilst reducing
applicator induced pain and sensation. Square-end (6mm2) [Y] and cylindrical
[Z] aluminium rods where engineered so that the microneedle array (6mm2)
was not overhanging the end of the rods when mounted (Figure 2.1).
Figure 2.1. Square-end applicator [Y] and cylindrical applicator [Z].
In addition, 7 potential new applicators were designed using plastic syringes or 
cylindrical applicator rods as their base structure (Figure 2.2). They were as 
follows:
[A] An inverted 2ml plastic syringe with the plunger surface heated and 
smoothed to remove any protrusions.
[B] Cylindrical aluminium rod applicator with rubber (3mm x 2mm) wrapped 
around at the application end.
[C] Cylindrical aluminium rod applicator with elastic (4mm x 1mm) wrapped 
around at the application end.
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[D] Cylindrical aluminium rod applicator with rubber removed from a syringe 
bung (2mm x 1mm) wrapped around the application end.
[E] Cylindrical aluminium rod applicator with foam measuring (5mm x 4mm) 
wrapped around the application end.
[F] Cylindrical aluminium rod applicator with rubber (6mm x 2mm) wrapped 
around the application end with 6mm by 9mm diameter foam on the 
application face.
[G] Cylindrical aluminium rod applicator with 6mm diameter foam attached on 
the application face.
Figure 2.2. Photographs of the microneedle applicator designs.
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2.2.2.2 Ethical approval and participant consent approval
Prior to beginning testing of the applicators, ethical approval was obtained from 
the Welsh School of Pharmacy (WSP) Research Ethics Committee for the 
administration of applicators to volunteers and for recording their oral 
commentary. Informed consent (Appendix I) was obtained from each participant 
in adherence with the Declaration of Helsinki and a written explanation of the 
study provided at least one week before their first visit. At the first visit each 
participant read and signed consent forms after the nature of the study had 
been explained. Each participant was informed that they could withdraw from 
the study at any stage without any explanation from them. Subjects were also 
given the opportunity to ask questions before deciding to participate.
2.2.2.3 Audio recording of participants
Throughout each session with each participant, two dictaphones were placed in 
close proximity to the participant to record the entire dialogue between 
participant and coordinator. At the start of each session, the participant was 
asked to “describe clearly what they feel as each applicator is applied”.
2.2.2.4 Design of the McGill pain questionnaire short-form (MPQ-SF) 
for measuring pain and sensory perception
The pain and sensation questionnaire used was the standard McGill pain
questionnaire short-form (MPQ-SF) as described in Chapter 1, that is, visual
analogue scale (VAS) to measure pain, 15 key descriptive words to measure
sensation (representing sensory and affective words) and a present pain index
or evaluative overall pain index (EOPI) (see Appendix II) (Melzack 1987).
Immediately post-application of each applicator, the VAS was registered first by
participants marking on a 10cm horizontal line marked at opposing ends with
‘No pain’ and ‘Worst pain imaginable’. Subsequently the participant was asked
to rate each descriptive word of the MPQ-SF: “As each word is read out to you
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please state if it describes a sensation you felt during or after the application. 
Rate it as either none, mild, moderate and severe. ”
2.2.2.5 Scoring the MPQ-SF
As the MPQ-SF used was a reliable and validated questionnaire, it was scored 
using the criteria as laid out by Melzack (1987) (Wright et al. 2001). Each VAS 
was measured in millimetres starting at the ‘No pain’ end along the length of the 
100mm to where the participant had marked the horizontal line. Each 
descriptive word was scored by giving a score of 0 for words the participants 
had responded to as ‘none’; 1 for the words marked as ‘mild’; 2 for those 
marked as ‘moderate’; and 3 for those marked as ‘severe’. All the scores were 
totalled for the sensory descriptive words, affective words and subsequently 
combined for an overall total score for all 15 descriptor words. The EOPI was 
scored from 1 to 5 corresponding to the numerical rank of the terms ‘No pain = 
0’ ‘Mild = 1’, ‘Discomforting = 2’, ‘Distressing = 3’, ‘Horrible = 4 ’ and 
‘Excruciating = 5 ’. Thereafter the VAS, scores from key descriptive words, and 
EOPI scores were totalled to enable comparison of each of the 4 applicators. 
Thus the applicators could be ranked in order of lowest to highest score as a 
measure of least painful and sensation inducing, to highest pain and sensation 
inducing.
2.2.2.6 Assessment of pain and sensation caused by different 
applicator designs
To test the applicator designs for the pain and sensations perceived by human
volunteers, the volar forearm was deemed a suitable anatomical region as it
was easily accessible on participants and represented an area where
microneedle devices may, in future, be clinically administered. However, during
the clinical study (Chapter 3), ethics approved the buttock as the most suitable
region for needle administration, due to the subsequent biopsies of the
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administration sites (Chapter 4). Initially all seven, [A] to [G] applicator devices 
were applied to one volunteer (V1). V1’s oral comments were audio-recorded 
and the two least discomforting of the seven applicators were chosen for 
comparison with the square-ended [Y] and cylindrical [Z] aluminium rods 
(Figure 2.1). Subsequently 12 additional participants were recruited making the 
total 13 participants (6 male and 7 female, though recruitment was not gender 
specific).
Testing the applicators on the 13 volunteers took place over two sessions: the 
first session informed and consented the participants before both square-ended 
[Y] and cylindrical [Z] applicators (Figure 2.1) were applied in a rolling fashion 
(as explained in Section 2.2.3) to either their left or right volar forearm in a 
single blind and randomised manner. The participants were asked to look away 
during each application to ensure single-blind application. After one application, 
the MPQ-SF in its standard form was administered (Appendix II). Subsequently 
the remaining two applicators were applied to the other forearm and the MPQ- 
SF repeated.
The second session was conducted at least 1 hour after the first to allow the 
participants to have time between applications so that their perceptions 
between applications were not overlapping. Only the 2 specific applicators, [A] 
and [E], from the 7 applicator designs [A] to [G] in Figure 2.2 were assessed. 
Each applicator was applied to either the right or left forearm and the MPQ-SF  
repeated. Recovery time of at least 1 hour between applications to the same 
forearm ensured previous applications had not increased the sensitivity of the 
forearm. This whole process of application and recovery was repeated for each
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application. Each session was audio-recorded and participants were advised to 
vocalise their comments throughout the applications.
2.2.3 Mounting microneedle arrays to applicators in preparation for 
application to skin
A thin coat of Araldite epoxy was applied to the top of the applicators and, using 
tweezers, a single array of microneedles was carefully placed in the centre of 
the top of each applicator. Subsequently the applicators were left standing 
upright for 18 hours with the array facing upwards. Light microscopy inspection 
of the array surface was used to determine whether the epoxy had bonded the 
base of the array to the applicator and confirm that the microneedles had not 
been adversely affected.
2.2.4 Ex-vivo testing of microneedle arrays mounted to the two least 
painful applicators
Full-thickness human breast skin was obtained from mastectomy or breast 
reduction with Gwent Healthcare NHS Trust ethical committee approval and 
informed patient consent. Skin was excised from a variety of donors ranging 
from 45 to 65 years of age at the Royal Gwent Hospital, Newport. Excised skin 
was transported from the operating suite direct to WSP in Dulbecco's Modified 
Eagle Medium (DMEM) culture media (44.5ml DMEM, 5ml 10% foetal bovine 
serum and 0.5ml 1% penicillin and streptomycin) (Coulman et al. 2006; Pearton 
et al. 2008). Skin was stored at -20°C for a maximum of 6 months, before being 
left to thaw to room temperature for 1 hour prior to use. All experiments using 
ex-vivo skin samples were performed in a Containment Two designated 
laboratory. In all cases, the skin was pinned down to a corkboard support 
before the application of microneedles mounted to inverted-syringe plunger and 
the foam-tipped applicator.
47
The 2 least painful applications, that is the 2 with the lowest MPQ-SF scores 
were the foam-tipped and inverted-syringe (Figure 2.3). Therefore these were 
then tested to determine if they could effectively apply a microneedle array to 
facilitate effective skin puncture in human skin samples ex-vivo.
Figure 2.3. Foam-tipped applicator [E] and inverted-syringe applicator [A],
Three different application techniques were selected and tested to determine 
which was the most effective method:
1] Rolling the array firmly onto the skin from a 45° angle to the skin surface, 
massaging the applicator for 10 seconds whilst in the vertical position and then 
rolling the array off the skin 45° from the skin (Figure 2.4)
2] Pushing the applicator straight down perpendicular onto the skin, massaging 
the applicator for 10 seconds then lifting it off the skin.
3] Stabbing the applicator down perpendicular on to the skin with force, holding 
down for 10 seconds and then lifting off the skin.
48
Held and 
shaken for 
10 seconds
Corkboard
Applicator
Microneedle array
Figure 2.4. Method of applying the microneedle arrays to the skin by mounting on an 
applicator rod and rolling onto the skin. Applicator rolled onto skin at a 45° angle 
through to the upright position whereby the microneedles penetrate the skin and 
massaged for 10 seconds, before being rolled off at a 45° angle.
2.2.4.1 Pre-clinical assessment of microneedle puncture efficiency 
using TEWL
Transepidermal water loss (TEWL) is used clinically as a measure of skin 
permeation. Thus TEWL was used to assess skin permeation post-application 
of 280pm microneedles to ex-vivo skin samples. Immediately after each 
application, testing the techniques in Section 2.2.3, TEWL measurements were 
taken using a DERMALAB TEWL probe and unit from Cortex Technology 
(Cohen et al. 2009a). The TEWL probe was rested firmly on the skin surface 
and held perpendicular to the skin with care taken not to blow or disrupt the 
airflow over the probe. Humidity and temperature readings were taken at 
regular intervals to ensure the temperature or humidity in the containment room 
did not increase significantly. If the temperature altered from a range of 18-20°C 
the reading was discarded and repeated once the temperature returned within 
range.
49
2.2.4.2 Topical assessment of microneedle punctures post­
application to skin
Immediately after the microneedle-mounted applicator device had been applied, 
the skin was topically treated with 10% methylene blue dye solution for a 
minimum of 5 minutes before the excess dye was wiped from the skin surface 
using 70% ethanol wipes. The samples were then observed en-face under light 
microscopy. The puncture made by each microneedle array for each application 
was visualised by the blue staining, counted and recorded.
2.2.5 Microscopic characterisation of the microneedle arrays to be 
used for clinical trial
Each microneedle array can vary in morphology whilst some may be damaged 
during production, thus prior to use each microneedle on every array was 
thoroughly inspected by SEM and light microscopy and each array catalogued 
into a database.
2.2.5.1 Characterisation by light microscopy
Due to the cost of SEM, each array was initially assessed under light
microscopy to examine for any larger defects to the surface or morphology of
the microneedle arrays. The mounted microneedle array was carefully 
positioned on the stage of the Olympus BX-50 microscope, illuminated with a 
fibre optic light source and photographed. The angle and orientation of the each 
array was altered systematically to visualise every side of each microneedle on 
each row.
2.2.5.2 Characterisation by scanning electron microscopy
All microneedle arrays used in this study were characterised by scanning
electron microscopy (SEM). SEM is a high magnification, high resolution,
imaging technique containing a heated tungsten filament with an electron gun
above the sample stage sealed in a vacuum chamber. The sample microneedle
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array was mounted onto an aluminium stub and placed on the stage of the 
Philips XL-20 Scanning Electron Microscope. Sputter coating with gold was not 
required as the platinum-coated microneedles were sufficiently electron dense. 
The sample was irradiated by a thin beam of electrons resulting in a secondary 
emission of electrons from the sample surface that were collected by the 
detector and produced a signal which was translated into a two-dimensional 
image.
2.3 Results
Thirteen volunteers were used to test the levels of pain and sensation caused 
by 4 application devices. Initially, two applicator designs were selected from 
the 7 designs that were administered to Volunteer 1 (V1) based on their level of 
comfort during application. These applicators, the foam-tipped rod and inverted- 
syringe plunger, were compared to the square-ended [Y] and cylindrical [Z] 
metal rods. Subsequently, ex-vivo testing of 280pm length microneedles 
mounted to the syringe plunger determined a suitable application technique for 
consistent skin puncture.
2.3.1 Pain and sensation assessment of different applicator devices 
on human volunteers
A preliminary study aimed to establish the simplest method of applying 
microneedles with the resources available. As microneedles were already being 
applied in the laboratory by means of mounting an array onto a rod, variations 
on this setup were used to establish the simplest applicator which caused the 
least sensation and pain. Initially 7 applicator devices (Figure 2.2) were applied 
only to V1, who then commented what they felt during the application of each 
device. Based on this rudimentary assessment, the foam-tipped and inverted- 
syringe applicators (Figure 2.3) were compared to the original square-end [Y]
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and cylindrical [Z] applicators (Figure 2.1). These 4 applicators were tested
on 13 human volunteers, including V1.
2.3.1.1 Audio-recorded comments from applying all seven applicator
devices to a single volunteer
Recorded comments made by the subjects during the application of the 
applicator devices were verbatim transcribed (Table 2.1). These comments 
determined which 2 applicator devices would be compared against the 
aluminium square-ended [Y] and cylindrical rods [Z].
Table 2.1 verbatim-transcribed comments vocalised by Volunteer 1 (V1) when each 
applicator [A]-[G] was tested on the forearm.____________________________________
Device Verbatim-transcribed comment
[A] “Does not feel sharp on the skin. Pressure can be felt but no pain. ”
[B] “Causes less sharpness than the square applicator but feels very similar to 
the round applicator. ”
[C] “Similar to applicator B, causes less sharpness than the square applicator 
but feels very similar to the round applicator. ”
[D] “Feels the same as the round applicator. ”
[E] “Feels soft on the skin. Causes no pain or does not feel sharp. ”
[F] “Cannot really feel the applicator on the skin. Causes no pain. ”
[G] “Similar to applicator F, causes no pain. ”
2.3.1.2 Assessing pain and sensation using the MPQ-SF post­
application of 4 applicator devices
The pain and sensation of 4 applicators, the 2 original applicators of square-end 
[Y] and cylindrical [Z] morphology and the 2 new applicators (inverted syringe 
plunger [A] and foam-end cylindrical rod [E]) were compared against 
one another to determine which of the 2 were the least painful upon 
administration to the volar forearm of the 13 (including V1) study participants.
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Table 2.2 summarises the overall scores and percentage from the MPQ-SF the 
participants completed immediately post-application. The MPQ-SF was scored 
in accordance with Melzack’s scoring (1987) whereby the VAS measurement 
from 0-100mm was summed with the scores, none = 0, mild = 1, moderate = 2, 
severe = 3, for each descriptor word and the present pain index of 0-5.
Table 2.2. Overall totals calculated from the MPQ-SF for simple comparison of pain
and sensation between the types of applicators.
Square-
ended
[Y]
Applicator
Cylindrical
[Z]
type
Foam-
tipped
[E]
Inverted-
syringe
[A]
Total Score 182 117 44 79
The standard square-ended [Y] and cylindrical [Z] rods both caused greater 
sensation and pain when compared to either the foam-ended [E] or inverted- 
syringe [A].
2.3.1.3 Audio-recorded comments when 4 applicator devices were 
applied to 13 human volunteers (including V1)
All volunteers were asked to vocalise any sensation felt during the application 
of each device, though participants 12 and 13 required further prompting by the 
researcher asking “anything?” or “did you feel anything then?” at the time of 
application to encourage oral commentary. Table 2.3 contains all the verbatim- 
transcribed comments that each participant vocalised during the application of 
the 4 different applicator devices.
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Table 2.3. Verbatim-transcribed comments vocalised when 4 applicator devices were applied to 13 human volunteers
Participant
No.
Cylindrical metal rod [Z]
Applicate 
Square-end metal rod [Y]
>r device
Foam-tipped metal rod [E] Inverted-syringe plunger [A]
1 "Cold feeling. Doesn’t feel too 
bad but I felt a bit of a sharp 
edge and some pressure.”
“That feels quite sharp. When the 
device went on it felt sharp uh then 
when you applied further pressure 
it felt sharper but I can’t feel 
anything now.”
“Something being applied to my 
skin but no real sharp 
sensation. Doesn’t feel too bad 
at all. It’s just like someone 
pressing their finger against 
your arm”
“Not feeling anything at the 
moment. Can feel the device 
going onto my arm. Doesn’t hurt 
just felt it going on really. Didn’t 
feel any pain”
2 "Just slight pressure, no pain.” “That felt colder. No pain but it felt 
a bit sharp”
“I can just feel a slight pressure 
but there’s no pain.”
“No pain, colder than the first 
one [foam]. Slight pressure 
again but felt different to the first 
one [foam]. The pressure felt 
more concentrated.”
3 “A bit of pressure but I think 
that’s your finger. Oh now 
something a little bit sharp.”
“Much sharper. The applicator is 
cold. Definitely felt that.”
“Can’t really feel much. Can feel 
something cold. A bit of a touch 
and a shake. No pain.”
“Can feel a bit of a pressing 
sensation. Little bit of sharpness 
but nothing painful as such. Now 
I can’t feel anything.”
4 “Feels a bit cold. I can feel 
something there but it’s not as 
pressing as the last one 
[square]”
“I can feel something. It’s not 
painful but something pressing. 
Now I can’t feel anything.”
“Can’t feel anything. That’s cold. 
Pressing a bit but not as much 
as the others.”
“Something is in contact with my 
skin but there’s no pain or 
discomfort.”
5 “Urn same as before really 
[square]”
“Cold, kind of a pressure sensation 
but nothing major”
“Same as the last one [syringe]. 
Nothing at all. I’d say the first 
two [square and round] were a 
slight sensation but not really 
pain and nothing for the last two 
[syringe and foam].”
“No pain at all. Probably less 
than the first 2 [square and 
round]”
6 “I can feel something touching 
my skin. I know something’s 
there.”
“Something really sharp. That was 
quite painful.”
“Just a gentle touch.” “There is something touching my 
skin. There is no pain.”
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Table 2.3 continued.
Participant
No.
Cylindrical metal rod [Z]
Applicate 
Square-end metal rod [Y]
>r device
Foam-tipped metal rod [E] Inverted-syringe plunger [A]
7 “I can feel you hand, I think 
now something pressing. 
Something wiggling around a 
bit. I can feel a kind of 
pressure.”
“Something with a sharp edge, 
wiggling around. Pressure and 
sharpness.”
“I can feel your hands then a 
cold sensation.”
“Pressure, a little bit sharp.”
8 “Can’t really feel much at all. 
No, nothing. Just pressure.”
Can’t really feel much at all. Little 
bit of a pin prick feeling but not 
painful.”
“No nothing, well a little bit of 
pressure but no sharpness or 
pain or anything.”
“Can’t really feel much again, 
like the second one [round].”
9 “No pain.” “Oh, that was quite sharp.” “Nothing that’s fine. “Could feel it but no pain at all.”
10 “Nothing, just a bit of 
pressure.”
“That feels a bit sharp.” “I can feel something there. Just 
a little bit of pressure.”
“Can’t really feel anything.”
11 “Nothing, bit of pressure.” “Felt stabbing.” “Nothing at all.” “A prick.”
12 [prompted with “Did you feel 
anything then?”] “No, nothing 
at all.”
[prompted with “Anything with this 
one?”] “Urn yes, it didn’t actually 
hurt but I could feel something 
touching my arm.”
[prompted with “Anything?”] 
“Nothing at all.”
[prompted with “Did you feel 
anything?”] “No, not really. Little 
bit of pressure I guess.”
13 “[Prompted with “Anything 
then?”] “Not really, little bit 
more than the other one but 
nothing really”
“Ooh a bit sharper than the others 
but it didn’t hurt.”
[Prompted with “Did you feel 
anything?”] “Not really, little bit 
of pressure, but no pain.”
[Prompted with “Anything?] 
“Nothing.”
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Whilst 7 participants stated the square-end [Y] applicator felt “sharp” or 
“sharper”, the foam-tipped applicator [E] elicited comments of “no pain” 
from 4 participants. Overall the verbal comments imply the least painful and 
discomforting applicators are the foam-tipped [E] and the inverted-syringe [A].
Based on these results, the foam-tipped applicator [E] and the inverted- 
syringe applicator [A] were selected for potential use as applicators for the 
clinical trial. However, due to the ease and convenience of supply, the 
inverted-syringe applicator was the only one used for ex-vivo testing. The 
syringes were simple inverted, surface ridges on the plunger were smoothed 
down with heat and an array was adhered using epoxy to the surface. Finally 
each applicator was visually inspected under light microscopy to be of the 
same design.
2.3.2 Ex-vivo skin testing of applicators
A 280pm silicon microneedle array was mounted to the inverted 2ml syringe 
plunger. This was then applied to excised human skin using 3 different 
application techniques explained in Section 2.2.3. An example en-face 
photograph of methylene blue stained skin post puncturing when 
microneedles were applied using the rolling technique is shown in Figure 2.5. 
Whilst the microneedles appeared to puncture the skin efficiently, the intensity 
and spread of blue stain at each channel was not completely consistent within 
a single array pattern. The percentage increase in TEWL post-application of 
microneedle arrays using the 3 differing application techniques, as well as the 
visualised number of methylene blue stained punctures caused by the 
microneedle applications are graphically represented in Figure 2.6. Figure 2.6
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evidences that punching the applicator onto the skin surface elicited greater 
TEWL from the skin surface, though all the microneedles did not penetrate the 
skin surface.
Figure 2.5. Example photograph of methylene blue stained channels visualised under 
the light microscope post-application using the rolling technique of a 7 by 7, 280fim 
microneedle array to ex-vivo skin.
As TEWL is a difficult technique to use and often prone to variance in the 
external environment (Cohen et al. 2009a) TEWL measurements were 
repeated with 25 separate applications: 5 different samples, each from a 
different female donor (as described in Section 2.2.4) and each had 5 
separate applications. ‘Rolling’ the microneedles by rotating an array through 
45° onto the skin provided a simple and consistent method of application with 
mean TEWL increase post-application of device of 85% (standard deviation 
(SD) = 5%) and mean of 35 (SD= 1) (out of 36 possible) punctures stained by 
methylene blue. Pushing and punching the microneedle device onto the skin 
resulted in a mean TEWL increase of 34% (SD= 15%) and 81% (SD= 6%)
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respectively, whilst the number of stained microneedle punctures were 
16(SD=7) and 23 (SD= 5), respectively for the pushing and punching 
application techniques. The only method that resulted in all 36 of the 280pm 
length microneedles penetrating the skin was the rolling technique.
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Figure 2.6. Testing the puncture efficiency of 3 application methods. Each of the 3 
application methods was tested ex-vivo on human skin to see which produced 
consistent punctures from a total of 36 microneedles. TEWL measurements (Red) 
were taken prior to methylene blue staining (blue) and the percentage increase post­
application of the microneedle device was recorded. The rolling, pushing and 
punching techniques had a mean increase in TEWL of 85% (SD= 5%), 34% (SD= 
15%) and 81% (SD= 6%) respectively. Whilst the number of identifiable punctures 
following the rolling, pushing, punching techniques was 35 (SD= 1) 16 (SD= 7) and 
23 (SD=5) respectively.
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2.3.3 Microscopic analysis of the microneedle arrays pre­
application
All the 280pm and 180pm microneedle arrays used in the clinical trial where 
checked for damage by SEM and stereomicroscopy prior to use. Example 
images, in Figure 2.7, of 180pm and 280pm microneedle arrays demonstrate 
the robust and precise production etching process, which produces arrays 
consisting of 36 intact and identically shaped octagonal-pyramid 
microneedles. Three damaged arrays were removed from the stock that was 
to be used in the clinical trial because sharper and stable microneedles would 
penetrate the skin more easily, whilst also reducing the risk of microneedles 
breaking in the skin.
2.3.4 Characterisation of microneedle arrays post skin application
Single applications of silicon microneedle arrays onto the skin without using 
an attached applicator caused the base of the fragile array to fracture. 
However when applied once whilst attached to the applicator rods and 
inverted syringe plunger, the microneedle arrays did not fracture or fragment.
2.4 Discussion
All novel technologies and drugs for human use are required to be extensively 
tested in the laboratory prior to administering to human volunteers. Therefore, 
trials are conducted in phases for laboratory, animal and human testing. For 
successful ethical approval, supporting data of all the techniques and the 
relevance of all treatments to participants must be documented. Therefore, 
pre-clinical testing is conducted in the laboratory to establish safe working 
parameters. In this chapter, the application of microneedles to human
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Figure 2.7. SEM micrographs and stereomicroscopy of the microneedle arrays pre­
application. [A] SEM of array consisting of 36-microneedles each of 280pm length.[B] 
280pm length single microneedle. [C] Stereomicroscopy image of intact 280pm 
length microneedle (bar = 280pm).
volunteers was considered. Thus a rudimentary applicator was developed to 
apply microneedles to the skin and tested, ex-vivo, to ensure the applicator 
improved skin penetration.
Whilst single hollow microneedles penetrate the skin successfully (Alarcon et 
al. 2007), the morphology and design of microneedle arrays is being 
optimised (Al-Qallaf and Das 2009). However, to-date, in-vitro animal studies 
(Koutsonanos et al. 2009; Li et al. 2009), and ex-vivo (Coulman et al. 2006) 
and in-vivo (Kaushik et al. 2001; Wermeling et al. 2008) studies on human 
skin have administered microneedle arrays by pushing the array into the skin 
surface without any specialised applicator design. Though metal or wooden 
rods (Coulman et al. 2006; Henry et al. 1998) and syringe barrels (Sivamani 
et al. 2005) have been used as applicators. Therefore, to understand and 
standardise the application process for applying microneedles to human skin, 
9 applicator designs ([A]-[G], and [Y] and [Z]) were tested without 
microneedles to provide data on how participants’ perception would be 
affected by the applicator used. Furthermore, the instruments for assessing 
the treatments, such as, the VAS, MPQ-SF and audio recording were tested 
in an effort to practice and assess their use prior to the main clinical trial.
The initial pre-clinical testing of 7 applicators [A]-[G] on Volunteer 1 (V1) 
provided a quick method of testing the audio recording process and 
selecting 2 of the applicator designs. Though this did not provide any 
statistical evidence for selecting the inverted-syringe plunger [A] or the foam- 
tipped rod [E], comments from V1 suggested these 2 designs as the least 
painful or discomforting (Table 2.1). The inverted-syringe plunger [A] provided
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a cheap and effective applicator device, which was readily available in the 
laboratory and clinic. Based on this availability and less discomforting 
sensations felt by the 13 volunteers, the inverted-syringe plunger [A] was 
selected for ex-vivo testing. Furthermore, study time for recruitment of 
volunteers and assessment was limited. Therefore, each of the 7 applicators 
([A]-[G]) were not applied on the remaining 12 volunteers, though repeats may 
have provided more conclusive evidence for which applicator design is most 
comfortable.
Though microneedles, when attached to an inverted-syringe [A] and applied 
using the rolling application technique, provided efficient and repeatable 
penetration to ex-vivo human skin, specialist devices may improve the 
application further. For example, Ding et al (2009) demonstrated effective 
penetration of an array of 300pm length microneedles using an electric 
applicator device, whilst Yang et al (2004) reduced penetration force using 
vibratory actuation.
The microneedles were characterised by SEM and light microscopy, which 
proved useful methods for assessing the stock of microneedle arrays. 
However, SEM is an expensive process (Zhou and Wang 2007), thus cheaper 
light microscopy was used to image and catalogue each microneedle array, 
whether consisting of 180pm length or 280pm length microneedles (Bal et al. 
2008; Jin et al. 2009; Pearton et al. 2008; Verbaan et al. 2007). Thereby 
ensuring that the microneedles used in ex-vivo testing were morphologically
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intact and identical in their layout, which reduced the potential for 
microneedles to break during application due to defects in their structure.
Pyramidal shaped silicon microneedles produced by wet-etching have 
previously been demonstrated to be morphologically identical (Wilke and 
Morrissey 2007; Wilke et al. 2005b) and puncture skin efficiently by rolling an 
applicator mounted microneedle array across the skin surface (Coulman et al. 
2006; Pearton et al. 2008). Future investigations, using SEM and light 
microscopy to observe microneedle applications, could determine optimum 
microneedle design for successful penetration. Novel techniques using optical 
coherence tomography could allow observation of microneedles penetrating 
the skin in real-time and characterise the effect of applying microneedles to 
the stratum corneum and epidermis (Coulman et al. 2010; Kim et al. 2009a)
Applying microneedle arrays to the ex-vivo skin successfully required practice. 
Initial applications resulted in the force required to push microneedles into the 
skin being dissipated through the base of the applicator resulting in reduced 
microneedle penetration. TEWL provided a secondary measure of skin 
integrity and permeability. When applying a large force to the skin surface, the 
skin deforms and releases moisture from pores and follicular ducts (Bal et al.
2008), therefore, greater force does not necessarily represent an 
improvement in penetration by the microneedles on an array (Ayittey et al.
2009).
Using the rolling application technique possibly reduced the “bed of nails” 
effect as each row of needles on the array came into contact with the skin in
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phases rather than simultaneously (Sivamani et al. 2007; Teo et al. 2005; 
Yang and Zahn 2004). Therefore, first the microneedles closest puncture the 
skin, then the adjacent row and so on until the whole array is being evenly 
pushed into the skin (when the applicator is in the vertical position). The 
forces induced by massaging the applicator through the vertical position 
for 10 second increases pressure at the microneedle tips, thereby improving 
puncture efficiency. Though the rolling technique remains a crude method of 
application, it was well rehearsed and practised to ensure repeatable 
successful puncture of the skin. Future studies, using pressure sensors 
mounted to the end of the microneedle applicator, could determine the 
mechanical forces needed for microneedles to puncture the skin (Davis et al. 
2004; McAllister et al. 2003). Whilst further development of the applicator 
design could incorporate a mechanism on the applicator so that excessive 
force is not used, as this may cause greater pain and negative sensation for 
the patient.
Oral commentary by volunteers acted as a spoken diary of the complete 
application process (Clarke 2009; Lewandowski et al. 2009) and highlighted 
key descriptors, ‘pressing’, ‘pricking’ and ‘cold’, which were absent from the 
MPQ-SF. These words are present in the long-form MPQ (Melzack 1975), 
however and may benefit from being included in the MPQ-SF for better 
understanding the intensity of these specific sensations, thus the MPQ-SF 
was adapted for use in the clinical study (Chapter 3) by including ‘pressing’, 
‘prickling’ and ‘cold’ as descriptors. The oral commentary provided supportive 
evidence by highlighting the exact perceptions with key details and analogies 
given by the participants (Arber 2007; Forbes et al. 2000; van Tilburg et al.
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2009). For example, the metal applicator rod design was scored as more 
painful using the MPQ-SF. However, the audio commentary enabled the 
participants to express exactly which part of the application process attributed 
to perceptions of pain and sensation. Thus, the adapted MPQ-SF in 
conjunction with the audio recording would provide a more complete picture of 
an individual’s assessment of pain and sensation caused by the microneedles 
themselves during the clinical study (Chapter 3). Oral commentary has not 
been used in any previous study of microneedle design, however V1’s 
comments in Table 2.1 demonstrate that audio recording provided a suitable 
method of real-time data collection.
2.4.1 Conclusions
The pre-clinical studies of applicator design provided evidence that a softer 
material, such as the smooth plastic of an inverted syringe provide a cheap, 
simple and effective applicator, which could be applied in a clinically 
acceptable manner by rotating the applicator over 45° degree after applying at 
a 45° angle to the skin surface for efficient and successful penetration of the 
stratum corneum. Testing the standard MPQ-SF highlighted that whilst it 
remains a useful tool for comparing the perception of applicators, the addition 
of three descriptors may enhance the data collected. Furthermore, audio 
recording provided an added dimension of understanding to the types of pain 
and sensations felt during the administration of different applicators to 
volunteers.
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Chapter 3
Assessing the pain and sensation caused by the 
application of microneedle devices and a 
hypodermic needle to 12 healthy volunteers
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3.1 Introduction
Chapter 2 explained the pre-clinical developmental and evaluation stage in 
which the instruments to measure pain and sensation were investigated and 
tested on human volunteers. The pre-clinical development of data collection 
instruments, as well as the pre-clinical testing and characterisation of 
microneedles, helped inform the clinical study reported in this chapter. 
Conducting a clinical study requires time for recruitment and logistic 
management to ensure staff and participants can attend (Perri et al. 2006; 
Raynor et al. 2009), whilst also ensuring instruments for data collection are 
not confusing to use (Vanichseni et al. 2004). Therefore, Chapter 3 outlines 
the clinical trial methodology and reports the pain and sensations experienced 
by volunteers following application of silicon microneedle arrays and 
hypodermic needles to the buttock region.
3.1.1 Assessing pain perception
As introduced in Chapter 1, microneedle-based applications of drugs or 
vaccines are being investigated in humans, thus it is important to understand 
the nature of pain induced by microneedles, whilst also confirming the efficient 
puncture of skin. Pain has been defined in Section 1.1.4.1 by the International 
Association for the Study of Pain (2009). The administration of needles for 
vaccine delivery causes pain due to the needle impacting upon pain receptors 
residing in the dermal layer of skin (Arendt-Nielsen et al. 2006). Fear 
associated with needles can also increase the perception of pain (Hanas et al. 
2000; Nir et al. 2003). Through better understanding pain, medical 
interventions can be improved to afford greater comfort to patients, whilst
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ensuring successful delivery of a drug. Pain can be described by its intensity, 
descriptive words and location on the body. The various methods of 
assessing pain have been discussed in Chapter 1 and in Chapter 2 where 
visual analogue scale (VAS), short form McGill pain questionnaire (MPQ-SF) 
and audio recording were tested as assessment methods for establishing 
intensity of pain and sensations of applicator rods.
The pain and sensation assessments detailed in this chapter only consider 
the level of penetration caused by the application of microneedles and 
hypodermic needles, as no substances were administered using the needle 
devices. As reviewed in Section 1.1.4.6, previous studies did not attempt to 
use specific instruments to record the intensity of pain, but rather used 
subjective notes and VAS whilst simultaneously confirming that microneedle 
penetration was successful in-vivo (Gill et al. 2008; Kaushik et al. 2001; 
Miyano et al. 2005; Sivamani et al. 2005). Therefore the types of pain and 
sensation were not consistently assessed. Furthermore neither the 180pm nor 
280pm length silicon microneedle arrays have previously been tested on 
human volunteers.
3.1.2 Conducting clinical trials
The Medicines and Healthcare products Regulatory Agency (MHRA) defines 
a clinical trial as “an investigation in human subjects which is intended to 
discover or verify the clinical, pharmacological and/or other pharmacodynamic 
effects of one or more medicinal products, identify any adverse reactions or 
study the absorption, distribution, metabolism and excretion, with the object of 
ascertaining the safety and/or efficacy of those products. This definition
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includes pharmacokinetic studies” (MHRA, 2010). MHRA regulations only 
apply to trials of medicinal products where “substances or combinations of 
substances which either prevent or treat disease in human beings or are 
administered to human beings with a view to making a medical diagnosis or to 
restore, correct or modify physiological functions in humans” (MHRA, 2010). 
Based on the MHRA’s definition of what requires a clinical trial authorisation 
(CTA), the research undertaken within this thesis involving only medical 
devices (microneedle devices) does not require a CTA, however, as a novel 
medical device was tested on human volunteers, the terms ‘clinical trial’ or 
‘clinical study’ are used interchangeably in this thesis. Therefore clinical 
studies answer 2 major questions: is the new treatment effective in humans 
and is it safe for use on humans.
Whilst the clinical research in this chapter was not testing any new drugs or 
therapies in humans, understanding of “Good Clinical Practice” (GCP) 
guidelines (Dupin-Spriet 2005; EMEA 2002) and conducting the study in 
accordance with the ethical principles established by the Declaration of 
Helsinki (WMA, 2008), provided a framework for the conducting the research. 
Prior to conducting a trial, any risks must be weighed up and the benefits 
must outweigh and justify the risks for a trial to continue. The safety, legal and 
ethical rights of all participants should prevail over any scientific interests, thus 
fully informed consent must be freely given by all participants prior the trial. 
The study can only begin once an independent ethics committee has 
reviewed and confirmed compliance of the protocols and associated materials 
such as the patient information sheet and consent forms. Thus it was 
essential to develop a clear protocol for the whole trial process, to ensure the
same information was provided to each participant at recruitment and justify 
the purpose of the study.
A qualified physician must be responsible for any treatment administered 
during the trial. All information produced from the trial should be recorded in 
‘case report forms’ (CRF) and stored in such a way that allows its accurate 
reporting, interpretation and verification as well as protect the participants’ 
identities in accordance with regulatory requirements (EMEA 2002; Schmidt 
and Frewer 2007). Therefore a CRF was produced (Appendix VIII) to include 
the timetables for each researcher and participant, as well as, the data 
collection instruments, such as the VAS, adapted MPQ-SF and 
transepidermal water loss (TEWL) and instruction for the participants.
Ex-vivo tests (Chapter 2) have shown the difficulty of administering 280pm  
microneedles to human skin. Furthermore, Chapter 2 highlighted the potential 
problems of applicator choice and application technique that may arise when 
applying in-wVo to human volunteers. In-vivo, different anatomical regions of 
the skin underlying muscle and adipose tissue alter the rigidity and shape of 
the skin (Batisse et al. 2002; Montagna et al. 1992; Welzel et al. 2004). 
Therefore the location of the clinical microneedle and hypodermic needle 
applications needed to be carefully considered.
The clinical study was conducted to determine whether silicon microneedles 
of a maximum length of 280pm cause pain when administered to human 
volunteers. Furthermore, microneedles of this morphology have never been
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tested in-vivo. Thus, it is important to determine the intensity of pain and 
sensations induced in relation to a 25G hypodermic needle subcutaneous 
injection.
3.1.3 Aims and objectives
This chapter aims to show that the pain and sensation elicited by the 
application of microneedles is less than subcutaneous administration of 25G  
hypodermic needles to human volunteers.
Objectives:
•  To use VAS to assess and quantify the intensity of pain elicited when 
microneedles of 180pm and 280pm length, and a 25-gauge 
hypodermic needle, are applied in-vivo to human volunteers.
•  To identify pain and sensations using an adapted MPQ-SF post­
application of microneedles and hypodermic needle.
•  To establish any additional benefits of the use of audio recording as a 
method of recording important descriptions of pain and sensations 
experienced by participants following the application of 180pm and 
280pm length microneedle arrays and a 25-gauge hypodermic needle.
3.2 Materials and Methods
3.2.1 Materials
Sanyo TRC-525M dictaphone (Sanyo, Japan); Digital VAS meter DVAS10 
(Cardiff Biometrics Ltd, Wales); methylene blue dye powder (Sigma, UK); 25- 
gauge hypodermic needles (BD, Oxford, UK); microneedle arrays containing
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36 pyramidal microneedles of either 280pm or 180pm length (Tyndall National 
Institute, Ireland).
3.2.2 Ethical approval and consent
Prior to beginning the study, the study protocol (Appendix III) was submitted 
for ethical approval from the Gwent Healthcare NHS Trust R&D Committee 
and the South East Wales Research Ethics Committee (SEWREC). Ethics 
approval for the study was granted. Informed consent was obtained from each 
participant in adherence with the Declaration of Helsinki and a written 
explanation of the study provided before their first visit. At the first visit each 
participant read and signed consent forms (see Appendix VIII) after the nature 
of the study had been fully explained. Participants were informed that they 
could withdraw from the study at any stage without any explanation.
3.2.3 Personnel roles for the clinical study
Three main roles were assigned to ensure successful management of the 
trial. The lead physician, Dr. Anstey, was responsible for the ethics and 
medical support of this study. The Study Coordinator, Mohammed Haq, 
developed the specific details for the study, coordinated the trial activities and 
monitored adherence to good clinical practice (GCP) and ethical guidelines, 
together with the lead physician. The assisting physician, Dr. Kalavala, was 
responsible for clinical applications of needles and biopsy sample extraction 
from the volunteers, whilst ensuring their medical wellbeing and suitability for 
the study. In addition, Dr. Birchall and Dr. John supervised the study and 
assisted in data collection for pain and sensation and Miss. Smith assisted 
with transepidermal water loss (TEWL) data collection by placing the TEWL 
probe on female participants.
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3.2.4 Clinical application of microneedles
Chapter 2 helped to establish an applicator device that was shown to be of 
minimal discomfort and acceptable for use in this study. Accordingly, the 
180pm and 280pm silicon microneedle arrays were adhered to the flattened 
base of inverted syringe plungers as detailed in Chapter 2. These were 
sterilised by soaking in 70% ethanol for 12 hours in an aseptic laminar flow 
hood and then placed individually into pre-sterilised sealed bags until use. To 
aid the clinician when applying the devices, each syringe was colour coded to 
represent the length of microneedles mounted to it, thus the clinician was 
always aware of which device had been applied. Thus, avoiding the same 
device accidently being applied twice to a participant.
3.2.4.1 Anatomical location selected for needle device application
Ethics committee approval for biopsy of the puncture sites required an 
anatomical site that would not cause obvious scaring to the participant. 
Therefore the buttocks were chosen as the application site for all microneedle 
and hypodermic testing. The buttock was defined to be any region of the 
gluteus maximus muscle. However, as the buttock varies in elasticity and sub- 
dermal fat deposition depending on age, diet and gender, it was important to 
ensure a consistent location for application between volunteers. Therefore the 
application sites for each participant was the peripheral buttock region closer 
to the femur (Figure 3.1). This region of the buttock has less fat deposition 
and is firmer in muscle (Inan et al. 2005; Schilling and Wechsler 1986), thus 
the fleshy but less fatty nature is better representative of other anatomical 
regions where the microneedles may ideally be applied, for example, on the 
volar forearm or bicep region of the arm. Three sites, A, B and C were marked
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on each buttock. Sites A, B and C were each used for only one microneedle 
or hypodermic needle application depending on which needle device was 
randomised to the particular site (see Section 3.2.5).
Site A 
Site B
SiteC
Figure 3.1. Diagram to show the location of each application site on both buttocks. 
3.2.5 Trial Randomisation
Randomisation helps to reduce bias, including the effects of hidden variables 
and uncontrolled factors that might change over the length of the study
(Robinson et al. 2005; Schulz et al. 1996; Toroyan et al. 2000). The clinical
study was conducted with the 12 participants randomised into 4 groups based 
on the order of applications and time of biopsy:
Group 1: 3 participants having biopsies at 1 hour.
Group 2: 3 participants having their biopsies at 4 hours.
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Group 3: 3 participants having their biopsies at 8 hours.
Group 4: 3 participants having their biopsies at 24 hours.
A randomisation order was generated and tabulated (Table 3.1) to randomise 
which group each participant belonged to, based on their biopsy time (group 
1 - 4); which buttock they will have either the TEWL measurements or biopsy 
taken from (R = right, L = left); the order in which each needle device will be 
applied to both buttocks (1st, 2nd or 3rd); and the site of application (A, B or C) 
in relation to Figure 3.1.
The visual analogue scale (VAS) and perception questionnaire components of 
this study were conducted in a single-blind manner, whereby the participant 
did not know the type of application being applied, though the assessor was 
aware of which applicator was used. Each participant was treated on each 
buttock with 2 different microneedle arrays consisting of 36 pyramidal 
microneedles of either 180pm (180 MN) or 280pm (280MN) height, or a 25- 
gauge hypodermic needle.
3.2.6 Study Design
The trial was conducted in the Dermatology Day Unit at St. Woolos Hospital, 
Newport. Pain and sensation was assessed using the VAS and adapted short 
form McGill pain questionnaire (MPQ-SF) after applications of needle devices 
on either the right or the left buttock. Subsequently, following two 6mm 
biopsies, one from each microneedle array application site, and one 4mm 
biopsy from the hypodermic needle application site, wound healing was
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Table 3.1. Randomisation table showing the randomisation for each participant in terms of their group and location of each specific needle 
application (A, B or C in relation to Figure 3.1) and which buttock TEWL is measured on as well as which buttock pain, perception and biopsies 
were taken from (R = right buttock, L = left buttock in relation to the assessor when facing the buttock). 180 MN = 180pm length microneedle 
array; 280 MN= 280pm microneedle array; and hypodermic = 25G hypodermic needle.
Key;
Group 1 = Biopsy at 1 hr post-application 
Group 2 = Biopsy at 4hr post-application 
Group 3 = Biopsy at 8hr post-application 
Group 4 = Biopsy at 24hrs post-application
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5 3 L 180 MN A hypodermic B 280 MN c R 180 MN B hypodermic C 280 MN A
6 4 R 280 MN C hypodermic B 180 MN A L 280 MN B hypodermic C 180 MN A
7 4 L 180 MN A 280 MN B hypodermic C R 180 MN B hypodermic A 280 MN C
8 2 L 280 MN A 180 MN B hypodermic C R hypodermic C 280 MN A 180 MN B
9 3 R 180 MN B 280 MN C hypodermic A L 280 MN A 180 MN B hypodermic C
10 2 L 180 MN C hypodermic A 280 MN B R 180 MN A 280 MN B hypodermic C
11 1 L hypodermic C 180 MN A 280 MN B R 280 MN A 180 MN B hypodermic c
12 4 R 280 MN C 180 MN A hypodermic B L hypodermic C 280 MN B 180 MN A
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assessed (Chapter 4). The remaining right or left buttock was used to assess 
TEWL over a 24 hour period, with measurements taken pre-application, and 
post-application at 3 time points (immediately, 8 and 24 hours). Biopsy, 
wound healing and TEWL are described in Chapter 4.
3.2.6.1 Recruitment of participants for the study
The recruitment process for this study spanned over 6 weeks. Initially fliers 
were posted at St. Woolos Hospital. Each enquirer was checked against the 
recruitment criteria (Appendix III). If all criteria were met, participants were 
emailed or posted information packs. However, upon contacting the study 
coordinator for further information, potential participants voiced unease about 
exposing the buttock region and the biopsies procedure. Therefore, many 
enquirers withdrew from the trial. Subsequently, the trial coordinator placed 
recruitment posters in 5 general practice surgeries and 5 dermatology clinics 
across Cardiff and Newport; and university departments and postgraduate 
centres were also contacted by e-mail. All volunteers that participated in the 
trial were offered £120 honoraria plus travel expenses, a figure based upon 
the inconvenience for spending time at the unit and ratified by the SEWREC.
Records containing the name, contact details and availability of each potential 
participant were maintained in accordance with data protection legislation and 
ethical requirements (Earl-Slater 2002; Flather et al. 2001; Gad 2009). Each 
enquirer was telephoned and participant information packs were sent by email 
or delivered in person. During all conversations, discussions were limited to 
only the information contained in the information pack and consent form, 
including any safety issues. The discussions did not detail the pain and
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sensation measurement methods or specifics details of the randomised 
applications. This ensured that the participants were fully informed but the 
coordinator did not bias the participants. If after reading the information and 
considering the answers to any questions the participants were interested, 
they were provisionally booked into a trial day and e-mailed their specific 
timetable (Appendix V).
Subsequently, after the initial 9 participants were recruited, the trial dates of 
Saturday 10th to Monday 12th March 2007 were confirmed with all 
participants and study personnel. Upon arrival at the Dermatology Day Unit on 
the trial day, the participant sat in a quiet, comfortable clinic waiting area. Next 
the physician obtained the participant’s informed consent, which was essential 
before commencing the trial. The participant was reminded that they could 
withdraw from the study at any stage.
Meticulous planning ensured each participant was guided through the process 
independently to prevent interaction between multiple participants (Appendix 
V). Furthermore, the provision of two rooms allowed one participant to be 
undergoing the pain perception exercise whilst another was undergoing their 
TEWL evaluations (see Chapter 4). Thereafter each participant swapped 
rooms to complete their first visit. Participants were informally escorted 
between rooms, avoiding the waiting area, thereby preventing interaction with 
other participants to prevent disclosure of the procedure or their perceptions 
and sensations.
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After the first 9 participants had been processed, the trial was delayed 
for 2 weeks whilst the clinical coordinator recruited and managed the logistics 
to process the 3 final participants. It was important that these 3 new 
participants had not, in any way, discussed the trial with any of the previous 
participants as to bias their opinions or reveal method protocols prior to their 
participation. Therefore, before providing any further information, or 
recruitment, potential participants were asked about their knowledge of the 
trial. Enquirers with detailed knowledge of the trial were not recruited.
3.2.6.2 Assessing pain and sensation during the clinical study
To assess the perception of the needle applications, the participant completed 
the VAS and adapted MPQ-SF immediately after the application of each 
needle device. Data was recorded in the case report form (CRF) (Appendix 
VIII).
Preliminary tests conducted at the WSP with laboratory researchers 
suggested that applying the devices prior to the participant becoming 
comfortable and confident with the procedure would lead to inconsistent or 
minimal vocalisation and commentary on what they felt. Therefore the CRF 
(Appendix VIII) took into account the need to ‘break the ice’ with individual 
participants to ensure they were confident and comfortable with the study 
environment and the assessors. To ensure consistency during the trial, each 
instruction and exact question for the assessor to ask the participant was 
printed in the CRFs. This also prevented the assessor from deviating in their 
questions or indeed leading the participant.
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3.2.6.3 Summary of the first trial day methodology for assessment 
of pain and sensation to needle devices
Following written informed consent, each participant changed into a long 
hospital gown and rested on a medical couch on their front to allow access to 
their buttock. Initially 1 buttock was exposed and 3 areas marked in relation to 
a participant-specific template (Appendix VI). The participant was asked to 
relax and general conversation with the assessor enabled the participant to 
feel more comfortable with the whole process. Two dictaphones, one acting 
as a backup, were set to record. As the first needle device was applied the 
participant was asked to speak and explain what they felt using any words 
and descriptions that they felt to be suitable. Following application, the VAS 
and questionnaire were completed as per the CRF (Appendix VIII). This was 
repeated for each device and all additional comments were recorded in the 
CRF (Appendix VIII) and the dictaphones turned off. The participant was then 
taken to another room and asked to rest for 15 minutes, following which each 
needle device was applied to the adjacent buttock and TEWL measurements 
taken. The order of TEWL and pain measurements were determined by the 
participants’ timetable and which room was available, therefore Participants 3, 
7 and 12 had their TEWL measured before the pain and sensation. Further 
information on the TEWL study and wound healing responses are presented 
in Chapter 4.
3.2.6.4 Measuring pain using a visual analogue scale (VAS)
At the start of the trial each participant was informed how they would be 
assessed to measure pain intensity and sensation caused by each needle 
device. The pain intensity rating was taken immediately after application of 
each needle using an electronic sliding VAS whereby the participant moved a
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slider along a 10cm slide where one end represented ‘No Pain = 0cm’ and the 
other end the ‘Worst Pain Imaginable = 10cm’. This was done after each 
subject verbally described sensations as the needles were being applied. The 
slider was set to 0cm prior to each reading. A digital display, viewed only by 
the assessor, showed the distance the slider was moved and this result was 
recorded in the CRF. Each participant received the same instruction at each 
VAS reading: “To measure the pain intensity please move the slider to the 
position that best represents the pain felt during and after the application. The 
left end of the scale represents no pain and the right end of the scale 
represents the worst pain imaginable”. VAS is explained in Chapter 1.
3.2.6.4.1 Statistical analysis of VAS data
Non-parametric Wilcoxon signed rank test was performed using Prism 
GraphPad. Significance was shown when p<0.05.
3.2.6.5 Measuring sensation perception with an adapted
questionnaire
The perception questionnaire was adapted from the MPQ-SF as explained in 
Chapter 1 (Melzack 1987). It contains the four main assessment points of the 
MPQ-SF and three additional words (‘pressing’, ‘pricking’ and ‘cold’) taken 
from the long form MPQ, which exploratory research within our group 
(Chapter 2), have shown to be of specific relevance in this study.
To prevent leading the participants, the ‘Pain Rating Index’ of descriptor 
words was relabelled the ‘Sensation Rating Index’ as this provided the 
opportunity for subjects to consider sensations experienced other than pain. 
Participants were instructed, as follows, before each adapted MPQ-SF was
81
completed: “You will now be shown some descriptive words. As each word is 
read out to you please state if it describes a sensation you felt during or after 
the application. Rate it as either none, mild, moderate or severe. If you are 
unsure of the meaning please ask”.
3.2.6.6 Measuring Pain using the evaluative overall pain index 
(EOPI)
The EOPI is the penultimate section of the MPQ-SF and is used to rate the 
overall pain of the process, thus participant have time to reflect on the level of 
pain felt during the application of the specific device. The participants were 
asked to “Looking at the words, which one describes the overall intensity of 
the total pain you experienced during and after the application?” and rate on 
an increasing integer scale from ‘no pain = O’, ‘mild = 1’, ‘discomforting = 2’, 
‘distressing = 3 ’, ‘horrible = 4 ’ and ‘excruciating = 5”.
3.2.6.7 Audio recording of participants
Prior to any devices being applied each participant’s consent was taken to 
have the session audio recorded (Appendix VIII). As previously described, 
2 dictaphones were set up, unobtrusively but within the direct vicinity of the 
participant to ensure optimum clarity in the recording. The essential data from 
the participant’s audio commentary was recorded during and after the 
application of each device. To ensure the participants vocalised fully what 
they felt during the applications, they were instructed at the start to “Please 
describe any sensation you feel during the whole procedure".
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3.2.6.8 Establishing awareness of application site using location
diagram
To assess the ability of participants to identify the location of the sensations or 
pain they felt, participants were asked to mark on a diagram of the buttock 
region where they felt the application of each device (Appendix VIII).
3.3 Results
3.3.1 Conducting the study
The study was conducted over 7 days in a 4 week period. The results were 
recorded in a CRF (Appendix VIII) for each participant. Data for each 
participant is tabulated in Appendix X to show the order of application of 
the 3 devices; the VAS scores; the sensation words rated as ‘moderate’ and 
‘mild’, the ‘overall evaluative pain index’; the relative discomfort and painful 
nature of each device deduced from the audio recordings; and finally the 
tabulated verbatim transcripts for each needle device and overall comments.
3.3.2 Perception of pain and sensation during application
3.3.2.1 VAS score from microneedle application
The VAS scores taken for each device from participants (n=12) show that the 
180pm (180 MN) and 280pm (280 MN) length microneedles were significantly 
less painful than the hypodermic needle, p=0.027 and p=0.0005, respectively 
(Table 3.2). The 280pm length microneedles were also perceived to be 
significantly less painful than the 180pm length microneedles, p=0.039 (Figure 
3.2).
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Table 3.2. VAS scores (cm) for each participant. Pain intensity rated on a scale of 
Ocm for ‘no pain’ to 10cm for ‘worst pain imaginable’. 180pm (180 MN), 280pm (280 
MN) length microneedles were compared to 25G hypodermic needle administered 
subcutaneously.
Needle Device 1 2 3 4 5
Participant 
6 7 8 9 10 11 12
280 MN 0.14 0 0 0 1.00 0 0.14 0.01 0.88 0.46 0 0
180 MN 0.95 0.60 0 0 2.40 1.44 0.21 0.08 1.08 0.23 0 0.21
Hypodermic 0.25 0.54 1.14 0.11 2.30 2.17 0.28 0.74 2.23 0.92 2.65 1.69
E
o
280mn Hypodermic
Needle Type
Figure 3.2. Individual and mean VAS score for each needle device: 180pm (180MN) 
and 280pm (280MN) length microneedle arrays and 25G hypodermic needle. Graph 
shows the 280pm microneedle array application was the least painful, whilst both 
microneedle applications were less painful than 25G hypodermic needle.
All 12 participants reported the greater pain intensity for the hypodermic 
needle than both microneedle devices, though all participants registered the
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pain intensity under 3cm on the VAS. Eleven of the 12 participants found the 
180pm length microneedle array device to be more painful than the 280pm 
length microneedle array device. For 6 participants, the 280pm microneedle 
device registered no pain (0cm), whilst only Participants 5 and 9 reported the 
pain intensity to be above 0.5cm VAS (Table 3.2).
3.3.2.2 Assessing sensation using an adapted MPQ-SF sensory 
questionnaire
The adapted MPQ-SF sensory questionnaire consisted of the 15 descriptor 
terms and the three additional terms (‘pressing’, ‘prickling’ and ‘cold’ 
appended within a separate page of the CRF (Appendix VIII)). Each word was 
rated as ‘none’, ‘mild’, ‘moderate’ and ‘severe’. Figure 3.3 shows, that overall, 
greater variety of sensations were perceived for the hypodermic needle than 
either microneedle device, though none of the participant rated any of the 
descriptors as being ‘severe’. Sensory modalities rated for the hypodermic 
needle were also more ‘moderate’ than ‘mild’, with the term ‘moderate’ 
representing greater severity than ‘mild’. Five and 3 participants for the 
hypodermic and 180pm microneedles respectively, perceived mild ‘tender’ 
sensation, though no tenderness was experienced for the 280pm 
microneedles. The top 5 sensory modalities (that is, those words most 
frequently used by participants) from the adapted MPQ-SF are tabulated in 
Tables 3.3, 3.4 and 3.5 in order of the decreasing frequency for the 
hypodermic needle, 180pm microneedle and 280pm microneedles 
respectively.
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Figure 3.3. Sensory evaluation of each needle application using the adapted MPQ-SF. The adapted MPQ-SF descriptors were rated in order of 
increasing severity as ‘none’, ‘mild’, ‘moderate’ and ‘severe’. None of the participant rated any of the descriptors as being ‘severe’. Those 
sensations not showing a rating were rated as ‘none’.
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Table 3.3. Top 5 sensory expressions rated for the hypodermic needle as determined
by the participants’ responses to the MPQ-SF._______________ _________________
Sensation No. of participants Participant No.
Sharp n = 11
Mild n = 5 2, 4, 10, 11, 12
Moderate n = 6 1,3, 5, 7, 8 ,9
Pricking n = 11
Mild n = 7 1,2, 4, 6, 7 ,10,12
Moderate n = 4 3, 5, 8, 9
Stabbing n = 9
Mild n = 7 1,2, 4, 5, 6, 8, 11
Moderate n = 2 3,9
Pressing n = 8
Mild n = 6 2, 3, 6, 7, 9, 12
Moderate n = 2 5 ,8
Shooting n = 4
Mild n = 3 3, 5 ,6
Moderate n = 6 1
Table 3.4. Top 5 sensory expressions rated for 180pm microneedles as determined 
by the participants’ responses to the MPQ-SF._______________ _________________
Sensation No. of participants Participant No.
Pressing n = 11
Mild n = 4 4, 5, 8, 9
Moderate n = 7 1,2, 3, 6, 7,10,11
Heavy n = 7
Mild n = 3 3, 4,11
Moderate n = 4 1,2, 6 ,7
Pricking n = 6
Mild n = 6 2, 4, 5, 7, 8,12
Moderate n = 0
Stabbing n = 5
Mild n = 4 1,2, 5,9
Moderate n = 1 10
Sharp n = 5
Mild n = 5 2, 5, 7, 8,12
Moderate n = 0
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Table 3.5. Top 5 sensory expressions rated for 280pm microneedles as determined 
by the participants’ responses to the MPQ-SF.__________________________________
Sensation No. of participants Participant No.
Pressing n = 12
Mild n = 7 1,4, 5, 6, 9 ,11 ,12
Moderate n = 5 2, 3, 7, 8, 10
Heavy n = 7
Mild n = 6 2, 3, 6, 7, 9,11
Moderate n = 1 1
Sharp n = 7
Mild n = 7 1,4, 5, 7, 8, 9, 11
Moderate n = 0
Pricking n = 4
Mild n = 4 4, 5, 7, 8
Moderate n = 0
Stabbing n = 2
Mild n = 1 5
Moderate n = 1 10
3.3.2.3 Audio-recorded oral comments from participants during
application
Verbatim-transcribed comments (see Appendix IX) were read for each 
participant. Table 3.6, shows the pain and discomfort sensations as deduced 
from audio-recorded participant comments during and after the application of 
each device. The comments were tabulated based on whether the participant 
used the words ‘pain/painful’ or ‘discomfort/discomforting’ when describing the 
applications. Each comment from the 3 separate applications were compared, 
thus, for example Participant 1 comments suggested they felt most pain for 
the hypodermic needle, whilst the 280pm microneedles were least painful. 
The 180pm microneedles were not as painful as the hypodermic but more 
painful than the 280pm microneedles. Table 3.6 also shows the randomised 
application order for each participant and confirms that every participant found 
the hypodermic to be the most painful/discomforting of the 3 devices.
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Table 3.6. The pain and discomfort sensation as deduced from audio-recorded 
participant comments during and after the application of each device.__________
Participant & order of
Painful/ discomforting 
(Deduced from comments)
device (1st/2nd/3rd)
Least Middle Most
1 (280/hypo/180) 280 180 hypodermic
2 (hypo/280/180) 280 180 hypodermic
3 (hypo/180/280) 180/280 — hypodermic
4 (280/hypo/180) 180 280 hypodermic
5 (180/hypo/280) 280 180 hypodermic
6 (280/hypo/180) 280 180 hypodermic
7 (180/280/hypo) 180/280 — hypodermic
8 (280/180/hypo) 280 180 hypodermic
9 (180/280/hypo) 280/180 — hypodermic
10 (180/hypo/280) 180 280 hypodermic
11 (hypo/180/280) — 180/280 hypodermic
12 (280/180/hypo) 180/280 — hypodermic
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The microneedle arrays were perceived as being less painful or discomforting, 
though 5 participants felt the 180pm microneedle arrays were slightly more 
discomforting than the 280pm microneedle arrays.
For example, as Participant 5 explained:
"The second one (hypodermic) was the most painful, I could feel it the most 
Umm, the third one (280pm) I didn’t feel as much, but maybe that’s because I 
had the first two before. So I ’m maybe, again ’cause I ’ve had the first two I 
didn’t feel it, but the second one (hypodermic), oh, definitely the most painful. 
And I felt that one the most stabbing and it prickled it a bit".
3.3.2.3.1 Extracting key descriptions from the audio-recorded oral 
commentary
Analysis of the verbatim-transcribed, audio-recorded commentary (such a as 
shown in Appendix X) was used to identify key categories revealed from each 
participant’s transcript for each needle device (Tables 3.7 - 3.9) by calculating 
the frequency that these descriptors occurred in the audio comments. Square- 
bracketed words in Tables 3.7, 3.8 and 3.9 are to add clarity to the quotation 
from the transcripts. For example a participant may have indicated, ‘‘More 
discomforting than the last”, thus “the last” has been substituted with the 
device to which the individual referred in square brackets.
The oral commentary highlights that all participants found there to be greater 
sensation of pressure during either microneedle device application (Tables
3.7 and 3.8) compared to the hypodermic needle (Table 3.9).
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Table 3.7. Key description categories from oral commentary for the 180pm
microneedle device.
Transcript quotation Number of 
participants
Participant
number
No Pain 
(n=2)
No pain n = 1 12
Didn't hurt when put in n = 1 5
Slight pain n = 1 10
Pain
(n=4)
Dull pain n = 1 1
Not excessively painful n = 1 7
Hurt more when it was shaken n = 1 5
Discomforting
(n=3)
More discomforting than [280] n = 2 1 ,6
More discomforting than 
[hypodermic]
n = 1 6
Did feel slightly mild discomfort n = 1 12
Slightly sharp n = 2 1 ,2
Sharp
(n=6)
Slightly sharp towards the centre n = 1 7
Prickling n = 1 5
Little prick n = 1 4
Scratching the area n = 1 9
Pressing n = 2 2, 11
Big press n = 1 4
Firm pressing down n = 1 6
Pressure n = 2 1, 11
Pressure Quite a bit of pressure n = 1 10
(n=7) Quite a lot of pressure n = 1 10
Slight pressure n = 1 3
Continued pressure [during 
application]
n = 1 3
Heavy pressure pushing down n = 1 6
Greater feeling of pressure than 
280pm array
n = 1 1
Quite comfortable overall n = 1 4
Other
sensations
Feel it going in n = 1 6
Didn't really feel anything n = 1 5
Mild n = 1 1
Cold n = 1 2
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Table 3.8. Key description categories from oral commentary for the 280pm
microneedle device.
Transcript quotation Number of 
participants
Participant
number
No Pain 
(n=4)
No pain n = 3 2, 10, 12
Not painful n = 1 4
No sharp pain n = 1 2
Pressure n = 3 1 ,3 ,7
Dull pressure n = 1 1
Bit of pressure n = 1 8
Pressure
(n=9)
Lot of pressure n = 1 10
Pushing down n = 1 7
Pressing n = 2 2 ,6
Lot of pressing n = 1 11
Slightly heavier touch n = 1 12
Sharp
(n=3) Sharp n = 1 5
&
Pain
Less sharp pain increasing to 
more sharp pain n = 1 7
(n=1)
Tiny prick n = 1 4
Slight stinging n = 1 1
Gripping skin n = 1 7
Slightly heavier touch n = 1 12
Other
sensations
Feels like fingertip n = 1 8
Feels like point in centre of circle n = 1 12
Barely felt n = 1 4
No particular discomfort n = 1 1
Hurt less than hypodermic n = 1 5
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Table 3.9. Key description categories from oral commentary for the 25G hypodermic
needle.
Transcript quotation Number of 
participants
Participant
number
Pain
(n=5)
Very mild pain n = 1 12
Not a major pain n = 1 12
Really painful n = 1 6
Shooting pain on puncture n = 1 12
Sharp pain n = 2 1 ,9
A bit more painful [than the 280pm 
array] n = 1 4
Sharp
(n=5)
Quite sharp n = 1 6
Much sharper n = 1 5
Sharp scratch n = 1 2
Slightly sharper at start n = 1 7
Slight prick n = 1 3
Sharp prick n = 1 4
Pressure
(n=4)
Slight pressure n = 1 10
Pressure initially piercing skin n = 1 8
Less pressure [than 280pm array] n = 1 1
Pressing on skin n = 1 8
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The hypodermic needle was perceived as ‘sharp’ and ‘painful’. Oral 
descriptions from participants exemplify the variation in the sensation felt, for 
example “sharp” or “little prick”. The hypodermic needle only elicited 3 main 
descriptions of ‘pain’ ‘sharp’ and ‘pressure’ (Table 3.9) when compared to 
either microneedle devices, which described using a greater number of other 
sensations. Comparison between the microneedle devices reveals the 180pm 
microneedles elicited a greater ‘sharp’ sensation than the 280pm 
microneedles. Whilst the 280pm microneedles were described as being less 
‘discomforting’ than the 180pm microneedles.
3.3.2.4 Evaluative overall pain index (EOPI) scoring by participants
The EOPI was the final assessment of the adapted MPQ-SF. This related to 
the level of pain felt on an increasing integer scale of ‘no pain = O’, ‘mild = 1’, 
‘discomforting = 2’, ‘distressing = 3’, ‘horrible = 4 ’, and ‘excruciating = 5’. 
Table 3.10 collates the data from each participant to show the level of overall 
pain perceived by the application of each needle device. The hypodermic 
elicits the greatest level of pain, with 8 participants scoring the pain as 
‘discomforting’ whilst the 280pm microneedle was scored as ‘no pain’ 
by 10 participants.
3.3.2.5 Additional comments provided by participants after all the 
devices were applied
Each participant was asked to comment generally after all 3 needle devices 
had been applied: “Were there any additional comments you wanted to make 
in relation to the three devices or what just happened?”
94
Table 3.10. EOPI was scored for each needle device at the end of the adapted MPQ-
SF by participants. _____________________________________________________
Needle device 
180pm | 280pm | Hypodermic
EOPI Score Total number of participants 
(Participant number)
0 No pain 6
(3,4,7,8,10,11)
10
(1,2,3,4,6,7,8,10,11,12)
-
1 Mild 4
(5,6,9,12)
2
(5,9)
4
(1,2,7,10)
2 Discomforting 2
(1.2)
8
(3,4,5,6,8,9,11,12)
3 Distressing - -
4 Horrible - - -
5 Excruciating - - -
The verbatim transcripts, Table 3.11, show that only Participant 9 did not 
make any additional comments, whilst some participants commented 
generally on both microneedle devices as either being similar or when 
compared together against the hypodermic needle.
Summarising the transcripts of the oral commentary made post-application of 
each device (Table 3.11) in order of discomfort (Table 3.12) highlights the 
least discomfort or pain was caused by the 2 microneedle devices, whilst the 
hypodermic needle caused the greatest pain or discomfort. Four participants 
found the 180pm and the 280pm microneedle devices to be of similar 
discomfort, whilst another 5 participants felt the 280pm microneedles were 
less painful than the 180pm array and the hypodermic.
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Table 3.11. Verbatim transcribed oral comments made by each participant immediately post-application of all three needle devices
“ Were there any add itiona l com m ents you wanted to  make in re la tion to  the three devices o r w hat ju s t happened?”
280pm m icroneedle 180pm m icroneedle 25G hypoderm ic needle
1 Erm, the first one (280) was the easiest to 
tolerate. Erm there is more a feeling of 
pressure, more like somebody’s just 
pushing onto the skin without actually 
breaking the skin.
The last (180) umm application felt heavier and more 
pressure. Same kind of feeling as the first one (280), 
umm with perhaps just err bit more of err err pressure 
pain in the middle, perhaps just a sharp in the middle. 
So like the first one (280) but it felt like perhaps its 
pushing a bit deeper."
Umm the second one (hypodermic) felt like a 
sharp needle application, so sort of you know a 
sub cut injection. Umm it was sharp, and as as 
uncomfortable as subcut injections normally are. 
Umm not crazily discomforting.
2 The second one (280) was the least painful, 
or anything like that «N o  Comment» The first one (hypodermic) was the normal needle
3
Umm in terms of the, the second (180) and third (280) applications were similar. Umm there was no 
pain at all, umm it was just pressing, but I wouldn’t say it was a pain sensation. There was just a 
sensation of pressing down on the skin. So the last two (180, 280) were the most comfortable out of 
the three."
I thought the first (hypodermic) was hypodermic 
needle. Erm when it entered the skin there was, 
there wasn’t so much pressing, but there was 
more of err, there was a slight pain and it 
continued and umm that lasted until, until it was 
removed. It was quite cold as well.
4
Err, err, I barely felt the first one (280). But I 
did feel a tiny pricking sensation (for the 
280),
Umm third one (180) perhaps the most comfortable. 
Out of all the three I would probably prefer the third 
one (180) for an injection. "Err, I felt no the side 
effects apart from the odd press in the third one (180) 
and prickly sensations at times but that’s it.
Out of those three I probably thought the second 
(hypodermic) was the most uncomfortable.
5 Umm, the third one (280) I didn’t feel as 
much, but maybe that’s because I had the 
first 2 before.
«N o  Comment»
The second one (hypodermic) was the most 
painful, I could feel it the most, second one 
(hypodermic), oh, definitely the most painful. And I 
felt most were stabbing and it prickled it a bit
6
the first one (280) was like someone 
holding onto your arm
Erm, third one (180) felt as if it was being pressed 
down harder,
Erm, you could tell quite easily the second one 
(hypodermic) was the needle. That was definitely 
more uncomfortable than the other two. You could 
actually feel it in terms of it going into you.
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Table 3.11 Continued.
“ Were there any add itiona l com m ents you wanted to  make in re lation to  the three devices o r w ha t ju s t happened?”
280pm m icroneedle 180pm m icroneedle 25G hypoderm ic needle
7
I think the first two (180, 280) felt fine because pressure doesn’t feel as bad as this sharp. The first 
two (180, 280) were fine and not a lot of difference between the two.
Well I suppose you would it as a pain, a sharp 
pain on the third one (hypodermic) like your skin’s 
being nipped. But I think the third (hypodermic) 
was the worst.
8
You can sense that are the pricks there. 
Umm, that’s more for the first one.
Umm, yer you felt very different to, the application 
two (180) felt more, umm, you could feel it more. If 
that’s of any help"... "yer you could tell that more 
pressure was being applied, umm, and you could 
feel. I suppose the only way of describing it is if you 
get like err, like some leaves and they’ve got little 
prickly things on the back and you are pressing on 
them. Like a nettle leaf but without the actual sting in 
it. So you can feel that its gone in, it feels a bit like 
that so the more you press on it the more prickly but 
again it doesn’t feel painful. You can sense that are 
the pricks there.
Well the third application (hypodermic) you could 
tell was quite different to the other two, umm, and 
it did feel like pain a needle if I am honest. Umm, 
so I could feel it going in. felt far more sort of 
penetrating than the other two
9 « N o  Comments»
10 The first (180) and the last one (280), they were similar. Couldn’t feel any pain, could feel 
sensation and a lot, a lot of pressure.
There was probably actually slightly more pressure on the last one (280)."
The second one (hypodermic) was painful, then slightly 
painful.
11 The third one (280) was like a mixture 
between both."
The second one (180) was more intense 
pressing First one (hypodermic) was really sharp
12
I would definitely go for one of the first two (280, 180). Umm, err, I can’t really remember 
which one out of the first two was the least actually, umm but I think they were pretty, you 
know they were quite close by. Umm, yer so the first two (280, 180) were better.
least favourite was the last one (hypodermic), umm which 
well obviously I didn’t see but I am pretty confident that’s 
the standard sort of hypodermic needle, umm. Yer that was 
my least favourite cause that felt, that was quite.
Third one (hypodermic), yer, uncomfortable but not 
intolerable
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Table 3.12. Audio-recording of participants from Table 3.11 summarised depending 
on which device the participant indicates least discomfort. (280MN = 280pm length 
microneedles; 180MN = 180pm length microneedles; 25G = 25G hypodermic needle)
Least discomforting No. of participants Participant No.
280MN n = 5 1,2,5,6,8
180MN n = 2 4, 10
180MN = 280MN n = 4 3,7,9,12
Less than 25G, but not differentiated between 
microneedle devices.
n = 1 11
3.4 Discussion
In this clinical study, three main methods of data collection were used to 
determine the pain and sensation felt by participants by the application of 
three needle devices to their buttock. The audio commentary complimented 
the pain questionnaire and gave a more in-depth view of what each 
participant was experiencing during each application. The level of discomfort 
felt by each participant corroborated the quantitative visual analogue (VAS) 
data in identifying the hypodermic needle as the most painful and 
uncomfortable device. Oral commentary supports this well by detailing the 
exact perceptions with key details and analogies given by the participants.
Pre-clinical development of the clinical trial methods helped to refine the 
application of the VAS and MPQ-SF to this clinical study. When testing the 
applicator designs for the microneedle arrays (Chapter 2) the VAS was 
conducted using a traditional 10cm horizontal line, however for the clinical 
trial, an electronic slider with a digital display was used as a simple instrument 
to make real-time measurements of VAS, rather than measure a marked point 
on a horizontal line later. The digital VAS meter used during this study is used 
regularly in clinical practice and is designed to be free moving whilst providing 
accurate (+/-0.01cm) measurement of the distance the slider moves.
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Investigation by Woods et al. (2009), Jamison et al. (2002) and 
Price et al. (1994) compared different paper-based and computer-based 
analogue scale methods of collecting VAS data and found these to be valid 
and functionally interchangeable.
Importantly however, this study confirms that the sensations, including pain, 
felt from the applications of the silicon microneedle devices were relatively 
similar, and in each case significantly lower than for the hypodermic needle. 
VAS can be scored from 0cm to 10cm, though the mean for the hypodermic 
needle never reached over 2cm. Thus, even the hypodermic needle is not as 
painful as the pain caused by chronic or extreme acute pain (Choiniere and 
Amsel 1996). Indeed any pain experienced during this study was of a 
transient nature and at worst was non-severe in its nature. The VAS illustrates 
that pain associated to the use of all 3 needle devices in relation to a 
participant’s individual experiences is relatively low. Only Participant 5 rated 
the 180pm microneedles pain intensity as greater that 2cm, whilst 3 
participants (Participants 5, 9 and 11) rated the hypodermic needle to have a 
pain intensity of over 2cm on the VAS.
As the VAS was taken immediately after each application, prior to any other 
measurement, the participant was able to register their current feeling in 
relation to the “Worst Pain Imaginable”. Therefore, VAS was an important and 
highly sensitive way of capturing pain intensity, at the instance of application. 
Bergh et al. (2009) and Kelly et al. (2001) found the VAS to be a highly 
sensitive and reliable measure of pain intensity. Kelly et al. (2001) defined all
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VAS rating under 30mm as ‘mild pain’, 70mm or more were defined as 
‘severe pain’ and 31mm to 69mm as ‘moderate pain’. Whilst this may help 
characterise pain intensity it reduces the ability to observe smaller inter­
participant variations between needle devices, however it does show, when 
compared to other types of pain, that the pain from microneedle and 
hypodermic needles is relatively low.
As all sensation and perception assessments are highly subjective, these 
scales are of most value when comparing intra-participant changes rather 
than inter-participant changes. Where small groups of participants are being 
studied, and a significant treatment effect is found, it is important to consider 
what proportion of participants were accountable for the significant group 
affect. This study consisted of only 12 participants, each with their own 
interpretation and perception of what they felt during application of the 
devices. Therefore, it is difficult to examine the reproducibility of VAS in terms 
of inter-participant reliability, however a lack of correspondence between 
scores may be due to genuine differences in individuals' interpretation of the 
scale.
The VAS data shows that 5 participants registered more pain for the 180pm 
microneedles compared the 280pm microneedles, though it may initially seem 
illogical that the shorter 180pm microneedles caused greater pain than the 
280pm microneedles, a simple explanation is that this result is an artifact of 
the application process. As this study demonstrates (Chapter 3 and 4), the 
pain responses are based on an application technique that was previously
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tested in ex-vivo studies (Chapter 2) to ensure sufficient penetration of the 
stratum corneum to facilitate drug delivery. The amount of application force 
required to provide reliable skin penetration is analogous with the force used 
to massage an aching muscle. Extensive ex-vivo studies have clearly 
demonstrated that smaller microneedles, such as 180pm in length, need to be 
applied more firmly to the skin than the longer 280pm microneedles to ensure 
satisfactory skin penetration. Therefore the physician in this clinical study was 
trained to administer the shorter 180pm microneedles with more force. Future 
research to develop a suitable application device for consistent and 
reproducible application of microneedles may standardise clinical application.
Microneedle morphology, applicator design and application techniques could 
be responsible for increased sensations. Adapted MPQ-SF results determine 
the microneedle applications as being perceived as more ‘pressing’ and 
‘heavy’ than the ‘sharp’ and ‘pricking’ hypodermic needle application. These 
perceptions may be related to the surface area of the microneedle array. As 
microneedles are spread over a larger surface area than a single hypodermic 
needle, they may require more force to penetrate the skin. The hypodermic 
needle, however, was applied by the clinically accepted subcutaneous 
technique and though using finer needles could reduce pain, they will still 
enter deeper into the dermis than the microneedles, thus activate pain 
receptors. Sensation responses from the adapted MPQ-SF and oral 
commentary suggest that reducing the force required for microneedles to 
penetrate the stratum corneum would benefit patients and could be achieved
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by improvements in the microneedle array design, application device and 
technique.
A secondary pain assessment, the evaluative overall pain index (EOPI), was 
rated by participants relative to their overall pain experience at the end of the 
adapted MPQ-SF. Only 2 of the 12 participants reported the 180pm 
microneedles as ‘discomforting’ compared to the 280pm microneedles. Using 
the EOPI, 10 participants rated the 280pm microneedles as exhibiting ‘no 
pain’. Even the hypodermic needle was not rated to be greater than 
‘discomforting’. When compared to VAS, where 5 participants felt the 180pm 
microneedle device was more painful than the 280pm microneedle device, 
only 2 of these 5 participants rated the 180pm microneedles as more 
‘discomforting’ than the 280pm microneedles. Though a total of 8 participants 
also rated the hypodermic needle as ‘discomforting’. This difference in VAS 
and EOPI could be because participants had approximately 5 minutes to 
consider what they felt as they answered the adapted MPQ-SF.
Furthermore, unlike the VAS, which is a continuous sliding scale, the EOPI is 
a psychometric response scale, in which a person is asked to select a 
category label from a list indicating their perception. These labels have 
integers of 0-5 assigned with increasing pain (Melzack 2005, 2001; Wright et 
al. 2001). However the words used may be distinguished differently by 
individual participants, therefore some may feel that a device is more 
‘discomforting’ (integer two) than ‘mild’ (integer one) despite feeling that the 
‘mild’ device is in fact less painful than the ‘discomforting’ one. Indeed the
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EOPI is more complex and defined measure of pain, which may confuse the 
respondent, as it requires more thought than VAS (Fabbri et al. 2009; Katz 
and Melzack 1999; Wright et al. 2001).
The adapted MPQ-SF (Appendix VIII) was used in order to learn more about 
the types of sensations felt during the application of each microneedle or 
hypodermic needle device. In normal clinical use, the standard MPQ-SF 
(Melzack, 1975) is repeated at each clinical examination over the duration of 
care (Melzack 1987). Each level of pain or sensation intensities are used to 
compare between clinical assessments. Each clinical assessment is used to 
measure improvements or worsening of the medical condition and helps to 
determine the effectiveness of any intervention (Melzack 2005; Mystakidou et 
al. 2002; Wright et al. 2001). However, measuring the pain and sensation of 
three needle devices required one-off immediate responses post-application 
of the devices, thus multiple intra-participant comparisons of MPQ-SF scores, 
such those in Chapter 2 (Melzack 1987; Wright et al. 2001) were not required. 
Moreover, pain and sensations felt by the application of both the microneedle 
devices and the hypodermic needle were measured using the adapted MPQ- 
SF.
The adapted MPQ-SF included three key adjectives that were mentioned by 
participants in the pre-clinical applicator design testing (Chapter 2) and are 
also present in the MPQ (Melzack 1975). Therefore, ‘pressing’, ‘pricking’ and 
‘cold’ were included as a subsection of the adapted MPQ-SF in the CRF 
(Appendix VIII). These words were not originally tested by Melzack (1987) for 
the MPQ-SF, thus it would be invalid and unreliable to assign them to either
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the “sensory” or “affective” categories. Hence, quantified scoring would not 
have been validated for the context in which the adapted MPQ-SF was 
applied in this study.
Subsequent transient pain studies should test the adapted MPQ-SF further; 
possibly redevelop a new questionnaire for transient pain based on the MPQ- 
SF but with other key adjectives, which could be determined from a survey of 
transient pain. This would require extensive testing and validation to ensure 
reliability for use across varying sources of transient pain (Leonard et al. 
2009; Macmillan et al. 2008; Mystakidou et al. 2002). Validation of such a 
questionnaire may be excessive considering the pain and sensations 
measured would be transient in their nature and potentially with no long-term 
effects.
As detailed in Section 3.2.6, the order of sensory assessment was VAS 
followed by the adapted MPQ-SF, whilst audio-recorded oral comments, were 
recorded real-time during each needle device application. The researcher has 
then summarised these comments into an order of pain or discomfort 
depending on what was said by the participants (Table 3.6), though care must 
be taken to ensure over analysis of the commentary does not occur as this 
may lead to the assessor incorrectly interpreting the participants’ comments.
Analysis of the oral commentary, where only one participant made a specific 
comment, cannot be used to evidence generalised conclusions. However, 
audio recording did increase the level of detail of the type of pain and 
sensations experienced by participants during applications of the needle
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devices. These comments increased the integrity of the data (Werner and 
Benrimoj 2008) and correlated well to the adapted MPQ-SF as key sensory 
modalities such as ‘stabbing’, ‘sharp’, and ‘pressing’ were spoken by the 
participants during application of the devices and later marked on their 
questionnaire. As participants were exposed to the questionnaire after the first 
application, it is possible that they recalled some of the adjectives at the 
second and third applications, and therefore used the same or similar words 
to orally describe the application processes (Fabbri et al. 2009; Fischer et al. 
2009).
Each participant was audio recorded throughout the entire application 
process. The oral commentary represents the equivalent of a verbal diary for 
the duration of the application processes (Munyard et al. 1994). The audio 
recordings taken during the applications describe the timeline and real-time 
sensations as felt and vocalised by the participants. The depth of these 
descriptions is based solely on the parts of the application experience the 
participant chose to vocalise, as they were not prompted. Participants were 
instructed to say if they felt “nothing” for every stage of the applications and 
MPQ-SF, some might have refrained from speaking it due to experiencing 
some sensation that they were unable specifically describe orally. Differences 
in oral comments will have also depended on the participants’ oral ability and 
their depth of vocabulary (Arber 2007; Sokunbi et al. 2008; Zollo et al. 2009). 
Thus care needs to be taken not to ‘over-analyse’ the audio-recorded 
commentary.
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Despite audio recording throughout the whole procedure, from the 
applications of devices through the adapted MPQ-SF to the final comments, it 
is important to note that the participants were not instructed to provide a 
commentary at any stage other than during the application of each needle 
device and to comment after all 3 devices had been applied. Indeed, 
Participants 3, 5, 6 , 8 , 11 did not make oral comment (Appendix X) during the 
VAS or MPQ-SF assessments. Therefore, audio-recorded data at any stage 
other than the application or final comments cannot be used for inferring any 
differences in the inter-participant understanding of VAS or MPQ-SF as 
instruments for measuring pain and sensation. Further studies should instruct 
participants to comment at each stage. If they have no comment, they should 
be reminded to say “no commenf.
Each participant will have had differing experiences of pain, though past 
needle-related history was checked only to ensure they were not needle 
phobic. None of the participants admitted to being needle phobic, however, 
psychological factors may have increased the ‘fear factor’ to hypodermic 
needles (Deacon and Abramowitz 2006; Fassler 1985; Kettwich et al. 2007; 
Nir et al. 2003). Pain is subjective and how the participants’ perceived the 
needle devices depended on how much pain they had experienced in the past 
and also how much pain they could imagine. Therefore, despite single-blind 
application of each device to ensure the participant was uncertain of 
application order, participants may have been able to distinguish between the 
microneedle devices and the hypodermic needle at the very early stage of 
application, which may have reduced or increased tension during the 
subsequent application stages. This is a limitation of pain assessment as it
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involves qualifying or quantifying an individual’s unique personal perception. 
Despite this, the variability of inter-participants VAS scores post-application of 
needle devices was minimal. However, importantly, this research used intra­
participant comparisons to establish relative pain of each needle device.
Chapter 2 assessed applicator design on the volar forearm, whilst the clinical 
application of microneedle arrays was conducted on the buttock. 
These 2 areas of the body vary in their adiposity whereby the buttock had 
greater fat tissue and skin flexibility on young adults (Schilling and Wechsler
1986), whilst the volar forearm may have lower follicular concentration (Boles 
et al. 2000). Ideally any future testing of applications and applicators should 
be conducted at the same anatomical site to maintain consistency.
A further limitation of this study was that in clinical use, microneedles and the 
hypodermic needle would be used to administer an active ingredient. If a 
substance or combination of substances were to be delivered via 
microneedles, then pre-clinical animal and ex-vivo studies would have to be 
conducted to repeatedly show the proposed treatment to be safe and effective 
for use with humans (HMSO 2004). The human body processes and reacts to 
medicaments and medical devices in different ways to cells, excised tissues 
and animal models (Furuzawa-Carballeda et al. 2009; Gonzalez et al. 1999; 
Hwang et al. 2009; Kraemer et al. 2009; Swindle et al. 2003). When a 
hypodermic needle injects a solution into the epidermal and dermal tissues, 
which are forcibly displaced by the mechanical pressures and chemical 
properties of the solution injected. This can cause an increase in sensory 
activations; therefore, future studies should look at the overall scenario of a
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medicament being delivered via needle or microneedle injection in clinical 
use.
This pilot study has shown that even the pain caused by a 25G hypodermic 
needle is less than a VAS score of 3cm for each participant (Figure 3.2). 
Therefore future studies should establish what other factors, regardless of 
pain, affect vaccination delivery and uptake, and how microneedles can play a 
pivotal role in vaccination delivery. Future clinical studies assessing the 
administration of a drug using microneedles should consider incorporating a 
sensation questionnaire and audio recording of sensations during and after 
the administration process. This can serve to highlight the differences in 
sensations when a substance is administered transdermally in relation to the 
specific application technique. Focus group research to establish the 
detrimental and beneficial effects of specific sensations in patient groups 
could improve microneedle and applicator device design. This in turn may 
increase availability, acceptance and use of microneedles by clinicians and 
patient.
3.4.1 Conclusions
This study has shown that hypodermic injections are perceived as significantly 
more painful than microneedles, though currently microneedles still cause 
some pain and discomfort due in part to the application technique, which 
needs to be developed further for consistent applications. Whilst pain and 
sensation data acquired by audio recording complimented the pain 
questionnaire data, key descriptors, of ‘pressing’ and ‘heavy’ emerged as
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areas where the applicator design and application technique of microneedles 
could be improved to reduce discomforting sensations.
109
Chapter 4
The physical and biochemical effects of in-vivo 
microneedle administration on human volunteers
during a clinical study.
4.1 Introduction
Chapter 3 introduced the element of the clinical study focussing on pain and 
other sensory modalities caused by clinical microneedle administration. 
Chapter 4 aims to further assess microneedle efficacy and safety in relation to 
the nature of the punctures created in-vivo by 180pm and 280pm 
microneedles versus those created by 25G hypodermic needles. Microscopy 
and transepidermal water loss (TEWL) will enable observation of the physical 
changes in skin barrier caused by needle puncture (Badran et al. 2009; Bal et 
al. 2008; Verbaan et al. 2007). Simultaneously biochemical evaluation using 
immunohistochemistry (IHC) will highlight changes in inflammatory and 
proliferation markers (Freedberg et al. 2001; Hakvoort et al. 2000; Patel et al. 
2005).
Despite microneedles penetrating the skin, previous studies have shown that 
microneedle application to skin does not cause significant pain (Bal et al. 
2008; Gill et al. 2008; Sivamani et al. 2005). Information on the extent and 
nature of the wound responses resulting from administration of these devices 
is however lacking. Given that microneedles are being developed to deliver 
therapeutics and vaccines cutaneously (Birchall et al. 2005; Ding et al. 2009; 
Hantash et al. 2009; Pearton et al. 2008), it is essential to establish the skin’s 
response to the injury, especially as any alteration in the integrity of the skin 
might lead to pathogenic invasion or release arising from the cellular damage 
(Elias and Choi 2005; Pedersen and Jemec 2006; Poindexter et al. 2006; 
Sorensen et al. 2003). Therefore, it is important to compare the microneedle 
wounds to conventional hypodermic needle wounds from a physical and
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biological perspective to distinguish between the localised wound responses 
at puncture sites for each needle device.
4.1.1 Assessing skin puncture using Transepidermal Water Loss 
(TEWL), Methylene blue and haematoxylin and eosin (H & E) 
staining
As well as investigating wound healing post-application of microneedles, a 
measure of biological disruption, the skin will also be assessed to establish 
whether the microneedles have successfully penetrated the skin surface 
during clinical application, a measure of physical disruption. TEWL has been 
described in Section 1.1.2 and used to assess skin barrier disruption caused 
by the application of microneedles to human volunteers (Bal et al. 2008). 
TEWL combined with topical staining, using a blue dye, immediately post­
application of microneedles has also been used to determine skin penetration 
by microneedles ex-vivo (Ding et al. 2009). Chapter 4 aims to use TEWL 
measurements and external dye staining to confirm that microneedles of 
280pm and 180pm length puncture the skin of human volunteers.
Methylene blue is a hydrophilic, tricyclic phenothiazine dye with the chemical 
formula C6H18CIN3S and molecular weight of 319.85. Once in solution 
methylene blue forms a deep blue colour; the solubility of methylene blue is 
3.55g/100ml of water and 1.5g/100ml of alcohol. In aqueous solutions, 
methylene blue is present as a monomer and dimer, thus has two absorption 
peaks at 668nm and 609nm. When applied topically to skin, methylene blue 
does not diffuse through the hydrophobic lipid-rich corneocytes that comprise 
the stratum corneum (SC). Once methylene blue has penetrated the SC, 
methylene blue ions interact with proteins present in cellular membranes and
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interstitial fluid (Clifton and Leikin 2003; Genina et al. 2008; Little 1990; 
Mordon et al. 2003; Simmons et al. 2001; Talreja et al. 2001). Methylene blue 
has been extensively used as a topically applied stain to visualise the cellular 
layers of the stratum corneum (Clifton and Leikin 2003; Dykes et al. 2001; 
Zhai and Maibach 1996); highlighting cancers and lymph nodes (Simmons et 
al. 2001; Yaroslavsky et al. 2005) and surgical skin marking (Granick et al.
1987). Methylene blue has also used in the laboratory setting to monitor the 
affect of electric-pulse skin penetration (Johnson et al. 1998) and identify skin 
microconduits created by radio frequency wave ablation (Levin et al. 2005), 
microinjection (Noori et al. 2009), and microneedles (Coulman et al. 2010; 
Escobar-Chavez et al. 2010; Fernandez and et al. 2009; Gill and Prausnitz 
2007; Kolli and Banga 2008; Lee et al. 2011; Li et al. 2008; McAllister et al. 
2003; Mikolajewska et al. 2010; Pearton et al. 2010).
Tissue sectioning and counterstaining is used to highlight changes in skin 
strata and cells following puncture (Coleman 2006; Titford 2005). 
Haematoxylin (H) has an affinity for the nucleic acids of the cell nucleus whilst 
eosin (E) highlights the cytoplasm of cells. H & E staining therefore permits 
visualisation of morphological and numerical changes in viable cell 
populations. H & E can be applied by either leaving slides in a solution for a 
set time and then washing through solutions of acid-alcohol, or progressively 
by dipping the slides into stain solution until the required intensity is obtained 
(Coleman 2006; de Boer et al. 2007; Titford 2005; Tuli et al. 2006). Adjusting 
incubation times during joint staining enables variation in the contrast between 
cell nuclei and cytoplasm to enable clear visualisation.
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4.1.2 Wound healing processes due to minor injury in the skin
As detailed in Section 1.1.2, wound healing involves numerous complex 
processes involving cytokine and growth factor driven migration of 
keratinocytes (Diegelmann and Evans 2004; Kiritsy and Lynch 1993; Kondo 
2007). As described in Chapter 1 the skin is comprised of several separate 
layers. The most prevalent skin cell, the keratinocytes, interact with fibroblasts 
to coordinate a normal wound healing response that leads to scar formation. 
(Diegelmann and Evans 2004; Ejaz et al. 2009; Suter et al. 2009).
Skin healing is modulated by a plethora of cytokines and chemokines, which 
initiate and drive inflammation, proliferation and remodelling, to heal the skin 
(Barrientos et al. 2008; Freedberg et al. 2001; Spiekstra et al. 2007; Yager et 
al. 2007). During the clinical study (as described in Chapter 2) skin biopsies 
were taken from participants over a 24-hour period post-penetration by the 
three different needle devices. The wound healing responses investigated in 
this chapter will be inflammation and keratinocyte proliferation, which have 
both been shown to occur within the first 24 hours after wounding (Bacci et al. 
2006; Gillitzer and Goebeler 2001; Patel et al. 2005).
Inflammation occurs almost immediately after skin wounding. Cytokines such 
as TNF-a, IL-1p and TGF-p1 are released from epidermal cells to act as key 
inflammatory mediators (Barrientos et al. 2008; Gordon et al. 2009; Kondo 
2007; Li et al. 2007). These cytokines manipulate fibroblast and keratinocyte 
functions thereby controlling the proliferation and migration of keratinocytes to 
the wound bed (Barrientos et al. 2008; Spiekstra et al. 2007; Werner et al. 
2007). If any vasculature is damaged, neutrophils released from the leaking
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capillaries express TNF-a soon after wounding and induce other chemokines 
(Barrientos et al. 2008; Gillitzer and Goebeler 2001; Hertle et al. 1995; Sarret 
et al. 1992; Suter et al. 2009). During the later stages of wound healing, 
macrophages also express TNF-a (Paladini et al. 1996; Smith 2003; Smoller 
et al. 1989). Therefore given its intimate involvement in the inflammatory 
response, TNF-a provides a suitable marker for observing inflammation post- 
wounding by microneedles or hypodermic needle.
Pro-inflammatory cytokines and growth factors also affect the epidermal cells, 
activating keratinocytes above the basement membrane through altering 
keratin expression (Coulombe 2003; Coulombe et al. 1998; Hesse et al. 
2000). Keratins are either type I or II intermediate filament proteins which are 
expressed in pairs to form cytoskeletal structures within epithelial cells (Moll et 
al. 1982). Type I and type II keratin proteins are encoded by a multigene 
family (425 members each) and heteropolymerise with one another to 
produce intermediate-sized filaments in the cytoplasm of epithelial cells 
(Fuchs and Weber 1994). Type I keratins (K9-K21) range from 40 to 63kDa 
and are more acidic, whereas type II keratins (K1-K8) are larger (53-67kDa) 
and more basic (Paladini et al. 1996; Wawersik et al. 1997).
In normal healthy skin, K5 and K14 complexes are constitutively expressed in 
all keratinotcytes, however, only inactive epidermal keratinocytes express K1 
and K10 complexes (Cheng et al. 2008; Coulombe 1997; Suter et al. 2009). 
Shortly after wounding, keratinocytes proximal to the wound edge undergo 
cytoskeletal and morphological changes characterised by the down-regulation 
of K1 and K10 expression and increased expression of K16 and K17
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(Freedberg et al. 2001). Human cytokeratin 16 (K16; 48kDa) is of particular 
interest as it is constitutively expressed in keratinocytes in a variety of 
epithelial tissues and known to be upregulated during hyperproliferation or 
abnormal differentiation of epithelial cells (Freedberg et al. 2001; Paladini et 
al. 1996; Usui et al. 2008). Within 4 to 6 hours post-wounding, activated 
keratinocytes drive hyperproliferation of inactive keratinocytes at the wound 
edge by autocrine release of cytokines (Coulombe 1997). As the expression 
of K16 and K17 increases, between 6 to 24 hours post-wounding, the 
activated keratinocytes are less adhesive and migrate into the wound site 
(Freedberg et al. 2001; Usui et al. 2008). Subsequently, the wound site is 
populated by newly differentiated keratinocytes which return to their stable 
state expressing keratins K1 and K10, thereby restoring the skin’s protective 
barrier function (Freedberg et al. 2001; Paladini et al. 1996; Usui et al. 2008). 
In this chapter we aim to identify changes in K16 expression to explore the 
activation status of keratinocytes within the first 24 hours after application of 
microneedle devices and hypodermic needles in human volunteers.
4.1.3 Aims and Objectives
This study aims to characterise any wound healing repair responses apparent 
during the first 24 hours after microneedle or hypodermic needle application to 
human volunteers.
Objectives:
• To observe the penetration and closing of microneedle and hypodermic 
needle punctures up to 24 hours post-application using skin surface 
staining and transepidermal water loss (TEWL).
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•  To assess and characterise the architecture of the skin post-needle 
application using H & E staining.
• To establish if the known wound healing marker, K16, is up-regulated 
during the initial 24 hours post-application.
• To investigate the inflammatory response caused by microneedles and 
hypodermic needles by assessing the presence of TNF-a.
• To assess the impact of the microneedle or hypodermic puncture on 
activation and migration of dendritic cells.
•  To consider the structural integrity of the microneedles after a single 
application to human skin.
4.2 Materials and methods
4.2.1 Materials
Acetone; Dry Ice; Ethanol 99.8+% absolute duty free for HPLC CertiFied 
HPLC; Phosphate buffered saline (PBS); CD68 Dako Clone EBM11, Anti- 
Human Monoclonal Mouse, Dako (Ely, UK); K16 antibody Dako staining kit, 
Dako (Ely, UK); Canon IXUS 500 digital camera (Canon, UK), Dermatoscope, 
Methylene blue dye, propranolol hydrochloride (Fisher Scientific UK Ltd, UK), 
25-gauge hypodermic needles; 2% lignocaine with adrenaline local 
anaesthetic (Fisher Scientific UK Ltd, UK); 280pm and 180pm length 36- 
pyramidal solid microneedle arrays (Tyndall National Institute, Ireland). 
Tewameter, Courage & Khazaka GmbH (Koln, Germany).
All reagents were obtained from Fisher Scientific UK (Loughborough, UK) 
unless otherwise stated.
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All materials for IHC were obtained from RA Lamb Limited (Eastborne, UK), 
these include Optimal cutting tissue compound embedding media (OCT); 
Histobond adhesive microscope slide. Haematoxylin Gurrs’ Eosin aqueous 
solution 1%; Histomount, xylene (low sulphur) were obtained from Lab 3 
(Bristol, UK).
4.2.2 Ethical and consent approval
Prior to beginning the study, the study protocol (Appendix III) was submitted 
for ethical approval from the Gwent Healthcare NHS Trust R&D Committee 
and the South East Wales Research Ethics Committee (SEWREC). Ethics 
approval for the study was granted and Informed consent was obtained from 
each participant as in adherence with the Declaration of Helsinki. A written 
explanation of the study was provided before each participant’s first visit. 
Participants signed consent forms (see Appendix VIII) at the first visit after the 
nature of the study had been fully explained and were informed that they 
could withdraw from the study at any stage without any explanation.
4.2.3 Summary of the trial day methodology for transepidermal 
water loss (TEWL) measurement and skin biopsy
Participants visited St. Woolos Hospital on three separate occasions for 
TEWL measurements, whereby a TEWL reading was taken from the three 
sites of needle device application. A fourth visit was required for biopsies to 
be taken of the 3 application sites.
TEWL was measured using a Tewameter (Courage & Khazaka) (Figure 4.1) 
at 4 time points: immediately baseline, immediately post-application and 
at 8 and 24 hours post-application.
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The Tewameter TEWL probe is a delicate measuring device, which must be 
protected from shock, dirt and liquids at all times, and therefore was kept 
covered by a cap at all times when not in use. The sensors were never 
touched and care was taken to only hold the handle at the farthest point from 
the sensory end. Air-conditioning maintained the room temperature at 22°C 
and relative humidity of 45 ± 5%.
Figure 4.1. Tewameter® TM 210 was used for measuring TEWL.
The participant’s buttock was not exposed to strong sunlight, heat sources or 
air circulation, as these may have effected with the transepidermal water loss 
rate. Each participant was asked to not bathe or wash those areas of their 
buttock for the 24 hour period.
4.2.3.1 Participant preparation to measure TEWL
The participant was asked to lie comfortably and relax on their front or side 
with their marked buttock region exposed for 15 minutes prior to any readings 
being taken. The Tewameter probe was placed horizontal onto the skin
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surface and a clamp was used to secure the probe onto the skin. This 
prevented any interferences arising from hand movement or heating of the 
probe by the assessor’s hand.
4.2.3.2 Measurement of TEWL
Once the participant was comfortable the probe was positioned over the skin 
region to be measured. Using the clamp the probe was lowered onto the 
surface of the skin so the cylinder on the sensory end of the probe was 
vertical and resting gently on the skin surface. Throughout the measurement 
time, talking was not permitted and a notice was placed on the door to prevent 
entry, which would upset the airflow around the probe.
The measurement was performed for three minutes. The average TEWL of 
the previous 20 seconds and the standard deviation were recorded in the 
case report form (CRF) (Appendix VIII). The units of measurement 
are gm H20/sq.m/hour.
If there were any uncharacteristic spikes during the last 20 seconds of the 
3 minutes, the cursor was used to move to a more representative 20 seconds 
of the overall 3 minute duration. The probe was then recovered and moved to 
an undisturbed part of the room and left for 2 minutes before the next 
measurement was taken.
TEWL was measured at 4 time points: immediately baseline, immediately 
post-application and at 8 and 24 hours post-application as described in 
Chapter 2.
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4.2.4 Methylene blue application, imaging and biopsy of 
application sites
Depending on which group the participant was assigned to they returned at 
either 1, 4, 8 or 24 hours after the initial applications for visual assessment of 
skin punctures and skin biopsies.
4.2.4.1 Visual assessment of skin puncture
Following application of the microneedles and hypodermic needle, external 
staining of the skin with methylene blue was used to monitor microchannel 
healing and re-sealing. Using a cotton bud, methylene blue stain was only 
applied to each of the 3 application sites on the buttock region, which were 
then biopsied. The stain was allowed 10 minutes to dry before excess stain 
was removed using ethanol wipes. Subsequently the sites were visually 
assessed through the dermatoscope and photographed to determine whether 
the microconduits in the skin were visible.
4.2.4.2 Biopsy of application sites and cryo-transportation of skin 
samples
The primary aim of the clinical trial was to establish if there is any wound 
healing response within the epidermis and dermis of the skin after puncture by 
microneedles and hypodermic needles. Thus it was crucial to fix the skin 
immediately after biopsy to ensure that any healing response due to needle 
puncture, were not interfered with or altered by the biopsy process. The fixing 
and transfer of samples also needed to be considered to ensure all health and 
safety issues were dealt with. For these reasons a mock run-through of the 
protocol using ethically obtained excised human skin was conducted with Dr. 
Rebecca Porter at her Dermatology laboratory in The University Hospital of
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Wales, Cardiff. For further details of ethical and consented use of excised skin 
see Chapter 3.
4.2.4.2.1 Biopsying the application sites
Cryotubes were labelled with date, patient number and sample number. 
Corkboard was cut to ensure it could easily fit inside the cryotubes. Dry ice 
was added to a polystyrene icebox into which the labelled cryotubes were 
placed to be cooled. On a secure surface/bench near the participant, the 
fixing equipment (Figure 4.2) was prepared, ensuring it was suitably 
positioned for easy access and satisfying health and safety requirements.
The 3 application sites to be biopsied were injected with 2% lignocaine with 
adrenaline as local anaesthetic. The 2 microneedle-device sites were excised 
with 6mm diameter punch biopsies and closed with 2 Ethilon sutures. The 
hypodermic needle site was excised with a 4mm diameter punch biopsy and 
closed with a single Ethilon suture (Figure 4.3).
Tweezers Half Biopsy Sample in OCT
HexaneGlass Beaker
Dry Ice
I.M.SPlastic Tray
Figure 4.2. Diagram to show the snap-freezing fixing method for freshly biopsied
skin.
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Immediately after the biopsy, to ease mounting onto the cryostat, the circular 
skin sample was placed on a cutting board and cut down the middle in 
between the rows of punctures (Figure 4.4). To reduce damaging the 
microchannels, the biopsy samples were cut in between the rows of 
microneedle punctures, which were highlighted by methylene blue.
* ^
Figure 4.3. In-vivo example of the biopsy sites
Half of the biopsy sample was discarded. The other half was then mounted to 
cork by placing the flat side of the biopsy sample against the cork board using 
tweezers, ensuring that the skin surface lined up to the longer edge of the 
rectangular cork for correct orientation when cryosectioning (Figure 4.4). Skin 
samples were mounted on cork using optimal cutting tissue compound 
embedding media (OCT). OCT freezes over the sample, thus protecting and 
securing the sample to the cork mount. The mounted sample was quickly 
placed into a hexane beaker as shown in Figure 4.2 to freeze the OCT. Finally
123
the sample was placed into an appropriately labelled cryotube, which was 
stored in dry ice ready for transport. Until they were analysed, the cryotubes 
were stored at -80°C at The University Hospital of Wales, Cardiff.
Cork
OCT
Half of Biopsy sample
Methylene Blue puncture marks
Figure 4.4. Diagram to show orientation and mounting of biopsied skin prior to snap 
freezing.
4.2.5 Immunohistochemistry (IHC) of sectioned biopsy samples 
for wound healing analysis
The participant’s initials, biopsy site and the unique study number were used
to identify each skin sample. Frozen sections were cryosectioned jointly by
Dr Rebecca Porter at The University Hospital of Wales, Cardiff and
Mohammed Haq at Welsh School of Pharmacy, Cardiff and prepared for IHC
assessment of the wound healing response by identifying the up-regulation,
stasis or down-regulation of specific markers for ‘repair and stress responses’.
The frozen biopsy samples were mounted in the cryostat so as to section
across the length of the channels. The sections were mounted onto
microscope slides and stained with antibodies to keratins K16 to investigate
the degree of tissue damage, whilst an antibody to the dendritic marker, CD68
and inflammatory marker, TNFa was used to identify any enhanced
immunological and inflammatory reaction to the needle puncture.
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4.2.5.1 Preparation of cryosectioned biopsy samples taken post­
application of microneedles and hypodermic needle.
The skin samples were then frozen in OCT embedding medium in a cold 
ethanol bath on solid CO2 and cryosectioned at a thickness of 10pm using the 
Leica CM3050S cryostat. Cryosections were washed in PBS to remove the 
OCT embedding medium. Each slide was immersed in Harris’ haematoxylin 
(H) solution for 10 minutes for progressive H staining. Subsequently, after 
rinsing under running tap water for 1 minutes, differentiation in 0.3% acid 
alcohol (ethanol containing 0.3%HCI) for 10 seconds, rinsing under running 
tap water for 2 minutes, immersion in 1% eosin (E) solution for 1 second, and 
rinsing under running tap water for 2 minutes, the H & E-stained cryosections 
were permanently mounted with Histomount™ and a coverslip applied.
4.2.5.2 K16, TNFa and CD68 staining protocol
Unfixed cryosectioned samples mounted on slides were stored at -80°C until 
use. Initially the sample slides were placed in a staining trough. This was filled 
with acetone and left to stand for 15 minutes to fix the slides. The slides were 
then removed and left for 5 minutes to air dry. The slides were then placed 
into a clean staining trough, filled with 10% PBS for 5 minutes to remove any 
fixation deposits. This was repeated 3 times after which the excess was 
tapped off, and the slides carefully wiped using tissue around the samples to 
form a wet area over the sample. A wax pen was also used to form a barrier 
around the samples to keep them moist. The samples were placed in an 
incubation chamber and covered liberally in peroxidase for 5 minutes.
Following peroxidase blocking, the slides were rinsed in PBS and primary 
antibody solution was pipetted onto each slide. Dilutions for the primary
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antibodies were optimising by staining a range from 1:100 to 1:500 and 
altering incubation time from 1 hour to 24 hours. K16 was found to work 
optimally at 1:500 dilution with an incubation of 24 hours at 3°C, whilst K14, 
CD68 and TNFa were diluted 1:100 and incubated for 1 hour at room 
temperature.
After the primary antibody incubation, the slides were all washed twice in 2 
separate 10% PBS washes. The excess was tapped off and slides incubated 
with secondary antibody (anti-mouse monoclonal) for 30 minutes in the 
incubation chamber at room temperature.
Finally, the slides were rinsed in 10% PBS for five minutes, excess tapped off 
and chromogen (DAB) applied for a maximum of 5 minutes with continuous 
observation under microscope to prevent over-staining. To quench the 
staining, slides were placed in a PBS bath. Thereafter the slides were imaged 
through a microscope, counterstained with haematoxylin for 2 minutes, and 
quenched in a cold-water bath.
The slides were then dehydrated through an ethanol gradient from 30%, 50%, 
70%, 90% for 3 to 5 minutes in each. Subsequently the slides were 
transferred to a xylene gradient from 30%, 50%, 70%, 90% for 2 minutes in 
each. Finally, the slides were covered in Histomount and a cover slip applied. 
The slides were left to set and imaged under microscope before being stored.
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4.2.6 Imaging stained slides
The samples were now mounted on slides and protected by cover slips. Each 
slide was viewed and photographed under a microscope at 20x magnification. 
A graticule was used to establish scale to make suitable measurements of the 
images.
4.2.7 Microneedle deformation
To facilitate application during ex-vivo and in-vivo treatments, the microneedle
arrays are adhered to the solid base of an applicator. During the clinical trial, 
an inverted-syringe plunger was used as the applicator, the plastic affording 
some softness and flexibility during application whilst still enabling 
microneedle puncture of the skin. Stereomicroscopy and SEM imaging of the 
microneedles post-application was used to assess any surface damage to the 
microneedles or the arrays used during the study.
4.3 Results
The microneedles and hypodermic needle were applied to human volunteers. 
Subsequently the participants returned at 1, 4, 8 and 24 hours post­
application for topical staining and punch biopsy of the application sites. 
Furthermore the biopsy samples were snap-frozen on site, transported to 
secure storage and subsequently sectioned and analysed by 
immunohistochemistry to observe any wound healing or immunological 
responses.
4.3.1 Topical staining of needle punctures visualised
dermatoscopically
The participants all returned at their required time for methylene blue 
application and photography prior to the punch biopsy. Dermatoscopy allowed
127
a magnified view of the application site to be photographed. At the 1 hour time 
point the microneedle punctures were prominently stained and visualised as a 
defined and evenly spaced grid of 6 by 6 microneedle punctures. However, 
not all the microneedles of either 180pm or 280pm appeared to have 
punctured the skin surface, as no methylene blue stain was apparent as some 
of the points of the 6 by 6 array (Figure 4.5-4.8).
At 1 hour post-application, the microneedle and hypodermic channels would 
be expected to be most visible and this time point therefore best represents 
the puncture efficiency of each needle type. Figure 4.5 shows that the 180pm 
microneedle arrays did not penetrate the skin with every microneedle. 
However, of the 3 participants stained 1 hour post-application, the 280pm 
microneedles appeared to puncture the skin better than the 180pm 
microneedles, as both participant 1 and 3 have 100% punctures visible for the 
280pm microneedle application sites, but not for the 180pm microneedle 
sites (Figure 4.5).
The microneedle punctures are more prominent at 1 hour after application 
than at 24 hours after application. However at each time point there are clear 
differences in puncture staining between different participants suggesting the 
microneedles either did not penetrate as efficiently or the skin of each 
participant reacted differently to the application thus less methylene blue 
diffused through each microneedle induced puncture.
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Figure 4.8. Methylene blue stained application sites imaged by dermatoscopy 24 hours post-application of 180pm (180MN), 280pm (280MN) 
microneedles and 25G hypodermic needle.
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Comparison of the microneedle applications to the hypodermic needle shows 
significant differences caused by the size of needle penetrating the skin: At each 
time point the hypodermic needle has not only caused extensive trauma, but the 
skin tone has altered due to the erythematic reaction in the skin caused by the 
damage to subcutaneous and intra-dermal vasculature and the subsequent, 
inflammation, clotting and healing around the puncture site.
The shorter 180pm microneedle appears to penetrate less effectively or indeed 
the punctures are shallow enough to reseal quickly thereby preventing 
methylene blue to penetrate into the puncture. Figure 2 4.5-4.8 also show the 
microneedle channels in relation to hair follicles.
Regarding resealing of the observed microchannels, methylene blue staining 
showed skin repair appearing between 8 to 24 hours post-application. 
Photographs taken of the puncture sites show that the 280pm device initially 
made the greatest number of puncture marks, with a mean of 96% of the 36 
pyramidal needles puncturing the skin (Table 4.1). Whilst the 180pm was less 
penetrating, both the microneedle array puncture marks appear to be closing as 
there is a reduction over the 24 hour period in the staining of punctures (Figure
4.9).
4.3.2 Transepidermal Water Loss
TEWL measurements were taken over a period of 24 hours. Post-application of 
the needle devices TEWL measurements further demonstrated perturbation of 
the SC barrier with water loss increasing post application of each device. 
Mean TEWL increased immediately post-application for the hypodermic needle
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from 3.4 (range 13.6) - 8.7 (range 17.4) gm H20/sq.m/hour; from 4.85 (range
13.9) -8.7 (range 8.8) for 180|jm; and from 4.1 (range 11.1) - 6.1 (range 49.1) for 
the 280|jm array. Each recovered to baseline value by 24 hours.
Table 4.1. Percentage of puncture marks (out of a maximum of 36 channels) as 
observed by dermatoscopy for both the 180pm (180MN) and 280pm (280MN) 
microneedle arrays________ _____________________________________
Needle type 1
Time
4
hours)
8 24
180MN
89% 39% 50% 6%
52% 72% 19% 58%
61% 86% 75% 3%
Mean 67% 66% 48% 22%
280MN
97% 67% 97% 6%
100% 78% 42% 83%
92% 72% 89% 6%
Mean 96% 72% 76% 31%
100-
80-
£
□ 60-
c
£ 40-
s?
20-
i
x 180MN 
* 280 MN
"T"
10
T "
15
"T"
20 25
“1
30
Time (Hours)
Figure 4.9. Mean percentage of punctures marks observed through dermatoscopy at 
each biopsy time (1, 4, 8 and 24 hours post-application). Varying numbers of puncture 
marks were observed at the different time points over the 24 hour period. Puncture 
marks appear to reduce over the 24 hour period. The 180pm array appears to have 
penetrated less efficiently than the 280pm array and these punctures are potentially 
closing at a faster rate than those created by the 280pm array.
Figure 4.10 shows the increase in mean TEWL immediately post-application and 
the TEWL normalising over the 24 hour period. The initial increase in TEWL 
immediately post-application (pre-application v 1 hr) shows significant change for 
the 280pm (5.7-10.3gmH2O/sq.m/hour) and hypodermic devices (5.1-
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8.7gmH20/sq.m/hour) with p=0.0093 and p=0.0024 respectively, whilst p=0.34 
for the 180 (5.9-7.9gmH20/sq.m/hour) was insignificant. At 8 hours post­
application, the significance reduced to p=0.0049 (280pm), p=0.021
(hypodermic) and p=0.15 (180pm). By 24 hours the TEWL had returned to a 
normalised level with their being no significance for any device when compared 
to control: 180 (p=0.47), 280 (p=0.41), Hypodermic (p=0.79).
Figure 4.11 compares the visible puncture marks, as observed using methylene 
blue staining, to the TEWL measurements. Both the numbers of puncture marks 
and increases in TEWL were more pronounced for the 280pm microneedle 
compared with the 180pm microneedles. As the mean TEWL normalises over 
24 hours the mean puncture marks observed reduce too.
4.3.3 Transverse sectioning of biopsy samples for assessment of 
wound healing and immunological responses
Transverse sectioning of the biopsy samples enabled the punctures from 
microneedles and hypodermic needle to be observed through the stratum 
corneum to the dermis and deeper dermis for the hypodermic needle (Figure 
4.12-14). Figure 4.12 shows a 180pm microneedle puncture, which has 
penetrated the skin at an angle through to the epidermis, yet at this section of the 
microchannel, the stratum corneum (SC) appears intact. Certain sections, such 
as Figure 4.13A, revealed how the multiple 280pm microneedles along the array 
penetrated the skin, whilst the longer 280pm microneedles also penetrated 
deeper through the epidermis to the basement membrane (Figure 4.13C).
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Figure 4.10. Changes in mean TEWL over the 24 hour period post-application of 180pm, 280pm microneedles and hypodermic needle. TEWL readings 
were taken pre-application of device, immediately post-application and at 8 hours and 24 hours post-application. Graph shows the sudden increase 
post-application of each needle type, which then normalised over the 24-hour period. The mean TEWL and standard error of the mean are plotted. *time 
points have been offset by 20 minutes to enable the data points to be easily read.
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Figure 4.11. Comparison of mean TEWL with percentage puncture as observed by dermatoscopy over the 24 hour period post-application of 180pm 
and 280pm microneedle arrays. N.B. Time points have been offset by 20 minutes to enable the data points to be easily read.
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Figure 4.12. Transverse sections of biopsy samples taken post-methylene blue staining from Participant 11 at 1 hour post-application of 180pm 
microneedle array. [A] 180pm microneedle puncture at x20 magnification; [B] x20 magnification haematoxylin stained; [C] x40 magnification of individual 
puncture.
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Figure 4.13. Transverse sections of biopsy samples taken post-methylene blue staining from Participant 3 at 1 hour post-application of 280pm 
microneedle array. [A] 280pm microneedle puncture pre-stained x10 shows 2 neighbouring microneedle punctures; [B] 280pm microneedle puncture at 
x20 magnification; [C] 280pm microneedle puncture counterstained with haematoxylin at x40 magnification.
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Figure 4.14. Transverse sections of biopsy samples taken post-methylene blue staining 
from Participant 11 at 1 hour post-application of 280pm microneedle array highlight 
microneedle penetration is not perpendicular to the skin surface. Images [A]—[D] show 
the 280pm microneedle penetrated the skin at an angle thereby puncturing through 
some of the skin valleys, thus not all sections had breaks in their stratum corneum but 
did have microneedle punctures visible.
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Figure 4 .13A also demonstrates the size of 280pm microneedle punctures in 
relation to the ridges and troughs in the skin surface.
Microneedles do not penetrate the skin along a single plane as they are rolled 
onto the skin using the applicator rod (Figure 4.14). Therefore, sections showed 
signs of conduits passing through the epidermis but without evidence of SC 
damage, though higher intensity of haematoxylin and eosin (H & E) staining 
around the puncture site suggests rupture and compression of surrounding cells. 
Without visible methylene blue, it was very difficult to distinguish punctures from 
skin ridges. The hypodermic needle, however, created a large diameter wound 
through the deeper dermis, thus associated debris and blood clotting is present 
within the conduit (Figure 4.15). Figure 4.15 also highlights that whilst the 
hypodermic needle causes greater damage, the wound is starting to close by 8 
hours post-application of needle and the methylene blue has diffused through the 
epidermis.
Immunohistochemical analysis of biopsy samples showed up-regulation of the 
wound healing K16 marker (Figure 4.16A). K16 up-regulation was localised to 
the site of puncture by the hypodermic needle at 8 hours for Participant 2, with 
reduced up-regulation further from the puncture site and at the periphery of the 
sample. Contrast analysis of the image highlights the K16 intensity (Figure 
4.16B). K16 was shown to be up-regulated around the 280pm microneedle 
punctures at 24 hours post-application (Figure 4.16C) although this was not as 
clear as for hypodermic punctures. K16 was not up-regulated over the 24 hours 
period following 180pm microneedle applications (not shown). The K14 positive
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Figure 4.15. 25G hypodermic needle puncture disrupts dermal vasculature and elicits 
clotting. [A] The hypodermic needle applied to Participant 1 imaged at x10 magnification. 
The needle penetrated to the deeper dermis and through the biopsy sample. Signs of 
clotting and the magnitude of the wound are overt at 1 hour post-application; [B] 
Participant 5 was biopsied at 8 hours post application. At x20 magnification the wound 
created is healing and resealing. The methylene blue has diffused through the 
epidermis.
Figure 4.16. Transverse sections of hypodermic and microneedle punctured biopsy samples stained for K16. [A] Up-regulation of K16 in the epidermis 
around the site of puncture at 4 hours post-application; [B] altering the contrast highlights the localisation of K16 is more intense around the puncture 
site. [C] K16 was only shown to be up-regulated around the 280pm microneedle puncture site at 24 hours post-application of Participant 12; [D] K14 
positive control.
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control, Figure 4.16D, showed how the samples would look if the markers are 
present throughout the epidermis as K14 is expressed on the surface of all 
keratinocytes in the epidermis.
Figure 4.17 displays images stained for the immunological marker CD68. Up- 
regulation of CD68 was present around the hypodermic insertion site as early as 
4hrs post-application, suggesting a migration of maturing dendritic cells to the 
point of injury (Figure 4.17C). However, from 1 hour to 24 hours CD68 was not up- 
regulated or localised at either the 180pm microneedle (Figure 4.17D) or 280pm 
microneedle (Figure 4.17E) puncture sites. Other immunological marker, Langerin, 
was applied to transverse sections to establish the presence and location of 
Langerhans’ cells and whether they migrate in response to needle puncture. 
Figure 4.17F highlights the presence of Langerhans’ cells in the epidermis of 
Participant 6 (Figure 4.17F).
TNFa was chosen as a marker for inflammation as it is released from dendritic 
cells and blood cells after trauma. The hypodermic needle instigated an immediate 
inflammatory response with TNFa up-regulation seen at one hour post-application 
(Figure 4.18A). TNFa remained present at 4 hours post-application of the 
hypodermic needle (Figure 4.18B), though no evidence of TNFa up-regulation was 
found for either the 180pm (Figure 4.18C) or 280pm (Figure 4.18D) microneedle 
applications.
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Figure 4.17. IHC staining for immune dendritic cell markers CD68 and Langerin for the 
180|jm and 280|jm microneedles and hypodermic needle. [A] Haematoxylin counter 
stained control sample. [B] CD68 positive control with no needle puncture; [C] CD68 
localisation around the hypodermic site at 4 hours post-application; [D] CD68 distribution 
in sample punctured by 180pm microneedle shows no localisation up to 24 hours post­
application; [E] Haematoxylin counterstained 280pm microneedle puncture has no CD68 
localisation at 1 hour post-application. [F] Langerin stained sample with no puncture 
from Participant 6 highlights the presence of Langerhans” cells in the epidermis.
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Figure 4.18. TNFa stained biopsy samples from hypodermic needle [A-B] show up- 
regulation of TNFa but not for microneedle array applications [C-D]. [A] Sample from 
Participant 11 biopsy taken at 1 hour post application of Hypodermic needle; [B] sample 
from Participant 8, taken 4 hours post-application of hypodermic needle; [C] sample 
from Participant 8, post-application of 180pm microneedle array (counterstained with 
haematoxylin); [D] sample from Participant 9, taken 8 hours post-application of 280pm 
microneedle array.
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4.3.4 Characterisation of Microneedle Arrays
All the 280|jm and 180|jm microneedle arrays to be used in the clinical trial 
where checked for damage using SEM and stereomicroscopy (details in 
Chapter 2). Any damaged arrays were removed from the stock that was used in 
the clinical trial. All the microneedle arrays were re-characterised post­
application ex-vivo and following clinical application to human volunteers. Each 
of the 36 microneedles on the 12 arrays remained morphologically intact after 
single application to human volunteers. Figure 4.19 shows the post-application 
debris of human skin left on the array and microneedle surfaces, respectively.
4.4 Discussion
Basic visual assessment of skin puncture caused by the 180pm and 280pm 
microneedles and the 25G hypodermic needle provided an estimate of the 
physical damage caused by these needles penetrating the skin. If all 
36 microneedles penetrated the skin, a calculation of the cellular volume 
displaced by each array can be made. Comparing this displacement to that 
potentially caused by a fully inserted 25G hypodermic needle gives and idea of 
the different volumes of displacement between the different needle devices.
Assuming each microneedle has a perfect octagonal base, whereby each of 
outer lengths of the 8 sides is of equal dimensions. The octagonal base contains 
8 isosceles triangles (Figure 4.20). The area of each triangle can be calculated, 
whereby the perpendicular length from the base of each triangle is half of 
150pm.
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Figure 4.19. Example images from stereomicroscopy and SEM of 280|im array post­
application \n-vivo. Stereomicroscopy image [A] shows intact 280pm microneedle array 
with its surface covered in fine skin debris (Bar = 1mm); and SEM micrographs [B] 
showing skin from the participant wrapped around a single microneedle.
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Figure 4.20. Isosceles triangle depicting a one eighth segment of the cross section of 
the hilt of a single silicon microneedle.
Therefore, using trigonometry, the base-length of each triangle can be 
calculated:
X = 75 tan 22.5 = 31.06
The area of the isosceles triangle = 1/2(base)(height)
= 0.5 x 62.12 x 75 = 2329.5nm2 
The total area of the octagonal base = 8 x 2329.5 = 18636nm2 
Volume of pyramid = 1/3(base area)(height)
Volume of a single 180pm length microneedle:
= 1/3 x 18636 x 180 = 1.12 x 1 0 ^ m 3
Therefore, a 180pm-length 36-microneedle array will displace approximately 
0.040mm3, whilst a 280pm-length 36-microneedle array will displace
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approximately 0.06mm3. By comparison, if a 25G hypodermic needle 
penetrated the skin by the same length as the 280pm microneedle, it would 
cause a volume displacement at least 10 times that of a 280pm microneedle 
array. The tip of a hypodermic needle is bevelled and not cylindrical, thus the 
volume would be less than the approximate calculation below:
Volume of cylinder = 7t(radius2)(length) 
= n (0.5144/2)2 x 0.280 = 0.58mm3
Therefore, the hypodermic needle would cause greater morphological 
damage to the dermis and epidermis than either of the microneedle arrays. 
The reduced displaced volume by the microneedles leaves a smaller 
microconduit for the entry of medicaments; subsequently dosages and 
concentrations of any medicament may need to be modified for delivery by 
microneedles (Badran et al. 2009; Chen et al. 2009a; Coulman et al. 2009; 
Gupta et al. 2009; Hafeli et al. 2009; Ito et al. 2006a; Katikaneni et al. 2009; 
Rizwan et al. 2009). However, due the reduced puncture depth and volume, 
there might be limited physiological response and chances of pathogen entry 
will be greatly reduced.
Topically applied methylene blue dye was used to visualise needle puncture 
sites with en-face imaging. Whilst this provided a method to assess the level 
of puncture, subsequent transverse sectioning also highlighted the difficulties 
in finding microneedle punctures. As the time points increase post-application,
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the punctures can no longer be visualised, methylene blue staining therefore 
highlights the number of microconduits present at that time post-application 
(Figure 4.5-4.7).
The topical puncture staining at 1, 4, 8 and 24 hours after initial application 
collate with the increase in skin water loss over the 24 hour period suggesting 
the microneedles penetrate skin efficiently. The 280pm microneedles were 
more efficient at skin penetration, being as high as 90% effective at one hour 
post-application. These microconduits started to seal over the 24 hour period. 
The 180pm microneedle array did not cause as much disturbance to the skin 
barrier properties, whereas the 280pm array increased transepidermal water 
loss (TEWL) in a similar manner to the hypodermic needle. It therefore may 
be preferable to use the 280pm array over the 180pm array to ensure 
sufficient penetration through the stratum corneum (SC). However, it is 
acknowledged that TEWL is a very sensitive measurement of skin 
permeability. It is possible that TEWL can be affected by the participant’s 
movements, diet and atmosphere over the 24 hours despite taking 
precautions during the clinical study (Badran et al. 2009; Bal et al. 2008; Kolli 
and Banga 2008; Lanke et al. 2009; Netzlaff et al. 2006; Rosado et al. 2005b; 
Shimada et al. 2009; Verbaan et al. 2007; Zhai et al. 2007).
Microneedles puncture through the uppermost layer of the skin, the stratum 
corneum, and into the epidermis whilst the hypodermic penetrates into the 
deeper dermis. The keratinocytes in the epidermis mature from the basal and
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germinative layer where they undergo mitosis and proliferate. These then 
differentiate into the stratum spinosum where the morphology changes with 
the production of tonofilaments. Subsequently, the keratinocytes mature to 
keratohyalin granules and migrate to the outer stratum granulosum layer 
where programmed cell death occurs. These cells finally desquamate from 
the skin SC (Amjad et al. 2007; Colwell et al. 2007; Girardeau et al. 2009; 
Pappas 2009; Scardina et al. 2009; Suter et al. 2009; Usui et al. 2008).
The epidermis also contains Langerhans’ cells that reside suprabasally to 
provide immunological defence for the skin (Glenn and Kenney 2006; Kubo et 
al. 2009; Kurban and Bhawan 1990; Pickard et al. 2009; Wang et al. 2005a). 
Upon foreign antigen interaction, these cells migrate to lymphatic nodes thus 
causing coetaneous inflammation. The dermis contains vasculature, 
lymphatics and nerves as well as dermal fibroblasts, which provide 
intercellular support matrices and are implicated in wound healing. 
Macrophages, melanocytes and mast cells are also present in the dermis 
(Barrientos et al. 2008; Gratchev et al. 2008; Nishio et al. 2009; Park et al. 
2009; Sindrilaru et al. 2009).
When a hypodermic needle penetrates the skin it causes damage to the 
dermal vasculature and impacts on sensory receptors, which causes bleeding 
and pain, as well as a whole host of complex cellular processes to be 
activated. The details of how growth factors, cytokines, matrix-cell and cell­
cell interactions influence proliferation, differentiation and migration of cells in
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response to a wound is somewhat understood. Thus the injury caused by the 
hypodermic needle causes leakage of blood from the vessels which contains 
platelets and fibrinogen (Barrientos et al. 2008; Frechette et al. 2005; Martin 
and Leibovich 2005; Valeri et al. 2006). This produces a clot, to close the 
open wound site, allowing aggregation of injured cells and degrading platelets 
releasing chemotactic cytokines and growth factors. These proteins act as 
signalling molecule for inflammatory leukocytes, which are present in 
capillaries and migrate towards the puncture site (Gillitzer and Goebeler 2001; 
Martin 1997). In conjunction to this, the macrophages, mast cells, 
lymphocytes and neutrophils clear away the damaged cells and any 
pathogens and cellular debris (Martin 1997; Ravanti et al. 1999).
Therefore the underlying histological, biological and immunological effects of 
puncture from the formation and subsequent closure of microneedle and 
hypodermic needle punctures was studied. The histological disturbance to the 
skin due to microneedle and hypodermic needle was observed by transverse 
section. For example, in Figure 4.13C the broken SC and epidermal cells 
were pushed into the dermis region, which is highlighted by the intense 
regions of H&E stain along the side of the microconduit. Often the puncture 
did not penetrate through the basement membrane, potentially due the angle 
of puncture. However, the hypodermic needle ruptured a much larger volume 
of skin tissue (Figure 4.15B) and also penetrated blood vessels (Gill et al. 
2008; Papanastasiou and Hart 1995).
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Safety of a device is a major factor to consider when introducing anything into 
the skin. Methylene blue staining showed that the microchannels were very 
small in their nature, in some cases similar to the diameter of hair follicles, 
whilst TEWL returned to normal over a 24 hour period. Thus microneedles 
appear to not cause any long-term problems with the integrity of the skin, 
which responds to close the channels within 24 hours, thereby reducing the 
likelihood of infection. Furthermore, no significant immunological or wound 
healing responses were observed over the 24 hour period post-application of 
the microneedle devices, unlike the hypodermic needle where K16 and CD68 
were both up-regulated. This suggests that microneedle insult causes minimal 
injury to the skin. The small nature of the microconduits and the skin’s natural 
propensity to heal may prevent any passive pathogen entry through the 
microconduits.
The release of cytokines from the ruptured cells, the subsequent presence of 
blood cells and platelets, elicit a cascade of inflammatory responses due by 
the up-regulation of TNF. Therefore inflammation drives the wound healing 
response, whilst the damaged stratified epithelia causes a strong induction of 
K6 and K16 in post-mitotic keratinocytes located at the wound edge (Philipp et 
al. 2004; Roh and Lyle 2006; Simon R. Myers 2007; Suter et al. 2009; Usui et 
al. 2008). Paladini et al. (1996) concluded that induction of K6 and K16 occurs 
within six hours after injury to human epidermis. In-vitro studies in cultured 
cells have determined K6 and K16 filaments accumulate post-injury, whilst the 
keratin pair K5 and K14 remains constitutively expressed in epidermis.
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Further in-vivo work to assess mRNA might provide greater sensitivity to 
wound healing markers, whilst a larger sample store would enable 
immunohistochemistry (IHC) for both K6 and K16 markers.
In minor wounds, the innate inflammatory and immune responses are 
connected, but are two distinct processes. The inflammatory response is 
designed to neutralise pathogens and remove necrotic tissue, and 
subsequently initiate early regeneration and repair by formation of granulation 
tissue and epidermal migration by factors such as TNFa.
TNFa is a mediator that affects the up-regulation of proinflammatory 
cytokines. Ashcroft and Mills (2002) investigated TNFa levels in wounds of 
castrated and intact male mice. Five and 21 days after wounding castrated 
mice, expression of TNFa was lower than when compared to intact mice. 
TNFa cytokine is released by macrophages and epidermal cells, therefore, 
increasing the production of chemokines that attract neutrophils.
Dedicated in-vivo wound healing studies for microneedle and hypodermic 
needles would require extensive ethical approval for biopsies, however if 
sufficient samples were present, IHC for accumulation of K6, K16, and K17 
would correlate with major changes in epithelial architecture (Coulombe 2003; 
Coulombe et al. 1998; Paladini et al. 1996). Paladini et al (1996) and establish 
that K6, K16, and K17 proteins are all induced in epidermis at the proximal 
edge of the wound within hours after acute injury to mouse and human skin.
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Early in wound healing as suprabasal keratinocytes begin to differentiate with 
an increased expression of K16 (Coulombe et al. 1998; Paladini and 
Coulombe 1998; Paladini et al. 1995). As differentiation continues, the 
expression of K16 and K6 spreads distally from the edge of the wound but 
stops when reepithelialisation is completed (McGowan and Coulombe 1998; 
Wawersik et al. 2001). Activated keratinocyte generate cytoplasmic processes 
to aid cell migration by producing keratin intermediate filament networks 
(Coulombe et al. 1998; Usui et al. 2005). Approximately 48 hours after acute 
wounding, down-regulation of keratins 1, 10 and 2 occurs whilst K6 and K16 
remain expressed until wound closure which occurs between 24 and 72 hours 
post-injury (Garlick and Taichman 1994a; Usui et al. 2008). Macrophages 
reach their highest number in the normal acute human wound after 48 hours 
of injury (Barrientos et al. 2008; DiPietro 1995; Gillitzer and Goebeler 2001; 
Hays et al. 2008). CD68 is expressed throughout monocyte differentiation, 
usually more intense in macrophages than monocytes. Granulocytic 
precursors and mast cells may also exhibit CD68 positivity. Therefore further 
studies using samples of skin taken between 24 and 72 hours post-injury 
would ascertain the difference in wound closure between microneedles and 
hypodermic needles.
Further study into the biochemical aspects of wound healing caused by 
microneedle and hypodermic penetration, may be conducted by measuring 
mRNA of early markers. This would enable us to better understand the
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biochemical cascades and effects of skin injury. This could improve 
understanding of immunological responses to skin injury and thus improve the 
use of microneedle formulations for efficient and efficacious medicament 
delivery.
4.4.1 Conclusions
TEW L measurements, en face imaging and histological sections 
demonstrated that microneedles effectively puncture human skin in a 
superficial and transient manner. The inflammatory marker TN Fa and wound 
healing marker K16 are up-regulated locally to the hypodermic needle 
puncture by 4 hours post-application. Whilst the 180pm microneedle 
punctures did not exhibit any such response, the 280pm punctures did elicit a 
small but localised K16 response 8 hours post-application.
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Chapter 5
Developing a method of consistent application for 
polycarbonate microneedle arrays
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5.1 Introduction
To date microneedles have been developed using a variety of manufacturing 
techniques on different materials. Etching of silicon wafers was used to form 
the initial microneedle designs. For example, Tyndall National Institute in 
Ireland developed a manufacturing process that creates microneedles by wet- 
etching a silicon wafer to form the needle projections, which are coated in an 
angstrom-thickness layer of platinum (details in Chapter 2). However, whilst 
this manufacturing technique is extensively used in the development of silicon 
microchips for the microelectronics industry, the financial and environmental 
implications of bulk producing silicon microneedle arrays may be prohibitive for 
mass-market distribution. Recently our group has acquisitioned polycarbonate 
microneedle arrays. Polycarbonate microneedle arrays are manufactured 
using common and cheap plastic injection moulding techniques using a 
stainless steel laser-etched mould.
The polycarbonate microneedle arrays used in this study comprised a circular- 
based array with microneedles of 3 different heights with different morphology 
and pattern to the wet-etched silicon-based arrays, which has equally spaced 
microneedles across the square base of the array. Due to differences in 
material composition and manufacture process, the silicon and polycarbonate 
microneedles differ considerably in their morphology. The silicon microneedles
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have an 8-sided pyramidal structure, whereas the polycarbonate microneedles 
are single cylindrical protrusions from a 4mm deep polycarbonate base.
Whilst the silicon microneedles have been extensively tested within our 
research group, these polycarbonate microneedles require characterisation, 
proof of concept and refinement of their application method to establish 
whether they represent a viable alternative to wet-etched microneedle arrays.
During the clinical study (Chapters 3 and 4) the silicon 36-microneedle arrays 
were applied to human volunteers for pain and sensation testing and the depth 
of penetration and associated wound healing investigated. Prior to this study a 
preliminary applicator study was also conducted to establish a simple rod- 
based rolling application technique to apply the solid microneedles (see 
Chapter 2). At the time the clinical study showed that, for clinical application, it 
was better to have a circular shaped applicator to avoid sharp corners digging 
into the patient. Also the applicators with a softer surface were found to be 
more comfortable in their use than a metallic rod (Chapter 2). Therefore an 
inverted 2ml syringe plunger was used as the applicator rod for the 
microneedles during the clinical study.
Though the inverted-syringe plunger worked as an applicator, the clinician was 
required to undertake training to ensure consistent punctures from each of the 
36 microneedles on an array. It was evident that the forces of application may 
have had an effect on the level of pain or sensations felt by participants in the
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study. The application method may then limit the use of microneedles until 
such a stage where each application is consistent to enable accurate dose 
delivery.
Consistent application is essential for any new drug delivery method, to ensure 
correct dose delivery and drug efficacy. Commonly, hypodermic needles are 
applied by attaching to the end of a syringe through which the drug is then 
administered after inserting the needle into the skin or muscle. Even the 
smallest hypodermic needles 31G, which are 5-6mm in length, are attached to 
pen-like cylinders to deliver insulin for diabetics. Wang et al (2006) used a 
rotary drilling device for inserting single microneedles into skin. This reduced 
skin deformation, thus providing greater control of penetration depth. However 
this study also conceded that the skin did still deform and the insertion depth 
remained only proportional and not equal to needle length. Also for this 
technique to work on a multi-microneedle array, such as the polymer or wet- 
etched silicon ones, each microneedle would have to separately spin to allow 
it to drill.
Yang and Zahn (2004) reported that vibration of the microneedles reduced the 
required insertion force. This would over complicate the design for mass 
manufacture of an efficiently produced applicator. Others have used patch- 
based delivery systems to apply the microneedles to skin for a sustained drug 
release (Cormier et al. 2004; Nordquist et al. 2007; Widera et al. 2006b). 
Sivamani et al (2005) glued their hollow microneedle array to a syringe and
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pushed a volume of drug solution through the array. Despite various 
techniques being tested there are also many which are patented or patent- 
pending which involve more complex electrical or mechanical design features 
to apply either hollow or solid microneedles. Therefore it is important that both 
the microneedle design and method of application is developed 
simultaneously to ensure effective and efficient drug delivery.
5.1.1 Aims and Objectives
This chapter aims to develop a simple, reliable and clinically suitable method 
of application for polycarbonate microneedles.
Objectives:
•  To assess and characterise the morphology of polycarbonate 
microneedles.
•  To test the ex-vivo human skin penetration ability of polycarbonate 
microneedles using methylene blue staining methods.
•  To use TEW L to assess the level of human skin barrier disruption 
caused by polycarbonate microneedles.
•  Design and test simple applicators for applying polycarbonate 
microneedles to human skin.
• Establish a prototype design for reproducibly successful microneedle 
application.
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5.2 Materials and methods
5.2.1 Materials
Aluminium rods (Cardiff School of Engineering, Cardiff University); Araldite 
(Bostik Findley LTD, UK); Dulbecco’s Modified Eagle Medium (DMEM) 
(Invitrogen, UK); Double-sided sticky tape (3M, UK); Hand-held drilling and 
cutting tool; 2ml Plastipak syringe and syringe plunger (Becton Dickinson, 
Spain); Polycarbonate microneedles (Cardiff School of Engineering, Cardiff 
University); Polycaprolactone (PCL) (Sigma-Aldrich, USA); 5ml Round-bottom 
Falcon tubes 12mm x 75mm (Becton Dickinson, USA); Rubber stoppers 
(Washer for Va Tap Jumper Assembly, Robimatic, UK); Silicone Elastomer 
Base and Curing Agent, Polydimethylsiloxane (PDMS) (Sylgard, UK); Springs 
(Airedale Springs LTD, UK); wet-etched microneedles (Tyndall National 
Institute, Cork, Ireland); Gold sputter coater (EM Scope, Kent, UK); Philips XL- 
20 Scanning Electron Microscope (Philips, Eindhoven, Netherlands)
5.2.2 Characterisation of polycarbonate microneedles
The manufacturer provided basic information on the polycarbonate 
microneedles. The microneedles are injection moulded on a circular array 
base to provide 13 cylindrical projections forming a star pattern with varying 
length needles at different points from the centre to the outer edge of the 
array. Two distinct arrays are joined by a polycarbonate T-bar, whereby one 
array has the longest microneedle (approximately 700pm) in the centre, and 
the other array has the shortest (approximately 300pm) microneedle in the 
centre. On both arrays the centre and outer most microneedles are separate 
by a circular row of microneedles of approximately 400pm length.
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5.2.2.1 Light stereomicroscopy imaging of microneedles
Each polycarbonate microneedle array was photographed systematically to 
assess the overall design and morphology of the microneedles (for further 
details of light microscopy see Chapter 2.2).
5.2.2.2 Scanning electron microscopy (SEM) of microneedles
A sample of polycarbonate arrays were examined under high resolution SEM. 
As the polycarbonate arrays were not metal coated like the wet-etched 
platinum-coated silicon microneedles, each was mounted to an aluminium 
stub and gold sputter coated prior to SEM analysis (Chapter 2.2).
5.2.3 Preparation of ex-vivo human skin samples
Both microneedle arrays were applied in triplicate using each application 
method on excised and fully defrosted full thickness mastectomy skin. The 
skin samples, taken from consenting female patients with full ethical approval, 
were transported and stored in DMEM media, transferred to a -18°C freezer 
until use at which point the samples were defrosted and stretched and pinned 
to a cork board. No subcutaneous fat was removed from the samples. Further 
details of this procedure are described in Section 2.2.3.
5.2.4 Application of unmounted polycarbonate microneedles to ex-
vivo skin
Polycarbonate microneedle arrays were initially left attached to the T-bar 
skeleton and rolled into the skin so that the microneedles would push into the 
skin with sufficient force and angle to pierce, Figure 5.1 i. The application 
technique was varied using 2 other methods: A detached applicator rod push 
onto the array in a stabbing fashion and holding the array depressed into
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the skin for 10 seconds, Figure 5.1 ii; and rolling the detached applicator rod 
over the surface of the back of the array with the needles seated on the skin 
surface, Figure 5.1 iii.
5.2.5 Development of an applicator rod for microneedle application 
to ex-vivo skin
Each polycarbonate microneedle array was mounted on the rubber bung end 
of a 1ml syringe plunger. The plunger has a diameter of 4mm, which is similar 
to the diameter of the microneedle array (3mm). The arrays were araldite- 
glued onto 2 plungers that were labelled to distinguish between the 2 types of 
arrays, [A] and [B].
Another applicator rod was made from polycaprolactone (PCL). The cylindrical 
5mm diameter rod was cast in a polydimethylsiloxane (PDM S) mould. The 
PDMS mould was formed by adding 10 parts PDMS (10cm3) with 1 part 
catalyst and mixing vigorously to give a homogenous viscous solution in a 
Falcon tube. A glass rod was then inserted into the tube and carefully 
positioned in the centre line but 2cm from the base of the tube. This was 
clamped into place whilst the tube containing the mixture was clamped 
vertically and heated in a water bath at 60°C to partially set. Subsequently this 
was left to set for a minimum of 18 hours at 40°C under vacuum to remove all 
moisture and air bubbles from the hardening PDMS mould.
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10 sec
10 sec
A 0 sec
Figure 5.1. Application of unmounted polycarbonate microneedles, i) Application 
techniques tested without applicator rod; ii) stabbing aluminium applicator rod; and iii) 
rolling applicator rod. Arrows delineate the direction of force being applied. All forces 
were qualitatively maintained as constant by the researcher and applied for 10 
seconds.
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After 18 hours the clamps were released and the glass rod carefully removed 
from the mould. Next the mould was filled with PCL beads and heated to 
100°C for 2 hours to melt the PCL into the mould. This was done under 
vacuum to extract the air from the mould and remove moisture to ensure a 
solid PCL rod would form. The PDMS mould containing the PCL was then 
cooled at 4°C. The PCL rod was subsequently liberated from the mould. 
Instead of using glue to mount the microneedle array, the end of the PCL rod 
was heated on a hot plate to approximately 60°C till it became tacky and the 
array pushed onto it and left to cool and set.
5.2.6 Application techniques for microneedle arrays mounted on 
applicator rods and rubber stoppers
Once the microneedle arrays were mounted to the applicators these were 
applied in a rolling fashion across the skin surface. The skin was stretched and 
pinned to a corkboard and the local application sites were stretched between 
the fingertips as representative of the clinical method for inserting hypodermic 
needles.
Each applicator was held in a pen-like fashion (between the thumb and 
forefinger) and rolled over the skin. Each application method repeated 3 times. 
The applicator rods were held at three different heights from the base, 2.5cm, 
5cm and 7.5cm. Initially the syringe plunger applicator (Figure 5.2), array [A], 
was applied 9 times, i.e. triplicate for each height. Followed by plunger 
mounted with array [B] and finally PCL rods with arrays [A] and [B] were
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tested. The aim was to establish if the applicator rod length affected the 
efficiency of microneedle puncture.
The applicators were also compared to other potential applicators that might 
be readily available. The local DIY store (Homebase Ltd, Cardiff) had a few 
different size rubber stoppers, one of which had a stalk with the diameter only 
2mm larger than the diameter of the microneedle array. This was tested as an 
applicator as it is easy to hold and apply by rolling across the skin and also 
can be pushed down into the skin during the rolling in an effort to improve 
puncture efficiency (Figure 5.2).
Figure 5.2. Applying microneedles using a syringe plunger and a rubber stopper. A 
microneedle array was adhered to the rubber bung end of a 2ml syringe plunger and 
the rubber stopper. The plunger was held in a pen-like fashion at 3 different heights 
from the base and rolled over the skin, whilst the stopper was held at the round top. 
Force applied downwards and throughout the massaging motion (1-3), shown by blue 
arrows.
1 2 3
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5.2.7 Developing spring-based applicators for microneedle
administration to ex-v/Vo human skin
From all previous laboratory and clinical tests, microneedle arrays have been 
able to penetrate the skin consistently when rapidly ‘jabbed’ into the skin 
(Figure 5.3). Therefore to standardise this action of administration, a 
rudimentary mechanised applicator was developed. This entailed using 
various resources available in our laboratory, i.e. Falcon tubes, syringes, pens 
and paperclips. These were disassembled, cut and tooled using a small 
electric hand-held modelling tool to form an initial design for a spring actuated 
microneedle array applicator.
Figure 5.3. Applying microneedles using an aluminium rod. Application technique 
tested previously, Jabbing metal applicator rod with microneedle array mounted on 
the end into the skin from a height of approximately 5cm and pushing down and 
holding on the skin for 10 seconds.
An initial crude spring-loaded applicator was fabricated by trimming a 5ml 
round-bottomed Falcon tube to a length of 8cm and drilling a 2ml diameter 
hole through the bottom. A 2ml syringe plunger has a thumb press at one end 
and a rubber bung at the lower end where it would normally contact the fluid in
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the syringe. However, removing the flexible rubber bung left a round plastic 
stub that was cut off. Through this plastic stub a paperclip was inserted, folded 
and twisted. A spring from a ballpoint pen was placed over the paperclip wire 
before pushing the wire through the hole at the bottom of the Falcon tube. 
Finally a polycarbonate microneedle array [B] was attached and tested to 
puncture ex-vivo human skin. This device was compared to the rubber plug 
applicator with another array [B] araldite glued to the end of the bung.
Further evolutions of the design reduced the number of components by 
removing the paperclip wire and using a trimmed syringe plunger. The open 
end of the Falcon tube was cut to reduce the overall length of the tube from 
75mm to 70mm. The syringe plunger was protruding from the end by 3mm 
and the array was mounted onto the end.
The applicator was developed further using by using springs with known rating 
values (Airedale Springs LTD, UK). This allowed for better optimisation by 
testing different springs in the tube to ensure consistent microneedle 
puncturing of the skin.
5.2.8 Application technique used for prototype spring-based 
applicator device
The prototype applicator device (Figure 5.4) was used to apply the 
microneedle array. The cap was pulled back to compress the spring and raise
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Figure 5.4. Prototype spring-loaded applicator device. Microneedle applicator device 
was produced using only 4 separate components and assembled with a spring of 
known rating being inserted over the shaft of the syringe plunger (spring not shown), 
which was inserted into the Falcon tube. A microneedle array [B] was mounted to the 
end with double-sided sticky tape.
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the plunger, then the tube held vertically and perpendicular to the skin and 
lowered onto the skin. No additional force was applied other than resting the 
device on the skin. Subsequently the cap was released, causing the spring to 
decompress and force the plunger down, driving the microneedles into the 
skin. Thereafter the prototype device was held in place for a further 10 
seconds before being removed.
The application process was performed in triplicate with topical methylene blue 
stain applied pre- and post-application. A negative control using just the device 
without any array attached was also administered to the skin, whilst for 
comparison the rubber stopper was also applied by jabbing into the skin from 
an approximate height of 5cm and held with force into the skin for 10 seconds. 
At no stage was the skin heavily stretched though pins were used to hold it 
firmly in place on a corkboard.
5.2.9 Measuring skin puncture using Transepidermai Water Loss 
(TEWL)
To gauge whether the microneedles had successfully punctured the skin 
TEW L measurements were taken prior to applying the arrays and immediately 
post-application for each of the 18 applications. For details on TEW L see 
Chapters 2 and 4. Statistical analysis of TEW L data was conducted by 2-way 
ANOVA with Bonferroni post-tests analysis.
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5.2.10 Staining and imaging of ex-vivo skin post-application of
microneedles
Methylene blue (10pl of a 5%w/v solution) was applied topically pre- or post­
application to each site and allowed to air-dry for 10 minutes. Excess was 
wiped off using 70% alcohol wipes. The skin was finally examined by 
microscopy and photographed.
5.2.11 Transverse sectioning and staining of ex-vivo skin post­
application of polycarbonate microneedles
Post-application, the punctured ex-vivo skin samples were placed in formalin 
for 24 hours. Subsequently the samples were dehydrated for 3 hours through 
an ethanol gradient and transferred to molten paraffin wax for 18 hours. 
Thereafter the samples were orientated and set in moulds of wax before being 
sectioned using a microtome. The sections produced were mounted on slides 
and counterstained in haematoxylin. Further details of sectioning and staining 
can be found in Section 4.2.5.2.
5.3 Results
5.3.1 Characterisation of the polycarbonate microneedles
Each microneedle array contains 13 microneedles. There are 2 types of array 
attached to each ‘T-bar’. Figure 5.5 highlights the small size of each array in 
comparison to a 1p piece. The arrays are overhanging at each end and 
array [A] has the longest microneedle in the centre of the array and [B] has the 
shortest microneedle in the centre of the array.
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The microneedle heights of array [A] vary in 3 tiers, from 673|jm microneedle 
length in the centre, to 524pm and the outermost microneedle needles are 
335pm in length, whilst array [B] has the shortest microneedle of 335pm at the 
centre and the longest microneedles of 673pm at the periphery (Figure 5.6).
Figure 5.5. Polycarbonate arrays attached to manufacturing T skeleton. Left array is 
marked with a single stripe, whilst the right is marked with two stripes. (Bar = 5mm)
Figure 5.6. Two different polycarbonate microneedle arrays. [A] Array with longest 
microneedle in the centre decreasing in diameter to the shortest on the periphery. [B] 
Array with shortest microneedle in centre increasing in diameter to the longest on the 
periphery. (Bar = 1mm)
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On both arrays, as the needles span outwards along the diameter of the array, 
the distance between microneedles also increases. Though the distance 
between a microneedle at one diameter and its neighbour at the next diameter 
is identical when measuring from the centre of the base of each microneedle.
Closer microscopic examination of the polycarbonate arrays (Figure 5.7) 
reveals the microneedles on array A appear to have a sharper and more 
defined point that those of B. Though this is not necessarily representative of 
all the arrays in this batch as similar images of a sister ‘T-bar’ shows 2 arrays 
with equally pointed tips for each of the 13 microneedles on each array.
Figure 5.7. Lateral view of polycarbonate microneedles. Stereomicroscope images of 
arrays [A] and [B] shows differences in microneedle length at varying points along the 
diameter of the base. Signs of production defects are especially visible in this 
particular array (microneedle on far right of image) [B], (Bar = 1 mm)
SEM images (Figure 5.8) show the cylindrical nature of the microneedles, 
which project from the polycarbonate base as rounded needles and not 
angular or pyramidal structures. Figure 5.8 also highlights the imperfections on 
the microneedle surface.
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Figure 5.8. SEM images of polycarbonate microneedle arrays. 1) Two different arrays 
with reversed microneedle length gradients. (Bar = 0.5mm) Image highlights 
differences in microneedle length and girth across the array. 3) Microneedles are 
almost cylindrical, some less pointed than others and a few contain surface 
deformities at production.
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5.3.2 Application of unmounted polycarbonate microneedle arrays 
to ex-vivo skin
The en-face photograph of methylene blue stained skin post-application of 
microneedle arrays (Figure 5.9) exemplifies the problem of microneedles not 
penetrating the skin when applied with the 3 application methods using 
unmounted microneedles (Figure 5.1). The stratum corneum has not been 
pierced by any of the microneedles. This is further substantiated by the TEWL 
data (Figure 5.10), which shows no substantial increase in water loss between 
pre- and post-application at any of the 9 application sites. Significant 
differences in TEWL were noted between the 3 methods (P=0.337) or the 2 
different arrays (P=0.580).
Figure 5.9. Magnified image of polycarbonate microneedle array applied to skin using 
an aluminium rod to which the array was not mounted. Polycarbonate array and T-bar 
skeleton leave indent (solid line) after 10 second application to skin using applicator 
rod. Applicator rod indent is shown with broken line. Skin has been stained with 10pil 
of 5% methylene blue stain for 10 minutes. However, it is unclear if any microneedles 
punctured the skin, as no characteristic microconduit staining is visible. (Bar = 5mm)
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Figure 5.9 also shows that the array failed to penetrate despite the array being 
pushed into the skin with sufficient force to leave a temporary indent of array 
and T-bar in the skin surface. Thus at this stage, the force of pushing the array 
onto the skin is not the main concern but the application method by which this 
force is exerted needs to be reconsidered.
Array [A] 
Array [B]
i ii iii
Application Method from Figure 5.1
Figure 5.10. Assessing changes in skin barrier function using TEWL when applying 
unmounted microneedle arrays [A] and [B], Application methods are defined in 
Figure 5.1. TEWL increase was significantly affected (P>0.05) by the array type 
(P=0.580); the array type did significantly have the same effect at the different 
application methods (P=0.337) (2-way ANOVA, Bonferroni post-test).
5.3.3 Comparing application of microneedles to skin when
mounted to applicator rods
Polycarbonate microneedles were attached to the end of different applicator 
rods made from PCL (Figure 5.11) and syringe plungers (Figure 5.12). 
Subsequently the applicators were rolled over skin and the skin stained with 
methylene blue allowing the puncture marks (maximum of 13) to be counted.
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Figure 5.11. PCL rod formed from PDMS mould of a glass rod. Polycarbonate 
microneedle array was mounted on the end (right-hand side of photo). The rod was 
made to a length of 7.5cm and cut down to 5cm and 2.5cm to assess the length of 
leverage on microneedle puncture.
J
Figure 5.12. Syringe plunger as an applicator. The array was adhered to the rubber 
bung on the right hand side of the image. This was marked at 7.5cm, 5cm and 2.5cm 
along the shaft and held at each point for various applications. The shaft flexed too 
much at 7.5cm and 5cm, but was stable at 2.5cm. The rubber bung was too flexible 
on the end and the needles gripped the skin but appeared not to penetrate.
Figure 5.13 shows that the puncture efficiency of the arrays is not significantly 
(P=0.0041) affected by the heights at which the applicators are held. Further, 
there is significant difference (P=0.29) in efficiency between the 2 different 
microneedle arrays. The longer applicators suffered from too much flex, 
though the PCL was still solid at the base and the microneedles appeared to 
penetrate the skin. However, the syringe plunger not only flexed, but due to 
the array being mounted on the rubber end, the level of control and direction of 
the forces onto the skin were difficult to control when the rod was held at a 
higher point.
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Syringe & Array [A] 
Syringe & Array [B] 
ESI PCL rod & Array [B]
Length of Applicator
Figure 5.13. Puncture efficiency as visualised by methylene blue staining post­
application using applicators of varying lengths. Each array can only puncture a 
maximum 13 microconduits as each has 13 microneedles.
Initial testing using array [A] mounted onto the end of a PCL rod caused 
microneedles to collapse onto the base of the array, thus array [A] was 
excluded from the final TEWL study. Therefore, the final study to compare 
TEWL was conducted using the PCL and inverted syringe applicators held in a 
pen-like fashion, at only 2.5cm height from the base of the applicator, before 
being rolled over the skin. The PCL rod was cut to size, which also gave the 
advantage that pressure could be applied down along the shaft by pushing on 
the top of the rod during rolling. TEWL data (Figure 5.14) was tested by one­
way ANOVA and the PCL rod with array [B] was significantly (P=0.263) better 
at skin barrier disruption than either syringe plunger with array [A] or array [B].
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Figure 5.14. TEWL assessment of skin barrier function post-applications of 
microneedle arrays [A] and [B] when mounted to applicator syringe and PCL rod. 
Mean TEWL increases when the PCL rod with array [B] is applied to the skin, one­
way ANOVA with post hoc test highlights significance (P=0.263) in between the three 
devices.
Of the all applicators currently tested, the rubber stopper (Figure 5.15) 
applicator worked the best as most of the microneedles impacted on the skin, 
and the outer microneedles, which are the longest on this array, penetrated 
the skin (Figure 5.16). Microneedle array [A], which has the longest needle in 
the middle, appeared to consistently only puncture in the middle, although 
sometimes the middle length microneedles would penetrate, but not 
reproducibly.
5.3.4 Microneedle stability post-application using applicator rods
Microneedle arrays of [A] and [B] design were mounted on the different 
applicators and applied to assess their morphology and stability after ten 
applications. Array [A], remained relatively intact with only the longest central 
microneedle deforming after 10 applications. However, array [B], which has
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Figure 5.15. Rubber stopper used as applicator. The larger top surface provides area 
for grip whilst the short cylindrical stem is firm enough to not bend during rolling 
application. Microneedle array [B] mounted on the end.
Figure 5.16. Rubber stopper applicator was used to apply microneedle array [B]. En- 
face imaging shows clear impression and punctures into the skin from most of the 
microneedles. This is highlighted by methylene blue staining post-application. All 6 of 
the longest (~600pm) microneedles on the outer edge have penetrated, but the only 5 
of the ~400pm left punctures, whilst the shortest microneedle (~200pm) in the centre 
has not punctured at all.
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the longest microneedles at periphery, was heavily deformed whereby all of 
the tallest microneedles collapsed inwards during the applications using the 
PCL or the rubber stopper applicators (Figure 5.17). However, the syringe 
plunger did not cause either array [A] or [B] to deform (Figure 5.18).
Figure 5.17. Deformation of microneedle array mounted PCL rod and rubber stopper. 
Microneedle array [B] is deformed after a ten applications using the rolling technique.
Figure 5.18. Deformation of microneedle array mounted to rubber bung of syringe 
plunger. Microneedle array [A] and [B] are not deformed when applied 10 times using 
the syringe plunger, however these applications did not yield more than 1-3 puncture 
marks with methylene blue staining.
5.3.5 Developing the initial spring-based applicator prototype
Having tried syringe plungers and rubber stoppers as applicators for rolling the 
microneedle arrays over skin, it was clear that this application often caused
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deformation or complete collapse of the microneedle arrays whilst still not 
providing efficient or regular puncture of the skin. Thus it was determined the 
best way to administer such microneedles is for them to be rapidly 
administered perpendicular to the skin, thereby giving a straight trajectory for 
successful penetration.
The initial spring-loaded applicator had a weak spring in it, which meant that 
once the metal wire was pulled up and released, the plunger did not move 
smoothly within the piston-like design. Thus the skin was not penetrated at all. 
A rubber washer was added to the end to cushion the device on the skin, 
though this did not improve skin puncturing by the microneedles (Figure 5.19).
Figure 5.19. Stage 1 spring-loaded applicator. Applicator designed originally to have 
the open end with the rubber seal placed on the surface of the skin, the spring 
compressed by pulling up on the wires and then releasing. This is essentially a valve 
design with the plunger moving inside the outer casing.
Subsequently this device was improved using a more substantial spring from a 
ballpoint pen. This spring was 2cm long when uncompressed, however, the 
spring would deform and not coil evenly when compressed (Figure 5.20). Thus 
the syringe plunger was modified by narrowing the top end to make it thinner 
so as to be inserted into the spring, thereby acting as a guide and support for 
the spring. This ensured that when the spring was compressed it was
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straighter along the line of travel in relation to the plunger. This should ensure 
more of the force from the spring is efficiently delivered to the plunger.
Figure 5.20. Stage 2 spring-loaded applicator. The syringe plunger has been cut to 
slide inside the spring, thus when the plastic cap (right) is pulled back, the spring coils 
over the plunger and compresses straight. The black rubber stopper was needed to 
prevent this spring from popping out of the hole at the round-bottom end of the Falcon 
tube. This spring-loaded applicator with microneedle array mounted on the end was 
used to apply the microneedles into the skin from a vertical position perpendicular to 
the skin.
When the spring-loaded applicator is placed on the skin surface, a suction 
effect causes the skin to be raised into the open end of the applicator valve 
(Figure 5.21). Therefore, as the spring is released, the microneedles penetrate 
the skin and remain in-situ with the force from the uncompressed spring 
against the raised skin. Skin was pinned to the corkboard (Figure 5.22) and 
the type [B] microneedle arrays applied in comparison to a negative control by 
rolling of the microneedles (Figure 5.1 i) and rubber stopper mounted 
microneedles.
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Figure 5.21. Meniscus-like effect is formed inside the outer tube of the application 
device. As the skin is raised into the tube when it is rested into the skin, the spring is 
unable to fully uncompress. Therefore the spring continues to apply a constant force 
onto the skin during the ten-second application.
Closer examination of the applications was conducted under light microscopy 
(Figure 5.23). Methylene blue dye applied post-application and pre-application 
had penetrated into the skin through microconduit punctures created by the 
microneedles. There was no apparent puncture when only the applicator was 
rested and pushed onto the skin without firing the microneedles with any force. 
When the microneedles were released forcefully into the skin, the shortest 
microneedle in the centre appears to have not punctured, whilst the longest 
periphery ones have punctured effectively. Furthermore, the raised bleb 
around the needle application site distinctly marks where the applicator rested 
on the skin surface causing a level of suction to raise the surface of the skin 
into the opening of the applicator.
The impact of the resting outer tube formed around the microneedle punctures 
whilst the indent due to the outer edge of the array was also visible.
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Figure 5.22. Testing of spring-loaded applicator on an ex-vivo skin sample. 1-4: 
applications using the spring device stained post-application, 5-7: applications using 
the spring device stained pre-application. 1-3 and 5-7 were applications with the cap 
fully raised and spring fully compressed before release on the skin surface. However, 
application 4 was with the spring not compressed and just pushing the device into the 
skin. The stopper applicator was raised to a vertical height of 5cm and then jabbed 
into the skin with the same researcher attempting to maintain similar pressure, force 
and trajectory. The controls show a larger imprint of the spring device only, with no 
microneedle array attached. (Bar = 5mm)
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Figure 5.23. Closer examination of the application sites after initial spring-loaded application. Methylene blue dye applied post-application [1-3] and 
pre-application [5-7] has penetrated into the skin through microconduits created by the microneedles. Simply resting and pushing the applicator 
onto the skin shows no apparent puncture [4]. The shortest microneedle in the centre appears to have not punctured, whilst the longest peripheral 
ones have punctured effectively. The raised bleb around the needle application site distinctly marks where applicator rested on the skin surface 
causing a level of suction to raise the surface of the skin into the opening of the application.
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The skin did stretch during the application process for both the spring and 
rubber stopper devices. This can be seen by the rise and fall of the skin 
surface after application (Figure 5.23). If the spring is not fully compressed, 
rather the applicator is rested perpendicular onto the skin and pressed, the 
force exerted by the microneedles is insufficient to puncture the skin. Previous 
work in the laboratory (unpublished data), has established that an initial 
driving force is needed to penetrate the stratum corneum after which the 
device can have gentle pressure applied to maintain its position in the skin.
5.3.6 Developing the final prototype spring-based applicator
To further improve the efficiency and consistency of application, Airedale 
Springs Ltd (UK) were contacted to provide springs of different but known 
characteristics. Four identical closed and ungrounded compression springs 
(Table 5.1) were provided for use in an updated applicator device constructed 
to fit these springs (Figure 5.24). Table 5.1 highlights key details of the 
springs used in the final applicator. ‘Spring V was used in the prototype 
applicator to successfully puncture the skin.
Table 5.1. Details of spring provided by Airedale Springs Ltd
Total No. Total Wire Outside Spring Free
of Coils Dead Diameter Diameter of Rate Length
Coils (mm) Spring (mm) (N/mm) (mm)
Spring 1 12.56 2.00 0.610 7.80 0.310 30.00
Rated springs used in the prototype applicator appeared to provide a more 
consistent application method on ex-vivo skin samples. The en-face images of 
methylene blue show that the applicator worked using the polycarbonate 
array [B] (Figure 5.25) and silicon microneedles (Figure 5.26).
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Figure 5.24. Prototype spring-loaded applicator device. 1) Applicator with 
compression spring released. 2) Microneedle array [B] mounted on end of syringe 
plunger using double-sided sticky tape. 3) Microneedle array [B] remains intact after 
use. 4) Applicator loaded with spring compressed in chamber. 5) Applicator ready 
for use by placing on skin surface and releasing the spring by rotating the upper 
plastic holder (left of image).
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Figure 5.25. En-face image of skin punctured by polycarbonate microneedle array [B] 
applied using final prototype applicator. Polycarbonate array [B] applied five 
consecutive times whilst attached to the spring-loaded applicator. This applicator 
contained spring 1. (Bar = 5mm)
Figure 5.26. En-face image of skin puncture by wet-etched silicon microneedle array. 
Wet-etched silicon 250pm length microneedles on a on a 16-microneedle array also 
punctured the skin when applied using the prototype applicator, though the array 
shattered at first use. This applicator contained spring 1. (Bar = 5mm)
5.4 Discussion
This chapter aimed to develop a suitable method of application for newly 
acquired polycarbonate microneedles. The microneedles were initially imaged 
by scanning electron microscopy (SEM) and light microscopy, which
*  *  •
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highlighted some manufacturing deficiencies when comparing different 
microneedle arrays. Whilst the injection moulding process is relatively simple 
and cheap, the moulds that are used to form such intricate microneedles need 
to be prepared carefully to ensure a hundred percent reproducibility between 
arrays in the length of the microneedles and their surface texture. This will 
prevent differences in the level of puncture or indeed discrepancies in the 
microneedles ability to be coated, hold and release defined dosages of drug 
particles into the skin.
Weakness in polycarbonate microneedles is probably due to their design, 
where the base of each microneedle is neither wide nor supportive enough to 
limit the needles bending and flexing during application. Indeed, this might be 
why generally these polycarbonate microneedles do not penetrate the skin as 
easily as the previously studied silicon microneedles. Wang et al. (2009) 
developed hollow polymer microneedles using photolithography processes 
combined with micromoulding and developed a method for batch production 
of morphologically identical microneedles with a precise lumen and outer 
diameter. Meanwhile Gittard et al. (2009) used two-photon polymerization 
and polydimethylsiloxane (PDMS) micromoulding processes to create 
microneedles with suitable structural, mechanical, and biological properties for 
the delivery of protein-based agents, such as insulin. Future collaboration with 
engineers will enable polycarbonate microneedles to be batch produced 
within precise structural and mechanical tolerances for consistent drug 
delivery applications.
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Unmounted microneedle application techniques showed a slight, but not 
significant, increase in transepidermal water loss (TEWL) in skin. Further 
increases in TEW L were possible when additional forces were exerted by the 
use of the applicator rod. This rod was 10mm in diameter at the base and 
would have disturbed a larger area of the skin surface than the 4mm diameter 
array. The pressure on the skin surface from the array and applicator rod 
could have caused greater water loss through skin pores, sweat ducts and 
hair follicles.
As discussed in Chapter 2, TEWL is very sensitive to environment 
temperature and humidity and is therefore not ideally suited to measuring 
small changes. En-face staining and imaging assists in establishing the 
location and quantity of potential puncture in the skin (Bal et al. 2008; Lanke 
et al. 2009; Pearton et al. 2008), however, each stained puncture may not 
represent complete penetration and just highlight a deep indent in the skin 
surface caused by the microneedle. Thus, subsequent delivery experiments 
would be required to determine the level of penetration. Further repeats of 
TEWL would increase the power of the statistical data.
Though the microneedles did not penetrate the skin by simply pushing or 
rolling onto the skin surface, using syringe plungers as rods with the arrays 
attached to the black rubber end highlighted the need for a solid base to the 
applicator to preventing flexing and cushioning when push against the skin. 
The syringe plunger with the rubber bung is definitely not suited to sustained 
application. When the rubber bung is removed and the plastic of the plunger 
cut flat to mount the array onto directly, the flex in the plunger shaft remains a
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problem. Therefore, a more solid rod applicator, such as a stronger plastic rod 
or polycaprolactone (PCL) applicator was easy to hold and rotate without 
having any flexible link to the array. However after multiple applications or if 
too much force was applied, the PCL applicator also flexed and bent.
Hafeli et al. (2009) fabricated miniature syringes from a silicon plate with an 
array of hollow out-of-plane needles and a PDMS reservoir attached to the 
back of the plate to hold drug solution. Though Hafeli et al. (2009) conduced 
in-vivo testing on mice to demonstrate successful albumin delivery, it is 
unclear how reproducible or fragile the microneedle syringe and reservoir 
would be for clinical distribution and use on humans.
With some practice, using the rolling method (Figure 5.2) with the array 
mounted on the PCL rod, all 13 microneedles on arrays [A] and [B] did 
efficiently puncture the skin. However, microscopic inspection reveals that 
after 9 applications the microneedles on arrays [A] and [B] start to collapse 
and no longer make clear puncture indents, rather they just scratch the skin 
surface. This could potentially be due to design of the polycarbonate 
microneedles, which lack of pyramidal morphology that makes the silicon 
microneedles more rigid (Jin et al. 2009; Rizwan et al. 2009; Sivamani et al. 
2009).
Array [A] with the longest microneedle in the middle appeared to be more 
susceptible to damage and collapse during application. Array [B] however, did 
not suffer the same level of collapse. This could be due to the longest 
peripheral microneedles puncturing the skin and then as it rolls over the skin,
the central ones are pushed into the skin surface while the peripheral 
microneedles are still gripping the skin. Further study using array [A] could 
establish whether the collapse is because only the centre microneedle 
penetrates the skin at initial impact, whilst the peripheral ones are too short to 
grip the skin. Thus, whilst rolling across the skin, the middle needle collapses 
whereas the smaller peripheral microneedles hit the skin surface at a shallow 
angle and collapse.
However, simply attaching a microneedle array onto the end of a metal rod 
and stabbing it into the skin from a vertical height was far from simple, or 
indeed accurate, in terms of puncture efficiency and damage to the 
microneedles and the skin. Repeating such a procedure in clinical practice 
may cause severe bruising and discomfort to the patient, if the application 
was performed with too much force. Applicators for mass distribution, for 
example for vaccine delivery, should be cost effective in their manufacture 
using few components and suitable environmental and aesthetic properties 
(Abbas et al. 2005; Doab et al. 2009; Hafeli et al. 2009; Latkin et al. 2008). 
The applicator developed in our study is simple in design and each 
component can be manufactured using existing techniques and materials, 
including environmentally friendly plastics. This new spring-loaded application 
method is much more consistent at facilitating microneedle puncture of skin, 
however it still needs perfecting. As with other applicators the type [B] 
microneedle array punctures the skin more efficiently, but the shorter needles 
do not always penetrate the skin. This test needs to be repeated using the 
type [A] microneedle array, as these needles exhibit different characteristics. 
The forces and deflection of the array caused by the spring mechanism are all
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unknown and future studies are needed to quantify these attributes. Also, 
spring samples of varying sizes but known characteristics need to be tested to 
optimise the applicator design.
The final spring-loaded applicator was tooled so that, when the spring was 
unloaded, the microneedle array protruded from the opening of the device. 
Therefore as the spring was released from a compressed state the 
microneedles punctured the skin and the skin reacted by exerting a force on 
the microneedles causing the skin to deflect as the microneedles came to rest 
on the skin surface. At this point the spring was no longer fully uncompressed, 
rather the spring was exerting a small force to help maintain the microneedles 
in the created micro-conduits. We have shown that a spring with a rating of
0.310N/mm and free length of 30mm is adequate for replicable skin puncture. 
Collaboration with engineers would provide expertise to measure the weight 
and force applied onto the skin by initial decompression of the spring and the 
subsequent force by the incomplete decompression into the skin.
The outer tube could be altered in diameter as well, however, currently it may 
be better to retain one size for easier development and only alter the length. 
Also the narrow diameter may be of benefit as it causes a meniscus-like effect 
on the skin when the applicator is rested on the skin surface. The device 
could be made very small with the correct spring, tube length and diameter, 
though this might make it harder to hold and use.
Further investigations in the use of polymeric materials to form microneedles 
will provide for better structurally stable and efficiently puncturing
microneedles. Tightening manufacturing tolerances will reduce the differences 
in between microneedle array morphologies and improve their capacity to be 
coated and release drugs, for example, manufacturers can use hydrogels to 
establish the elasticity effects on microneedles and forces during drug delivery 
in an effort to standardise and optimize microneedle design (Chippada et al. 
2009). In addition, testing devices of different sizes, materials and spring 
ratings will ensure the development of a more compact, user-friendly 
applicator for optimum drug delivery by the microneedles.
5.4.1 Conclusions
To conclude, this research has characterised solid polycarbonate 
microneedles and progressed the development of a simple applicator device 
for the successful administration of these microneedles to human skin using 
cheap production methods and minimal parts.
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Chapter 6 
General Discussion
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6.1 General Discussion
Microneedles have been manufactured using technologies developed through 
the growth of the silicon semiconductor industry. Prausnitz group’s publication 
of the late 90’s (Henry et al. 1998) spurred researchers to consider the clinical 
benefits of microneedles as a less invasive and pain free method for drug 
delivery through the stratum corneum. Despite considerable progress in 
developing microneedles for therapeutic use, microneedles have yet to make 
the transition from laboratory to clinic. The clinical study presented in this 
thesis provided a small but important step forward in microneedle research. 
For the first time microneedles were shown to be successful at penetrating the 
skin of human volunteers whilst simultaneously proving to be minimally 
discomforting and preferable compared with hypodermic injection. This project 
also considered cutaneous wound healing responses post-application of a 
25G hypodermic needle and microneedles in human volunteers and 
progressed the development of a suitable microneedle applicator device for 
polymer microneedles.
The main study presented in this thesis involved measuring sensory 
perceptions and biological responses to silicon microneedles being applied to 
human volunteers. Therefore, prior to clinical applications, preliminary 
research was required to consider the organisation, management and delivery 
of the study. This included producing a suitable protocol (Appendix III) and 
establishing techniques for the appropriate measurement of pain, sensation 
and biological response during and post-application of the microneedles. 
Previously, silicon microneedles have been applied using fingertips (Bal et al.
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2008; Henry et al. 1998; McAllister et al. 2003) or metallic rods (as tested in 
Chapter 2). Pre-clinical testing revealed the fragility of silicon-based 
microneedles when applied without applicators, as the base of the array was 
not supported firmly and thus the mechanical forces during impact with the 
skin caused the array to shatter. Evaluation of simple applicator designs 
identified inverted syringe plungers as practical, simple, yet effective 
applicators for administering silicon microneedles in a clinical 
setting (Chapter 2). The rudimentary applicator provided consistent levels of 
skin penetration, although improper use of these applicators could cause 
microneedles to graze the skin causing wounding, or minimal puncture thus 
reducing medicament uptake into the skin.
Transepidermal water loss (TEW L) measurement and topical staining of the 
application site were used to assess the ability of microneedles to puncture 
the skin when applied using an applicator device. Methylene blue does not 
actively diffuse through the stratum corneum (SC). However if the SC is 
compromised, methylene blue diffuses through consequently highlighting 
those areas of skin damage. Previous (Coulman et al. 2006; Kolli and Banga
2008) and recent (Kalluri and Banga 2011; Li et al. 2010; Li et al. 2009) 
microneedle studies have demonstrated that methylene blue reliably 
highlights microneedle puncture. Methylene blue is also used as a histological 
stain to highlight cell membranes (Yaroslavsky et al. 2005). During the 
research in this thesis methylene blue was applied topically during application 
of microneedle devices (silicon or polycarbonate), thus any passive diffusion 
of methylene blue stained the microneedle-formed conduits, as well as any 
damage caused by the base of the arrays (Sections 2.3.2 and 5.3).
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Methylene blue staining highlighted the microneedle punctures whilst affirming 
that the base of the arrays did not cause any damage to the SC. However, 
when rolled onto the skin, the sharp edge and corners of the base of the 
silicon microneedle arrays caused SC damage, as visualised by microneedle 
staining. Concurrently TEW L measurement also demonstrated that 
microneedles had breached the SC both ex-vivo (Section 2.32) and in-vivo 
(Sections 4.3.2). As the microneedle punctures are a theoretical maximum of 
150pm in width and 280pm in depth, rigorous precautions at the time of 
measurement were taken as TEW L is acknowledged as an extremely 
sensitive measurement of skin permeability (Fluhr et al. 2006; Shah et al. 
2005; Suehiro et al. 2004) and is likely affected by the participant’s 
movements, diet and atmosphere over the 24 hour study period. TEWL data 
correlated with the methylene blue skin staining, showing an increase in 
TEWL immediately post-application of microneedle device, which diminished 
to baseline over the 24 hour study period (Chapter 4). The TEWL values also 
reflect the relative efficiency of skin puncture with significant differences in 
TEWL observed when using 280pm microneedles compared with 180pm 
microneedles (Chapter 4).
The encouraging skin puncture results were obtained using silicon 
microneedle arrays, 36 microneedles of length 180pm or 280pm, that had 
never previously been applied clinically and are substantially shorter than 
those used by other researchers (Bal et al. 2008; Ding et al. 2009; Kaushik et 
al. 2001; Sivamani et al. 2005). It was anticipated that the length of the 
microneedles would pose a challenge for effective clinical application, with
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their proximity to each other on the array confounding the problem of 
reproducible and complete insertion due to the “bed of nails” effect (Sivamani 
et al. 2007; Teo et al. 2006). Whilst silicon microneedles of this length proved 
to effectively puncture human skin further work continues to enhance and 
optimise the production techniques and materials used to make microneedles, 
with particular focus on metal and polymer microneedles of different 
morphologies (Ayittey et al. 2009; Chippada et al. 2009).
To ensure appropriate sensory modality measurements were made during the 
clinical study (Chapter 3), suitable pain and sensory-description measurement 
instruments, the short form McGill pain questionnaire (MPQ-SF) and audio 
recordings were tested alongside the applicator devices (Chapter 2). 
Extensive literature searches highlighted the lack of any suitable transient 
pain measurement instrument. However, the MPQ-SF has been used for 
acute and chronic pain studies using the visual analogue scale (VAS) for 
initial assessment of pain intensity (Gubin et al. 2009; Titler et al. 2009). Thus, 
the MPQ-SF proved a suitable instrument to assess the level of sensations 
felt by the participants during the application of needle devices. Audio 
recording is most commonly used during focus groups and interviews. In this 
study audio recording created a verbal diary for capturing the pain and 
sensations experienced real-time during microneedle and hypodermic needle 
application.
Following the pre-clinical development of the microneedle applicator, silicon 
microneedles were applied to human volunteers (Chapter 3) to establish the 
sensory perception of each microneedle device compared to a
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25G hypodermic needle, whilst still evidencing the reproducibility of 
transcutaneous punctures created by each microneedle on the arrays. VAS 
scores identified the hypodermic needle to be significantly more painful on 
insertion than either 180pm or 280pm microneedle arrays. Audio recording of 
each participant’s comments captured further details of sensory modalities 
allowing for cross-reference against VAS data. For example, initial VAS 
results showed the shorter 180pm microneedles to be more painful than the 
longer 280pm microneedles, however, audio comments from participants 
describe the main difference in sensation during the application of each 
device being attributed to the level of ‘pressing’ which is understandable given 
the method of application. It is therefore not so surprising that the shorter 
180pm microneedles caused more ‘pain’ than the longer 280pm microneedles 
given that the administering clinician may well be applying greater force 
during application of the shorter microneedles to ensure skin penetration.
Other pain studies have used VAS scores to determine that microneedles 
cause significantly less pain than hypodermic needles (Bal et al. 2008; Gill et 
al. 2008). Gill et al. (2008) determined that increasing microneedle length from 
480pm to 1450pm caused a significant increase in pain, as shown by the 
mean VAS scores of 2±2mm (mean ± standard deviation) for the 480pm to 
15±17mm for the 1450pm microneedles, respectively. Gill et al. (2008) 
recorded the hypodermic needle to be significantly more painful than any 
microneedle device with a mean VAS score of 24±16mm. Whilst these other 
studies provide context, in our study the 180pm and 280pm length 
microneedles were of much smaller dimensions.
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Skin staining has been used to illustrate successful penetration through the 
SC into the epidermis in various ex-vivo human skin studies (Birchall et al. 
2005; McAllister et al. 2003; Park et al. 2005; Pearton et al. 2008; Pearton et 
al. 2010). However, our clinical study used methylene blue staining of the 
human skin surface following in-vivo needle insertion. Staining showed the 
intensity of punctures reduced over a 24 hour period post-application of 
microneedle devices, suggesting the transient microconduits formed by 
microneedle penetration were resealing (Section 4.3.1). Physical resealing of 
skin channels and wound healing responses post-application of 280pm and 
180pm length microneedles and a 25G hypodermic needle were further 
explored in Chapter 4. These studies highlighted the greater cellular damage 
caused by the subcutaneous insertion of a hypodermic needle in relation to 
intra-epidermal insertion of microneedles, which can be indistinguishable from 
the natural troughs in between the ridges of the skin surface (Section 4.3.3). 
Transverse sections of in-vivo treated human skin demonstrated the ability of 
skin to deform around the microneedles. Consequently, some microneedles 
only penetrated the SC and not deeper into the epidermis. Previously, no 
other in-vivo penetration studies on human skin, involving biopsy of the 
application site, have been conducted. Although, puncture and resealing of 
microneedle punctures have been assessed by biopsy and transverse 
sectioning of in-vivo treated animal models. For example, 559pm length 
maltose microneedles created microchannels of 160pm depth in rabbit skin 
which resealed within 15 hours post-application (Kalluri and Banga 2011).
204
Regarding in-vivo human studies not involving biopsies, estimations of 
penetration depth have been based on the corneocytes debris on 
microneedles. For example, microneedles of 500pm length penetrated to a 
depth of 120pm when being applied to the human skin (Shirkhanzadeh 2005). 
As new non-destructive optical imaging techniques become available, the 
need for biopsying samples to measure mechanical interaction between 
microneedles and skin diminishes. Real-time interferometric imaging by 
optical coherence tomography (OCT) can resolve the skin’s stratified 
architecture in-vivo. Therefore, OCT has been used to observe and measure 
the morphological alterations in skin during and after microneedle penetration 
(Coulman et al. 2010; Donnelly et al. 2011; Enfield et al. 2010). For example, 
both Donnelly et al. (2011) and Coulman et al. (2010) demonstrated that 
microneedles do not penetrate the skin their full length. Furthermore, 
Coulman et al. (2010) suggested that microneedles of varying materials and 
dimensions did not penetrate as greatly as estimated measurements from 
histological techniques. Notably, all microconduits collapsed upon needle 
removal. Even when a 26G hypodermic needle was administered and 
removed, the skin contracted forming a microconduit that was wider in the 
epidermis and narrowing at the SC.
Other in-vivo studies, have measured systemic plasma concentrations of 
molecules such as nicotine and insulin that were administered by microneedle 
insertions (Martanto et al. 2004; Sivamani et al. 2005). However, Teo et al. 
(2005) unsuccessfully attempted to deliver insulin through hollow
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microneedle, concluding that the design of the microneedles needed 
improving for systemic delivery. Conversely, influenza virus-like particles 
(VLPs) did elicit systemically measurable immune responses when 
microneedles coated with VLPs were administered to mice (Song et al. 2010).
Chapter 4 aimed to investigate the wound healing responses within the first 
24 hours after microneedle application to human volunteers. However the 
breadth of biochemical and physiological healing responses that occur after 
cutaneous wounding (as explained in Sections 1.1.2 and 4.1.2), required 
greater sample numbers and resources than permitted during this 
postgraduate research. Investigations into wound healing responses following 
puncture by 180pm microneedles showed no increase in K16 expression 
within the 24 hour study period (Section 4.3.3). However, at 24 hours post­
puncture by 280pm microneedles, there was some evidence of K16 
expression localised to the microconduit. This upregulation was minimal when 
compared to the K16 upregulation elicited after only 8 hours by the 
hypodermic needle puncture. The hypodermic needle insult initiates an 
immediate response of inflammatory markers and platelet release from 
damaged underlying vasculature (Hussein et al. 2007; Jeremy et al. 2003; Ko 
and Marinkovich 2010; Koch et al. 2006; Tamariz-Dominguez et al. 2002).
Research into wound healing associated to microneedle puncture forms a 
small part of the larger picture of skin responses. Many studies have 
investigated the variations in skin based on the sex, age and exposure of the 
skin. However, for a microneedle to deliver efficaciously, the underlying
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immune responses and pharmacokinetics of the delivered drug formulation 
need to be thoroughly researched in an effort to optimise targeted delivery 
using microneedles (Fu et al. 2007; Girardeau et al. 2009; Mine et al. 2008; 
Querleux et al. 2009; Rees 2004; Stamatas et al. 2009). Solid microneedle 
structures developed from silicon, polymers or metals are likely be the first 
commercially available devices as they exploit well established production 
processes. Coating of solid microneedles will enable a suitable drug dosage 
to be loaded and delivered to target cells under the skin surface (Gill and 
Prausnitz 2007; Prausnitz et al. 2009; Quan et al. 2009).
Chapter 5 aimed to optimise an application device for administering 
polycarbonate microneedle arrays to human skin. Microneedle application 
requires a suitable force and velocity to be applied during skin insertion to 
ensure reproducible and efficient piercing of the SC. Patent searches reveal 
the use of impact insertion devices for the application of microneedles 
(Rizwan et al. 2009; Singh et al. 2011; Verbaan et al. 2008). Verbaan et al. 
(2008) mounted the microneedle array to a metal rod and inserted the rod into 
a 20cm long device through a metal coil. An electrical current was applied to 
the coil to create a magnetic field ejecting the metal rod at a calibrated 
velocity into the skin. The applicator provided reproducible and consistent skin 
punctures. To simplify applicator design, spring-loaded devices have also 
being designed and tested (Frederickson 2010; Singh et al. 2011). BD 
Soluvia™ (BD, New Jersey, USA) is a commercially available microinjection 
system which uses a centrally mounted spring to insertion of a single 
microneedle (Laurent et al. 2007). 3M (Minnesota, USA) are currently 
recruiting participants for a clinical trial to test their microneedle arrays using
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spring-loaded applicator devices (ClinicalTrials.gov 2010b). Whilst also 
characterising a new type of polymer microneedle array, Chapter 5 aimed to 
investigate similar methods for applying these microneedles to skin in a 
simple and reproducible manner.
A spring-loaded device was manufactured using readily available plastics 
from the laboratory (Section 5.3.5). The device contained parts machined to fit 
into a simple cylindrical tube containing a spring to apply a rapid downward 
force to the microneedle array. Whilst silicon forms solid microneedle 
structures, the array base was shown to be fragile when insufficiently 
supported by the applicator, causing the array to fracture at its corners during 
application. Indeed, when the array was placed on the skin prior to insertion 
using by the spring-loaded applicator, the silicon array shattered. The 
polycarbonate microneedles deformed when applied using a rolling 
application method. However, design of the spring-loaded applicator enabled 
the device to rest on the skin surface with the microneedles raised inside the 
chamber. This ensured that upon release of the spring, the microneedles 
impacted perpendicular to the skin surface. Further development using 
specially manufactured steel springs resulted in an applicator that provided a 
reproducible method for applying polycarbonate microneedles (Section 5.3.6),
i.e. all the microneedles on the array penetrated ex-vivo human skin and did 
not deform on impact as with the rolling application method.
6.2 Limitations and further work
Throughout this thesis, research was undertaken on human skin. Prior to 
clinical testing, medical devices and investigational drugs would normally
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undergo in-vivo animal testing. However microneedle dimensions would need 
to be scaled down for in-vivo animal administration, altering the drug loading 
capacity, release kinetics and possibly the microneedle manufacture process. 
Furthermore animal skin models vary considerably in follicular density, skin 
thickness, subcutaneous fat and muscle density, which alter the depth and 
penetration characteristics of microneedles. Whilst ex-vivo human skin testing 
is therefore relevant and important it is not without limitations. Ex-vivo human 
skin samples are sourced from surgical procedures such as mastectomy and 
breast reduction. These samples can be unpredictable in size and quality and 
are generally only obtained from older patient groups. Thus limitations in 
sourcing skin samples prevents microneedle testing at different anatomical 
locations, such as the upper arm, which may be more relevant for clinical 
application.
Research into healing of the skin post-application of microneedles was limited 
due to the small sample size, whereby only 12 participants had microneedles 
applied. Twelve participants are a low number for any study, but the low 
sample number was compounded further as biopsy sites were limited to one 
application of each device per person per time point. The snap freezing 
process in the clinical study required the biopsy sample to be orientated 
quickly and mounted to cork for cryosectioning. This led to half of each biopsy 
sample being discarded, thereby halving the number of potential microneedle 
punctures for analysis on each sample. Furthermore, immunohistochemistry 
(IHC) of sectioned samples is wasteful, as each sample has to be carefully 
mounted within the cryostat and sectioning settings optimised for transverse 
sectioning to be collected onto a microscope slide (Webster and Webster
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2007). Therefore, during the storage, sectioning, optimising and collection, the 
samples are affected by temperature changes and humidity causing ice 
crystals to form and tearing or curling of sections. Though each process was 
carefully rehearsed, future work, using a larger collection of samples would 
increase the chances of collecting complete sections with the whole array 
pattern of microneedle conduits visible and permit more thorough evaluation 
of wound responses to the needle insertions.
Uniquely, this study focused on the pain and sensations experienced to 
microneedle use when they were applied in such a way as to ensure sufficient 
penetration of the skin’s outer layer. Though participants in this study found 
microneedle treatment to be acceptable, further research is needed to 
develop the microneedle devices for transition from the laboratory to the clinic. 
To this end, establishing social science studies to investigate the clinician and 
patient needs and requirements will improve microneedle device designs, 
whilst market research will ensure microneedle design, manufacture and 
marketing is directed for suitable medicinal or cosmetic purposes. Studies of 
this nature may also help to inform improved patient information leaflets and 
determine the self-ad mi nistrable nature of microneedle devices.
Due to skin’s elastic properties, the forces required to consistently puncture 
the skin with microneedles may vary and were not quantitatively controlled 
during the clinical trial (Chapter 3). It was, however, evident that a better 
application technique or device was required for microneedles to be delivered 
consistently and reproducibly.
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Microneedle penetration did not appear to cause TN Fa upregulation. Limited 
K16 upregulation was observed only for the 280pm microneedles. Further 
optimisation of the IHC procedure may improve the visible staining of K16 or 
TNFa. However, as the wound created by microneedles is so small, more 
sensitive analysis using polymerase chain reaction (PCR) could amplify the 
mRNA signal of a specific marker protein, such as mRNA for K16. Thus, 
analysis of nucleic acid may reveal differences in precursors to inflammatory 
and wound healing markers (Smith et al. 1999; Wu et al. 2009). Performing 
PCR would require the biopsy sample to be homogenised and thus reduce 
sample stock further (Tuli et al. 2006; Zampetti et al. 2009). PCR, and IHC 
analysis of skin punctured with microneedles when a drug or gene is delivered 
would improve understanding of the effects of formulation and penetration 
depth for a required biological response. Whilst these studies have been 
undertaken on ex-vivo tissue, in-vivo investigations are required. Furthermore, 
due to ethical considerations, control samples were not biopsied to establish 
the ‘normal’ biochemical activity in each participant. During future clinical 
studies, biopsy samples for each participant with no devices applied would act 
as control samples and improve comparisons post-application of devices.
Delivering an active ingredient or gene would enable measurements of 
plasma concentrations of the drug or visualisation of the gene product 
following microneedle application (Ito et al. 2006a; Pearton et al. 2008; 
Prausnitz et al. 2009; So et al. 2009). This would enable different size arrays 
with various microneedle shapes and numbers to be tested in parallel, thereby 
verifying the pharmacokinetics of a drug and optimising the level of
211
penetration needed for successful delivery. Measuring the therapeutic 
responses would move the trial into a new phase of clinical research.
Whilst microneedles can be applied once and removed, microneedle patches 
are also being considered for long-term dosage release of coated drug 
(Cormier et al. 2004; Jin et al. 2009; Nordquist et al. 2007). Further clinical 
studies will need to show the effects of long-term placement of microneedles 
in the skin and this may alter the wound healing and immunological responses 
to having microneedles of various materials in-situ in the body. Thus further 
safety studies will determine the clinical use and duration of applications of 
different microneedle devices.
Despite the ability to apply microneedles into the skin, another vital 
requirement is becoming ever apparent. Increasingly microneedles are being 
designed to incorporate, or be coated by, the drug or vaccine. Thus once 
applied to the skin, the microneedle is required to remain in-situ until the skin 
has absorbed the dosage. Consequently, to enable the microneedles to 
remain in-situ, any applicator must be detachable from the microneedle 
arrays. Furthermore, depending on the release kinetics of any molecule 
coated on, or contained within, the microneedles, a suitable method may be 
required to hold the microneedle in place. It is important therefore that 
microneedle design, applicator design and application technique, and drug 
formulation must all be considered in unison to optimise molecular delivery 
into the skin.
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Unfortunately, due to constraints in engineering resources, it was not possible 
to test different applicator designs with various types of microneedles. 
Collaboration with biomechanical engineers will improve understanding of the 
mechanical forces on the skin to optimise microneedle penetration (Davis et 
al. 2004), thereby improving spring-loaded application device design for 
subsequent laboratory and possibly clinical use. This could also enhance the 
safety of microneedle use and reduce needle-prick incidences by offering a 
single use pre-fabricated and packaged microneedle application device 
(Dumas et al. 2006; Jin et al. 2009; Pandit and Choudhary 2008; Van Damme 
et al. 2009). Regarding economical considerations, a small device, such as 
the one developed in Chapter 5, may prove to be relatively inexpensive as it 
utilises only 5 components, is small in size and would be cheaper to transport 
and store than conventional vials and hypodermic needle and syringes.
6.3 Conclusions
Silicon microneedles of 180pm and 280pm length were administered 
successfully to ex-vivo and in-vivo human skin when applied using an 
inverted-syringe applicator. Methylene blue staining and TEWL 
measurements determined the consistency of skin puncture. Pre-clinical 
testing determined that VAS, MPQ-SF and audio recording were suitable 
instruments for the measure of sensory modalities including pain. Assessment 
of pain using VAS proved that the 180pm and 280pm microneedles were 
significantly less painful than a 25G hypodermic needle. The adapted MPQ- 
SF and audio recording determined that the microneedle devices inducing 
minimal discomfort and highlighting specific sensations which may be
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addressed in future by optimising the design and application methods of 
microneedles.
Sectioning of human skin biopsies showed that the physical trauma caused by 
application of the microneedles was significantly less than that caused by the 
25G hypodermic needle. As a corollary, the wound healing response was 
greater for the hypodermic needle as shown by upregulation of K16 wound 
healing marker. Preliminary testing of a new microneedle design used in 
conjunction with a trajectory-based applicator device showed successful and 
reproducible penetration of ex-vivo human skin. These studies aim to help 
facilitate the transition of microneedles to the clinical setting.
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APPENDIX I
Applicator testing information sheet 
and consent form
VOLUNTEER INFORMATION SHEET 
An Assessment of Pain Perception of Potential Applicators for
Microneedle Arrays
Aim of the Study
To assess the intensity of pain caused by four potential applicators for 
microneedle arrays when applied to the arm. There will be no microneedles 
attached to the applicators.
What the Study Involves
The study will be split into two sessions. At the first session the first applicator 
will be applied to either your left or right forearm. After the application you will 
be asked to complete a short questionnaire that will assess any pain you felt. 
Then the second applicator will be applied to your other forearm and again you 
will be asked to complete the same short questionnaire. This should all take 
around 20 minutes.
Time will then be given for recovery of the application sites before the second 
session.
At the second session the third applicator will be applied to either your right or 
left forearm. After the application you will be asked to complete the same short 
questionnaire as previously. Then the fourth applicator will be applied to your 
other forearm and again you will be asked to complete the same short 
questionnaire. Again this should take around 20 minutes.
Your participation in the study will then be complete.
Thank you for your time.
V O LU N TE E R  SUBJECT CONSENT FO R M  
An Assessment of Pain Perception of Potential Applicators for Microneedle Arrays
P le a s e  in i t ia l  e a c h  b o x  to  in d ic a te  t h a t  y o u  h a v e  r e a d  a n d  a g re e  to  e a c h  s ta te m e n t,
1. I confirm that I have read and understand the information sheet for------------------- -------
this study, that I have had the opportunity to ask questions and that I
have received satisfactory answers to the questions I have asked. -------
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected.
3. I understand that data collected for this study may be used in
publications about the study. ____
4. I agree to take part in the above study. -------
NAME OF SUBJECT DATE SIGNATURE
(Please print your name and date your own signature)
Name of Person taking consent 
(Investigator)
Date Signature
APPENDIX II
Standard short form McGill Pain 
Questionnaire (MPQ-SF) for applicator
testing
Participant Number Application Number
An Assessment of Pain Peraeiition of Potential Appikatorsfor Microneedle Anrays
Pain Perception Questionnaire
1) Visual Analogue Scale
"To measure the pain intensity please mark on the Itne below with a vertical line where you 
feel best represents the pain felt during and after the application. The left end of the scale 
represents no pain and the right end of the scale represents the worst pain imaginable."
No pain Worst pain 
imaginable
2) Key Descriptive Words
"You will now be shown some descriptive words. As each word is read out to you please 
state if it describes a sensation you felt during or after the application. Rate it as either none, 
mild, moderate or severe."
i
None Mild Moderate Severe
Throbbing 0 1 2 3
SnOODng 0 1 2 3
Slabbing 0 1 2 3
Sharp 0 1 2 3
Cramping 0 1 2 3
Gnawing 0 1 2 3
Hot
burning
0 1 2 3
Aching 0 1 2 3
Heaw 0 1 2 3
Tender 0 1 2 3
Splitting 0 1 2 3
Tiring-
exhausting
0 1 2 3
Sickening 0 1 2 3
Fearful 0 1 2 3
Punlshlng-
cruel
0 1 2 3
3) Present Pain Index
"Looking at the words, which one describes the overall intensity of the total pain you 
experienced during and after the application?"
0 No pain
1 Mikl
2 Discomforting
3 Distressing
4 Horrible
5 Excruciating
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1 PROTOCOL SUMMARY
AN ASSESSM ENT O F P A IN , PER C E PTIO N  AND W O U N D  H E A L IN G  
F O L L O W IN G  A P P L IC A T IO N  O F S IL IC O N  M IC R O N E E D LE  ARRAYS.
Investigators:
Dr Anstey, Dr Birchall, D r John, M I Haq, Dr Porter, D r Kalavala.
Lav Summary:
Tiny microneedles, which are able to pierce the outermost barrier layer of skin 
without stimulating the underlying pain receptors or blood vessels, have been 
developed and exploited at the Welsh School of Pharmacy as a new method of 
delivering medicaments and vaccines through the skin. However, these needle 
arrays may still produce sensations in the skin and cause some damage to the 
skin’s outer layers. This study w ill investigate the pain and perception of 
microneedle application in 12 volunteers and gain further unique information 
regarding the rate and extent o f healing o f the resulting damage. Pain and 
perception w ill be measured by Visual analogue scale (VA S) and recorded 
comments; skin barrier function w ill be measured by dye staining and trans- 
epidermal water loss (TEW L), and the nature of the wound healing response w ill 
be measured by assessment o f skin samples using fluorescently labelled 
antibodies, following excision o f three injection sites using the punch biopsy 
technique.
Objectives:
• To determine the pain and perception o f microneedle application.
• To determine the damage to skin barrier function after microneedle 
application.
• To determine and compare the wound healing process o f skin sites 
after the application o f microneedles.
Study population:
12 healthy human volunteers, male or female, aged 18 to 65 years. Suitability 
w ill be determined by a full medical history and lack o f significant abnormalities.
Study Site:
A ll visits and assessments w ill be carried out in the Dermatology Day Unit at St 
Woolos Hospital, Newport.
Number o f Visits:
Each subject w ill be asked to attend for up to 5 visits.
Design
This w ill be an open randomised study in 12 subjects. 3 volunteer subjects will be 
randomised to each of 4 groups attending for a maximum of 5 visits. Treatment 
sites w ill be on the buttock area. The subjects w ill be treated with two types of
5
Version 1.6 08 November 2006
Academic Protocol 11 Department of Dermatology, Royal Gwent Hospital, Newport
microneedle device (180pm and 280pm microneedle length) and a hypodermic 
needle. Subjects w ill have two sets o f 3 needle applications followed by 3 
biopsies (2x 6mm, lx  4mm) at either 1, 4, 8 or 24 hours after application. Visual 
analogue scales and audio-recorded descriptions by the subjects w ill be used to 
compare pain, discomfort and perception o f microneedles and hypodermic needle. 
MicroChannel healing and re-sealing following application of the microneedles 
w ill be monitored by dermatoscope and external staining. TEW L measurements 
w ill be taken, immediately after injection, before biopsy and at 8 and 24 hours. 
The wound healing response w ill be measured by immunohistochemistiy 
assessment o f skin samples using fluorescently labelled antibodies.
Methodology
Baseline V isit Written consent w ill be taken. 6 areas w ill be marked out on 
the buttocks using a template (3 on each buttock). The subjects w ill be 
asked to rest for 15 minutes. Six needle applications w ill then be 
administered, 1 each o f 2 different microneedle arrays and a standard 
hypodermic injection to each buttock. VAS scores and comments on pain 
and perception w ill be recorded. TEW L measurements w ill be taken at 3 
sites and a control site on one buttock.
Biopsy Visit A t either 1,4, 8 or 24 (visit 3) hours after needle applications, 
TEW L measurements w ill be repeated on one buttock. The 3 sites on the 
other buttock w ill be assessed by dermatoscope then stained with
methylene blue stain and photographed before biopsies are taken.
+8 hours after needle applications. Subjects in groups 1, 2 and 4 (visit 2) w ill be 
asked to rest for 15 minutes before TEW L measurements are taken at the 
non-biopsy and control sites.
+24 hours after needle applications. Subjects in groups 1, 2 and 3 will be asked 
to rest for 15 minutes before TEW L measurements are taken at the non­
biopsy and control sites.
Visit 5.Removal o f sutures.
Needles:
Two sizes o f 36-microneedle arrays, 180pm and 280pm in length, and a
hypodermic needle 0.5 x 16mm (orange) w ill be used.
Pain Perception:
The subjects w ill be asked to score pain or discomfort on a 10 cm VAS meter for 
each injection and their verbal comments w ill be audio-recorded, then transcribed.
TEWL:
TEW L w ill be carried out using a Tewameter (Courage &  Khazaka) in a room 
with a controlled atmosphere (22 °C, relative humidity 45 ±  5%).
Dermatoscope
Assessment o f skin channels using a dermatoscope.
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Skin Staining:
MicroChannel healing and re-sealing following application of the microneedles 
w ill be monitored by external staining of the skin with methylene blue stain.
Skin Biopsies:
The 3 sites to be biopsied w ill be injected with 2% lignocaine with adrenaline, 
local anaesthetic. The 2 microneedle sites w ill be excised with 6mm punch 
biopsies and closed with 2 Ethilon sutures. The standard needle site w ill be 
excised with a 4mm punch biopsy and closed with a single suture. Skin samples 
w ill be snap frozen in OCT and placed in separate, labelled, vials for 
transportation to Cardiff University to be processed for immunohistochemistry 
assessments.
Immunohistochemistry:
The skin samples w ill be processed to provide frozen sections for 
immunohistochemistry assessment o f the wound healing response by identifying 
the up-regulation, stasis or down-regulation o f specific markers for ‘repair and 
stress responses’ . Antibodies to keratins K6, K16 and K17 w ill be used to 
investigate the degree o f tissue damage and an antibody to the proliferation 
marker, K i67, w ill be used to identify any enhanced cellular proliferation that may 
occur.
Statistical analysis:
As this is a pilot study with small numbers, descriptive analysis w ill be used 
initially. Suitable statistical analysis may be applied to TEW L data i f  appropriate.
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2 INTRODUCTION
2.1 BACKG RO UND
The skin represents an appropriate and convenient target organ for the localised and systemic 
delivery o f conventional drugs, gene therapies and vaccines. The skin, however, contains a 
protective barrier layer and therefore most drugs and larger molecules cannot permeate. 
Microfabricated microneedle arrays, i.e. plates o f tiny needles, are able to pierce the skin 
barrier layer, the stratum comeum, in a minimally invasive manner to provide a series of 
transient pathways for the delivery of therapeutics to the underlying skin epidermis. The 
needles are designed to be o f sufficient length to pierce the outermost barrier layer without 
impinging on the underlying pain receptors or blood vessels and therefore microneedle 
application, as opposed to conventional needle injection, is potentially pain-free and does not 
cause bleeding. Over the past five years the Welsh School o f Pharmacy has become 
established as the leading U K  institution for the exploitation o f microfabricated microneedles 
for transcutaneous drug and gene delivery and were the first group worldwide to demonstrate 
the ability o f microneedles to facilitate gene delivery and expression in excised human skin1. 
In this study the researchers involved in developing microneedle technology w ill collaborate 
with dermatology scientists in The School o f Medicine, Cardiff University and clinicians at 
Gwent Healthcare NHS Trust to address a range o f important questions relating to 
microneedle use in clinical practice. The lack o f pain associated with the use o f prototype 
silicon microneedles has been previously determined and reported as analogous with placebo 
control (no microneedles).2,3 Preliminary studies have already identified the morphology of 
microneedles for efficient skin penetration.1,4,5 Fresh human skin from cosmetic surgery has 
been used in previous studies to investigate the relationship between microneedle geometry 
and applied force and the size and shape of the resultant microchannels.
2.2 R A T IO N A L E
Funding has recently been secured to manufacture up to 200 design-specific microneedle 
arrays from our principal engineering collaborators. In this project we w ill use our novel 
microneedles to test pain and perception o f microneedle application in volunteers and gain 
further unique information regarding the rate and extent of healing of the resulting skin 
microchannels.
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2.3 SAM PLE S IZE  C A L C U LA TIO N
This is a small pilot study and experience from previous studies has informed the sample size 
chosen.
3 OBJECTIVES
• To determine the pain and perception o f microneedle application.
• To determine the damage to skin barrier function after microneedle 
application.
• To determine and compare the wound healing process o f skin sites 
after application o f microneedles.
4 STUDY DESIGN
4.1 S U M M A R Y
This w ill be an open randomised study in 12 subjects attending for up to 5 visits. 3 volunteer 
subjects w ill be randomised to each of 4 groups. Treatment sites w ill be on the buttock area. 
The subjects w ill be treated with two types of microneedle device (180pm and 280pm 
microneedle length) and a hypodermic needle. Subjects w ill have two sets of 3 needle 
applications followed by 3 biopsies (2x 6mm, lx  4mm) at either 1, 4, 8 or 24 hours after 
application. Visual analogue scales and audio-recorded descriptions by the subjects will be 
used to compare pain, discomfort and perception o f microneedles and hypodermic needle 
versus placebo. MicroChannel healing and re-sealing following application of the 
microneedles w ill be monitored by external staining prior to biopsy. TEW L measurements 
will be taken before needle application, immediately after application and at 8 and 24 hours 
after application. The wound healing response w ill be measured by immunohistochemistry 
assessment o f skin samples using fluorescently labelled antibodies.
4.2 R E C R U IT M E N T
12 healthy human volunteers, male or female and aged between 18 and 65 years, w ill be 
recruited and randomised to one o f four groups. Suitability w ill be determined by a frill 
medical history and lack o f significant abnormalities.
4.3 STU D Y D U R A T IO N
It is anticipated that the study w ill take six months to complete and will start as soon as all 
ethical requirements are satisfied.
9
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4.4 R A N D O M IS A TIO N
The 12 subjects w ill be randomised to four groups of 3 subjects:
Group 1 w ill have 3 sites biopsied at 1 hour after needle applications.
Group 2 w ill have 3 sites biopsied at 4 hours after needle applications.
Group 3 w ill have 3 sites biopsied at 8 hours after needle applications.
Group 4 w ill have 3 sites biopsied at 24 hours after needle applications.
5 STUDY POPULATION
5.1 IN C LU S IO N  C R IT E R IA
(i) 18 -  65 years, male or female.
(ii) No significant clinical or skin abnormalities.
(iii) The patient has signed the consent form after the nature of the study has been 
fully explained.
5.2 E X C LU S IO N  C R IT E R IA
(i) Patients with conditions likely to interfere with the study results.
(ii) Use of experimental drug within the previous 30 days.
(iii) Patients unable or unwilling to give consent to participate.
6 OUTCOME MEASURES
6.1 P R IM A R Y  O U TC O M E  MEASURE
Assessment o f the wound healing response by identifying the up-regulation, stasis or down- 
regulation of specific markers for ‘repair and stress responses’, specifically antibodies to 
keratins K6 K16 and K17 to assess the degree o f tissue damage and Ki67 to identify any 
enhanced cellular proliferation that may occur.6,7
6.2 SECO NDARY O U TC O M E MEASURES
Damage to skin barrier function and time taken for skin to repair measured by trans-epidermal 
water loss8 and skin staining.
Pain and perception o f the different needle type injections measured by VAS and verbal 
comments.
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7 METHODOLOGY
7.1 SUBJECT V IS IT S  
Group 1.
Visit 1 Written consent w ill be taken. 6 areas w ill be marked out on the buttocks using a 
template (3 on each buttock). The subjects will be asked to rest for 15 minutes. Six needle 
applications w ill then be administered, 1 each of 180pm and 280pm 36-microneedle arrays 
and a standard subcutaneous injection to each buttock. VAS scores and comments on pain 
and perception w ill be recorded. TEWL measurements w ill be taken at 3 sites and a control 
site on one buttock. 50 minutes after needle applications TEW L measurements w ill be 
repeated on one buttock. The 3 sites on the other buttock w ill be stained and assessed before 
being biopsied.
Visit 2 8 hours after injection subjects w ill be asked to rest for 15 minutes before TEW L 
measurements are taken at the non-biopsy and control sites.
Visit 3 24 hours after injection subjects w ill be asked to rest for 15 minutes before TEW L 
measurements are taken at the non-biopsy and control sites.
Visit 4 10-14 days after biopsy the sutures w ill be removed.
Group 2.
Visit 1 Written consent w ill be taken. 6 areas w ill be marked out on the buttocks using a 
template (3 on each buttock). The subjects w ill be asked to rest for 15 minutes. Six needle 
applications w ill then be administered, 1 each of 180pm and 280pm 49-microneedle arrays 
and a standard subcutaneous injection to each buttock. VAS scores and comments on pain 
and perception w ill be recorded. TEWL measurements w ill be taken at 3 sites and a control 
site on one buttock.
Visit 2 3/4 hours after needle applications TEW L measurements w ill be repeated on one 
buttock. The 3 sites on the other buttock w ill be stained and assessed before being biopsied.
Visit 3 8 hours after injection subjects w ill be asked to rest for 15 minutes before TEW L 
measurements are taken at the non-biopsy and control sites.
Visit 4 24 hours after injection subjects w ill be asked to rest for 15 minutes before TEW L 
measurements are taken at the non-biopsy and control sites.
Visit 5 10-14 days after biopsy the sutures w ill be removed.
11
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Group 3.
Visit 1 Written consent w ill be taken. 6 areas w ill be marked out on the buttocks using a 
template (3 on each buttock). The subjects w ill be asked to rest for 15 minutes. Six needle 
applications w ill then be administered, 1 each of 180pm and 280pm 36-microneedle arrays 
and a standard subcutaneous injection to each buttock. VAS scores and comments on pain 
and perception w ill be recorded. TEW L measurements w ill be taken at 3 sites and a control 
site on one buttock.
Visit 2 7/4 hours after needle applications TEW L measurements w ill be repeated on one 
buttock. The 3 sites on the other buttock w ill be stained and assessed before being biopsied.
Visit 3 24 hours after injection subjects w ill be asked to rest for 15 minutes before TEW L 
measurements are taken at the non-biopsy and control sites.
Visit 4 10-14 days after biopsy the sutures w ill be removed.
Group 4.
Visit 1 Written consent w ill be taken. 6 areas w ill be marked out on the buttocks using a 
template (3 on each buttock). The subjects will be asked to rest for 15 minutes. Six needle 
applications w ill then be administered: 1 each of 180pm and 280pm 36-microneedle arrays 
and a standard subcutaneous injection to each buttock. VAS scores and comments on pain 
and perception w ill be recorded. TEW L measurements w ill be taken at 3 sites and a control 
site on one buttock.
Visit 2 8 hours after injection subjects w ill be asked to rest for 15 minutes before TEW L 
measurements are taken at the non-biopsy and control sites.
Visit 3 23/4 hours after needle applications TEW L measurements w ill be repeated on one 
buttock. The 3 sites on the other buttock w ill be stained and assessed before being biopsied.
Visit 4 10-14 days after biopsy the sutures w ill be removed.
7.1.1 B io p s ie s
The 3 sites to be biopsied w ill be injected with 2% lignocaine with adrenaline, local 
anaesthetic. The 2 microneedle sites w ill be excised with 6mm punch biopsies and closed 
with 2 Ethilon sutures. The standard needle site w ill be excised with a 4mm punch biopsy 
and closed with a single suture. Skin samples w ill be snap frozen in OCT and placed in 
separate, labelled, vials.
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7.2 ASSESSMENTS
7.2.1 Pa in  a n d  P e r c e p t io n
The subjects w ill be asked to score pain or discomfort using validated assessment tools such 
as a 10 cm VAS meter for each injection where 0 represents no pain and 10 cm represents the 
worst pain imaginable. Their verbal comments w ill be audio-recorded and then transcribed.
7.2.2 Dermatoscope
The application sites w ill be assessed using a hand-held Dermatoscope to confirm the 
incidence o f micro-channels immediately after application. In the unlikely event that there is 
no evidence o f any microchannels, the biopsies w ill not be taken and the subject w ill be 
withdrawn from the study.
7.2.3 Sk in  St a in in g
MicroChannel healing and re-sealing following application o f the microneedles and 
hypodermic needle w ill be monitored by external staining o f the skin w ith methylene blue 
stain just prior to the sites being biopsied. A  standard volume o f stain w ill be applied to each 
site. The site w ill then be swabbed to remove the stain from the surface. The sites will be 
visually assessed and photographed to determine whether the microchannels are still open or 
have re-sealed.
7.2.4 T e w l
Assessments w ill be made using a Tewameter (Courage &  Khazaka) and w ill be carried out in 
a room with a controlled atmosphere (22 °C, relative humidity 45 ±  5% ).8
Assessments w ill be made, immediately after injection prior to biopsies for groups 1 &  2, and 
at 8 and 24 hours after injection.
7.2.5 Immunohistochemistry
Skin samples w ill be identified by subject initials, biopsy site and the subject’s unique study 
number. Samples w ill snap frozen in OCT and placed in separate labelled vials for 
transportation to the Department of Dermatology, Wales College o f Medicine, Cardiff 
University to be processed for immunohistochemistry assessment.
Frozen sections w ill be prepared for immunohistochemistry assessment o f the wound healing
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response by identifying the up-regulation, stasis or down-regulation o f specific markers for 
‘repair and stress responses’. Antibodies to keratins K6, K16 and K17 w ill be used to 
investigate the degree o f tissue damage and an antibody to the proliferation marker, Ki67, w ill 
be used to identify any enhanced cellular proliferation that may occur.6,7
8 MONITORING AND DATA HANDLING
All study documentation may be examined by regulatory authorities for monitoring the 
quality o f the research during the course o f the study.
A ll Case Report Forms (CRFs) and skin samples w ill be identified only by subject initials, 
date of birth, and their unique study number. A ll original consent forms and CRFs w ill be 
kept in a secure location.
The results o f this study w ill be confidential and any report or publication arising from it w ill 
not reveal the subject’s identity. A ll handling and processing of data w ill comply with the 
Data Protection Act, 1998.
9 STATISTICAL ANALYSIS
As this is a pilot study with small numbers descriptive analysis w ill be used initially. Suitable 
statistical analysis may be applied to TEW L data i f  appropriate.
10 ETHICAL CONSIDERATIONS
10.1 E TH IC S  C O M M IT T E E S  A PPRO VA L
Before starting the study, ethical approval w ill be obtained from the Local Research 
Ethics Com mittee. Approval w ill also be sought from  Gwent Healthcare NHS Trust 
Scrutiny and Risk Review Committees.
10.2 IN FO R M E D  C O N SENT
The principles o f the Declaration o f Helsinki w ill be adhered to. A written explanation of the 
study will be given to all volunteer subjects at least one week before their first study visit.
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At the first study visit all subjects w ill be required to give their written consent before starting 
the study and after the nature o f the study has been fully explained. The subjects w ill be 
informed that they are able to withdraw from the study at any stage without being required to 
state a reason and without prejudice to any future care.
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Participant rules post-application
D
Version 1.1 09/03/2007
RULES AND REQUIREMENTS FOR VOLUNTEER SUB JECT
AN ASSESSMENT OF PAIN, PERCEPTION AND WOUND 
HEALING FOLLOWING APPLICATION OF SILICON 
MICRONEEDLE ARRAYS
• Absolutely NO Alcohol 24 hours before or during the 24 period of the trial.
•  Absolutely NO recreational drug use or use of prescription medicines other than 
regular medicines as disclosed in your medical history.
• Absolutely NO moisturising creams or makeup to be used on buttocks from 8pm 
the night before the trail and during the 24 period of the trial.
•  Absolutely NO bathing for the duration of the trial.
**  PI ease arrive exactly at the times stated on your timetable**
Location:
St Woolos Hospital 
Dept, of Dermatology 
2nd Floor Main Building
APPENDIX V
Example of timetable given to each
participant
Timetable for Participant 1
Location: Dermatology Department, St 
Woolos Hospital, Newport
Updated Times (To 
complete on day) Start Time Saturday 10th March Time Required
10.35 AM ARRIVAL & START 2hrs 30 mins
1.05 PM Break 3hrs 40 mins
8:25 PM ARRIVAL VISIT 2 40 mins
9:05 PM END of Day 1
Start Time Sunday 11th March
12:20 PM ARRIVAL AND START 45 mins
1:05 PM END
Thank you for taking part.
Please return in 10-14 days to have stitches removed.
APPENDIX VI
Example Template of application sites 
to guide physician
Application Sites for Participant X
2nd
Left Buttock (TEWL)
C^^^Hypodermic
1st
Right Buttock 
(Perception)
1st
Application
3rd
Application 180
3rd
Application
1st
Application 280
2nd
Application
2nd
Application Hypodermic
APPENDIX VII
Example of timetable given to each 
coordinator on trial day
Dr Kalavala's Timetable
Saturday 10th March
Time Room 1 (Perception) Room 2 (TEWL) Time EXTRA 
BIOPSY (AA)
08:15 ALL STAFF ARRIVAL & SET UP BED 2
09:05 280pm microneedle length array 
applied site C, stained, VAS recorded 
(6)
09:05 09:05
09:10 09:10 09:10
09:15 Hypodermic needle applied site B, 
stained, VAS recorded (6)
09:15 09:15
09:20
09:25
180pm microneedle length array 
applied site A stained, VAS recorded 
(6)
09:25 180pm microneedle applied site B 
Hypodermic applied site A 
280pm microneedle applied site C 
(7)
09:25
09:55 180pm microneedle length array 
applied site A, stained, VAS recorded 
<7)
09:55 09:55
10:00 10:00 10:00
10:05 280pm microneedle length array 
applied site B, stained, VAS recorded 
<7!
10:05 10:05
10:10 10:10 10:10
10:15 Hypodermic needle applied site C, 
stained. VAS recorded (7)
10:15 10:15
10:20 10:20 10:20
10:25 10:25 280pm microneedle applied site B 
Hypodermic applied site C 
180pm microneedle applied site A 
(6)
10:25
10:30 10:30 10:30
10:50 280pm microneedle length array 
applied site B. stained, VAS recorded 
(1)
10:50 10:50
10:55 10:55 10:55
11:00 Hypodermic needle applied site C, 
stained, VAS recorded (1)
11:00 11:00
11.05 11:05 11:05
11:10 180pm microneedle length array 
applied site A, stained, VAS recorded 
(1)
11:10 11:10
11:15 11:15 11:15
11:30 11:30 Hypodermic applied site C 
280pm microneedle applied site B 
180pm microneedle applied site A 
(12)
11:30
11:35 11:35 11:35
11:50 11:50 | 11:50|site B Biopsy |
APPENDIX VIII
Case report form (CRF)
P E R C E P T IO N  A N D  W O U N D  H E  A L IN O
FOLLOWING APPLICATION OF 
SILICON MICRONEEDLE ARRAYS
P artic ipant Initials:
Participant Study Number:
Department of Dermatology 
Royal Gwent Hospital 
Cardiff Road
Newport 
Gwent NP20 2UB
Clinical Record Form Department of Dermatology, Royal
Gwent Hospital, Newport
Participant
Number: 1
Visit 1 : Screen visit Date: D D / M M  12001
PARTICIPANT DETAILS 
(Complete & Tick as appropriate)
Date of Birth dd.mm.yy • • Age (18+)
Male/Female Race   Skin Type ______
ELIGIBILITY: The subject is: Yes No
Male or female, aged 18-65 years
Has no significant clinical or skin abnormalities 
likely to interfere with the results
Has signed the consent form after the nature of the study 
has been fully explained
The subject is not pregnant or lactating (females only)
Only if the answer to each question is yes, is the patient is eligible to take part 
in the study.
Signed: Date:
(Investigator)
Group Assignment:
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Clinical Record Form Department o f Dermatology, Royal Participant
Gwent Hospital, Newport Number:
Visit 1 : Screen visit Date: D D / M M  /2007
Medical History
None
Description Date Start Date Stop
Ongoing
Ongoing
-
Ongoing
Current Medication 
None
Therapy & Indication Date Start Date Stop
Ongoing
Ongoing
Ongoing
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Q w c n l  H e a l t h c a r e  
N H S  Trus t \
'A
Y m d d i r i e d o l a e t h  QSQ 
Q o f a i  i e chyd  Q w e n t
Royal Gwent Hospital
Cardiff Road 
Newport 
South Wales 
NP20 2UB 
Tel: 01633 234234
gj
Oo
r<>
' / / V .
Ysbyty Brenhinol Gwent
Ffordd Caerdydd 
Casnewydd 
De Cymru 
NP20 2UB 
Ffon: 01633 234234
V O L U N T E E R  StfBJJgG'JR C O N S E N T F O R M
An Assessment O f Pain, Perception And Wound Healing Following Application O f Silicon
Microneedle Arrays
Please initial each box to indicate that you have read and agree to each statement.
1. I confirm that 1 have read and understand the information sheet, 
version 2.0 (05.01.07) fo r this study, that I have had the opportunity 
to ask questions and that I have received satisfactory answers to the 
questions I have asked.
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected.
3. I understand that sections o f  any o f my study notes may be looked at 
by responsible individuals from regulatory authorities where it is 
relevant to my taking part in research. I give permission for these 
individuals to have access to my records.
4. I understand that anonymous data about me, as collected for this 
study, including information about my health may be used in 
publications about the study.
5. I am happy for you to inform  my GP that I shall be participating in 
this study.
6. I consent to photographs being taken o f me as a record for 
microchannel staining, fo r teaching healthcare professionals or for 
medical publications only. I understand that i f  the photographs are 
used for teaching purposes or medical publications, my identity w ill 
not be disclosed.
7. I agree to take part in the above study.
NAME OF SUBJECT DATE
(Please print your name and date your own signature)
SIGNATURE
NAME OF PERSON TAKING CONSENT DATE SIGNATURE
(Investigator/ subinvestigator)
Academic Protocol 11 w w w .g w e n t - t r .w a le g ^ g ^ s e , , , Version 1.2 05 Jan 2007
RAsMgStM fcl copy for patient. l^ M f t jg fg s p ita l  notes. Ysbyty Brenhinol Gwent
C Y M R U
G w e n t  H e a l t h c a r e  
N H S  Trus t •S?ft
O
VI.'A
Y m d d i r i e d o l a e t h  Q \ Q  
Q o f a l  l e chyd  Q w e n t
Royal Gwent Hospital
Cardiff Road
Newport
South Wales
NP20 2UB
Tel: 01633 234234
Ysbyty Brenhinol Gwent
Ffordd Caerdydd
Ffon: 01633 234234
Casnewydd 
De Cymru 
NP202UB
V O L U N T E E R  S U B JE C T C O N S E N T F O R M  -  A U D IO  R E C O R D IN G  
An Assessment O f Pain, Perception And Wound Healing Following Application O f Silicon
Microneedle Arrays
Please initial each box to indicate that you have read and agree to each statement.
1. I confirm that I have read and understand the information sheet, -------
version 2.0 (05.01.07) for this study, that I have had the opportunity
to ask questions and that I have received satisfactory answers to the -------
questions I have asked.
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, w ithout giving any reason, without my 
medical care or legal rights being affected.
3. I understand that my participation w ill be audio recorded and_________ ____
transcribed later and this w ill be added to my study notes, which
may be looked at by responsible individuals from regulatory ____
authorities where it is relevant to my taking part in research. I give 
permission for these individuals to have access to my records.
4. I consent to audio recordings being taken o f me as a record for-----------------------
perception and these w ill be transcribed and held with my records
and used for teaching healthcare professionals or for medical -------
publications only. I understand that i f  the audio recordings or 
transcribed notes are used for teaching purposes or medical 
publications, my identity w ill not be disclosed.
5. I agree to take part in  the above study.
NAME OF SUBJECT DATE SIGNATURE
(Please print your name and date your own signature)
Name of Person taking consent Date Signature
(Investigator/ subinvestigator)
copy for patient. I i ^ s p i t a l  notes. Ysbyty Brenhinol Gwent
C Y M I U
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Clinical Record Form Department o f Dermatology, Royal Participant
Gwent Hospital, Newport Number:
Visit 2:
PAIN Perception
&
TEWL
Date:
: / /2007
Time:
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Clinical Record Form Department of Dermatology, Royal 
Gwent Hospital, Newport
1. Audio Recording
Participant
Number: 1
Q:
“Hi, hope you had a safe journey in today, can I  just check your name please. Ok, 
here’s what we are going to do: Please lie down on the coach and make yourself 
comfortable. We are going to apply the devices we are using in the study and we are 
going to record the S E N S A T IO N  that you feel when the things are being applied. Ok?
[TEST TAPE RECORDER]
I need to check this is working first of all. Just tell me your name and tell me where you 
are from.
[PLAY BACK TAPE] [START RECORDING]
As you can hear, to get information on the tape we will need you to speak loudly and as 
clearly as possible.
First thing we are going to do is to apply a dummy device just you show you how we 
want to do this. So we are just going to push this device onto the skin and we want you to 
explain exactly what you are feeling and whether you feel any S E N S A T IO N  at all. 
And it’s very important that we do get some spoken words as this is the information we 
are actually using the study. Ok?
Dr Kalavala will now apply the device.
[APPLY PLACEBO DEVICE - take any notes below]
[DURING APPLICATION] Please describe how that is feeling at the moment. 
[IMM EDIATELY AFTER] Do you feel anything now?
What we are going to do now is apply the first of our three devices and record 
your commentary and feelings whilst they are applied. So similarly to what we just did, 
please describe the SE N S A TIO N s clearly and loudly for the recording.
[DURING APPLICATION] Please describe how that is feeling at the moment. 
[IMMEDIATELY AFTER] Do you feel anything now?”
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Comments: Please record key comments below.
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Gwent Hospital, Newport
Participant
Number:
2. FIRST APPLICATION TO SITE B
3. VAS
Present PAIN Intensity (PPI): Visual Analogue Scale (VAS) (To be taken 
immediately after needle application using VAS tool)
Q:
“To measure the PAIN intensity please move the slider to the position that 
best represents the PAIN felt during and after the application. The left end of 
the scale represents no PAIN and the right end of the scale represents the 
worst PAIN imaginable.”
m m
WORST P AIN
NO P A IN
IMAGINEABLE
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4. SENSATION Rating Index
“You will now be shown some descriptive words. As each word is read out to 
you please state if it describes a SENSATIO N you felt during or after the 
application. Rating the feeling as either none, mild, moderate or severe. If you 
are unsure of the meaning please ask.”
FIRST APPLICATION TO SITE B 
SENSATION Rating Index (PRI):
The words below describe average SENSATION. Place a tick K ]  in the column 
that represents the degree to which you feel that type of SENSATION.
None Mild
Throbbing 0 2 3
Shooting 0 2 3
Stabbing 0 2 3
Sharp 0 1 2 3
a Cramping 0 ■ 1 2 3
Gnawing 0 2 3
Hot-Burning 0 1 2 3
Aching 0 2 3
Heavy 0 2 3
Tender 0 1 2 3
Splitting 0 1 2 3
Tiring- Exhausting 0 1 - « 2 3
b Sickening 0 . . 1 , 2 3
Fearful 0 1 2 3
Punishing-Cruel 0 1 2 3
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Gwent Hospital, Newport Number:
/
Of**
“ Here are some other words to describe sensation. Place a tick [S] in the 
column that represents the degree to which you feel that type of 
SENSATIO N
■ '• ii None Mild • ■ ■ - " Moderate Severe
Pressing 0 1 2 3
Pricking 0 1 2 3
Cold 0 1 2 3
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Gwent Hospital, Newport Number: ^
5. Evaluative overall intensity of total PAIN experience.
Place a tick [S] in the appropriate column.
“Looking at the words, which one describes the overall intensity of the total 
PAIN you experienced during and after the application?”
Evaluative Intensity Score
0 No pain
1 Mild
2 Discomforting
3 Distressing
4 Horrible
5 Excruciating
Version 1.1 9th March 2007
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6. Location of application.
“Please clearly mark on the diagram below where you feel the application 
occurred using a cross. And circle where, if at all, any PA IN  is felt.”
X = first application
O = location of PAIN
Right side
Right A Left
Lei
Left Right
\
Right
tight
Left side
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Gwent Hospital, Newport
Participant
Number: 1
7. S E C O N D  APPLICATION TO SITE C
“What we are going to do now is apply the second of our three devices. So as you 
just did, please describe the SENSATIONs clearly and loudly for the recording. Again 
do say if you do not feel anything.
Dr Kalavala will now apply the device.
[DURING APPLICATION] Please describe how that is feeling at the moment. 
[IMMEDIATELY AFTER] Do you feel anything now?”
Comments: Please record key comments below.
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Gwent Hospital, Newport
Participant
Number: 1
8. VAS
P re se n t PAIN In te n s ity  (PPI): V is u a l A n a lo g u e  S ca le  (VAS) (To be taken 
immediately after needle application using VAS tool)
Q:
“ To m e a su re  th e  PAIN in te n s ity  p le a se  m o ve  th e  s lid e r  to  th e  p o s it io n  th a t 
bes t re p re s e n ts  th e  PAIN fe lt  d u r in g  a n d  a fte r  th is  a p p lic a tio n .”
mm
NO PAIN
WORST PAIN
IMAGINEABLE
Version 1.1 9th March 2007
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Clinical Record Form Department o f Dermatology, Royal Participant
Gwent Hospital, Newport Number:
9, SENSATION Rating Index
“As each word is read out to you please state if it describes a SENSATIO N  
you felt during or after this application. Rating the feeling as either none, mild, 
moderate or severe.”
SECOND APPLICATION TO SITE C 
SENSATION Rating Index (PRI):
The words below describe average SEN SA TIO N . Place a tick [S] in the column 
that represents the degree to which you feel that type of SENSATIO N.
(XRpiFF
IW V IR S IT Y
PKit-rscoi
O M W  
: I *
. 4 . ■
- * 
VoO'**
_[_
Throbbing 0
l None
2
I m m
3
• ;r-'
Shooting 0 2 3
Stabbing 0 2 3
Sharp 0 2 3
a Cramping 0 2 3
Gnawing 0 1 2 3
Hot-Burning 0 2 3
Aching 0 1 2 3
Heavy 0 2 3
Tender 0 1 2 3
Splitting 0 2 3
Tiring- Exhausting 0 1 2 3
b Sickening 0 1 2 3
Fearful 0 1 2 3
Pumshing-Cruel 0 2 3
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Gwent Hospital, Newport Number:
“ Here are some other words to describe sensation. Place a tick K ]  in the 
column that represents the degree to which you feel that type of 
SENSATION
None Mild Moderate Severe
Pressing 0 1 2 3
Pricking 0 1 2 3
Cold 0 1 2 3
'ClBao**
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5 Evaluative overall intensity of total PAIN experience.
Place a tick [v'] in the appropriate column.
“Looking at the words, which one describes the overall intensity of the total 
PAIN you experienced during and after the application?”
Evaluative Intensity Score
0 No PAIN
1 Mild
2 Discomforting
3 Distressing
4 Horrible
5 Excruciating
Version 1.1 9th March 2007
Cardiff
U M V M U T Y
Clinical Record Form Department o f Dermatology, Royal Participant
Gwent Hospital, Newport Number:
11. Location of application.
“Please clearly mark on the diagram below where you feel the application 
occurred using a cross. And circle where, if at all, any PAIN is felt.”
X = second application
O = location of PAIN
Version 1.1 9* March 2007
Cardiff
UM V fitS lT Y
i'li rYStiCH
Clinical Record Form Department of Dermatology, Royal 
Gwent Hospital, Newport
12. THIRD APPLICATION TO SITE A
Participant
Number: 1
“What we are going to do now is apply the final device. So as you just did, please 
describe the SENSATIO N s clearly and loudly for the recording. Again do say if you 
do not feel anything.”
Dr Kalavala will now apply the device.
[DURING APPLICATION] Please describe how that is feeling at the moment. 
[IMMEDIATELY AFTER] Do you feel anything now?”
Comments: Please record key comments below.
Version 1.1 9th March 2007
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13. VAS
Participant
Number: 1
Present PAIN Intensity (PPI): Visual Analogue Scale (VAS) (To be taken 
immediately after needle application using VAS tool)
Q:
“To measure the PAIN intensity please move the slider to the position that 
best represents the PAIN felt during and after this application.”
mm
NO P A IN
WORST P A IN
IMAGINEABLE
Version 1.1 9th March 2007
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Gwent Hospital, Newport Number:
14. SENSATIO N Rating Index
“As each word is read out to you please state if it describes a SENSATIO N  
you felt during or after this application. Rating the feeling as either none, mild, 
moderate or severe.”
THIRD APPLICATION TO SITE A 
SENSATIO N Rating Index (PRI):
The words below describe average SENSATION. Place a tick K ]  in the column 
that represents the degree to which you feel that type of SENSATIO N.
:
Throbbing 0 1
\ M l .]
2 3 •
Shooting 0 1 2 3
Stabbing 0 1 2 3
Sharp 0
___ _ . _ .
1 - 2 3
a Cramping 0 1
------ --------------
2 3
Gnawing 0 1 2 3
Hot-Burning 0 1 2 3
Aching 0 1 2 3
Heavy 0 1 2 3
Tender 0 1 2 3
Splitting * 2 3
Tiring- Exhausting 0 1 2 3
b Sickening 0 1 2 '■ ■ .. 3
Fearful 0 1 2 3
Punishing-Cruel 0 1 2 3
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“  Here are  so m e  o th e r  w o rd s  to  d e s c r ib e  s e n s a tio n . P lace  a t ic k  K ]  in  th e  
c o lu m n  th a t re p re s e n ts  th e  d e g re e  to  w h ic h  y o u  fee l th a t ty p e  o f 
SENSATION.
None Mild Moderate Severe
Pressing 0 1 2 3
Pricking 0 1 2 3
Cold 0 1 2 3
Version 1.1 9th March 2007
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5. Evaluative overall intensity of total PAIN experience.
Place a tick [S] in the appropriate column.
“ L o o k in g  a t th e  w o rd s , w h ic h  one  d e s c r ib e s  th e  o v e ra ll in te n s ity  o f th e  to ta l 
PAIN you  e x p e rie n c e d  d u r in g  and  a fte r  th e  a p p lic a t io n ? ”
tive  In te n s ity  S co re
0 No PAIN
1 M ild
2 D is c o m fo r t in g
3 D is tre s s in g
4 H o rrib le
5 E x c ru c ia tin g
Version 1.1 9th March 2007
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6. L o ca tio n  o f a p p lic a t io n .
“ P lease c le a rly  m a rk  o n  th e  d ia g ra m  b e lo w  w h e re  y o u  fe e l th is  a p p lic a tio n  
o cc u rre d  u s in g  a c ro s s . A n d  c irc le  w h e re , if  a t a ll, a n y  PAIN is  fe lt . ”
X = th ird  a p p lic a tio n
O = lo c a tio n  o f  PAIN
9th March 2007Version 1.1
Clinical Record Form Department o f Dermatology, Royal Participant
Gwent Hospital, Newport Number:
Comments: Please add any additional comments below.
S co rin g : (F o r In te rn a l U se O n ly )
First Application Second Third
I-a S-PRI
(Sensory P A IN  Rating Index)
I-b A-PRI
(Affective P A IN  Rating Index)
I-a+b T-PRI
(Total P A IN  Rating Index)
II PPI-VAS
(Present P A IN  Rating Intensity- 
Visual Analogue Scale)
III Evaluative overall intensity of total 
PA IN  experience
Cardiff
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Visit 2: Stain Photographs Date: D D/ M M /2007 Time: h h : m m
Instruction: TSTAIN IMMEDIATELY BEFORE BIOPSY1
1. Cover application sites with Methylene Blue Stain.
2. Allow 10 minutes to settle.
3. Wipe off excess using Ethanol wipes.
4. Check with Dermatoscope and photograph.
5. Write the filename below once photograph is uploaded to PC.
Site B:
Time: h h : in in
File  nam e:
Site C :
Time: h h : ni m
File  nam e:
Site A :
Time: h h : in m
File  nam e:
Version 1.1 9th March 2007
ORDiFF
U M V f t U T Y
Clinical Record Form Department of Dermatology, Royal Participant
Gwent Hospital, Newport Number:
Visit 2: Baseline TEWL Date: D D/ M M /2007 Time: li h : in m
1. Turn participant onto other side to take TE W L  from applications to their second 
buttock.
2. Participant to rest for 15 minutes.
3. CONTROL SITE TEWL measurement:
Time: h h : in ni
Mean TEW L:
• g/hm2
Standard Deviation
Version 1.1 9th March 2007
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4. PRE-application TEWL measurement site A:
Time: h h : m m
Mean TEWL:
• g/hm2
Standard Deviation
•
5. POST-application TEWL measurement site A:
Time: h h : m m
Mean TEWL:
• g/hm2
Standard Deviation
•
Version 1.1 9th March 2007
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6. PRE-application TEWL measurement site C:
Time: Si h : m 111
Mean TEWL:
• g/hm2
Standard Deviation
•
7. POST-application TEWL measurement site C:
Time: h h : m m
Mean TEWL:
• g/hm2
Standard Deviation
•
Version 1.1 9th March 2007
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8. PRE-application TEWL measurement site B:
Time: li h : m ni
Mean TEWL:
• g/hm2
Standard Deviation
•
9. POST-application TEWL measurement site B:
Time: h h : m m
Mean TEWL:
• g/hm2
Standard Deviation
•
Version 1.1 9th March 2007
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Visit 3: TEWL (S) 8hrs Date: I) D / M M /2007 Time: h h : ni m
1. TEWL measurement 8hrs
CONTROL SITE TEWL measurement:
Time: ii h : m in
Mean TEWL:
• g/hm2
Standard Deviation
Version 1.1 9th March 2007
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Gwent Hospital, Newport Num ber:
Site A: Time: h h : m m
Mean TEW L:
• g/hm2
Standard Deviation
•
Site C: Time: li h : m m
Mean TEW L:
*
• g/hm2
Standard Deviation
•
Site B: Time: h h : m m
Mean TEW L:
• g/hm2
Standard Deviation
•
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Visit 4: TEWL (aX 24hrs Date: D D / M  M  /2007 Time: h h : m ni
2. TEWL measurement 24hrs
CONTROL SITE TEWL measurement:
Time: h h : m ni
Mean TEWL:
• g/hm2
Standard Deviation
Version 1.1 9th March 2007
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Site A: Time: h h : m m
Mean TEWL:
• g/hm2
Standard Deviation
•
Site C: Tim e: h h : m m
Mean TEWL:
• g/hm2
Standard Deviation
•
Site B: Time: h h  : m in 
Mean TEWL:
• g/hm2
Standard Deviation
•
Version 1.1 9th March 2007
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Adverse Event Form
None
Event 1 D iagnosis Severity S tart Date Stop Date
Ongoing
Relationship to  treatm ent
Action taken
Definitely unrelated Unlikely Possible Probable Definitely related
Event 2 D iagnosis Severity S tart Date Stop Date
Ongoing
Relationship to  treatm ent
Definitely unrelated Unlikely Possible Probable Definitely related
Action taken
Comments
Participant
Number:
Cardiff
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Clinical Record Form Department of Dermatology, Royal Participant
Gwent Hospital, Newport Number:
Visit 5: Suture Removal Date: D I) /  M  M /2007 Time: h h : m in
Participant returned for removal of suture 
Payment Form Signed
A n y  o th e r  c o m m e n ts :
□
□
End of Study Date: : D [)/ M  M  /2007
Study Completion
The subject completed the study 
Discontinuation
Adverse event -  complete adverse event form 
Subject request 
Major protocol violation
Other -  please specify
As principle Investigator, I have reviewed this CRF and found it to be a complete and 
accurate record.
Signature Date:
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Example of complete verbatim 
transcription of audio-recorded data 
from the clinical trial
I
Transcribed commentary for participant 8
PLACEBO
P8: Yer, umm, I can feel these, umm, endo-pressure, like someone is 
pressing against me with perhaps a rough fingertip. And that’s about it now.
FIRST APPLICATION.
P8: again it feels like, err, fingertip. Umm, a bit of pressure, nothing else.
P8: its not really pain, there is a sensation there but not really pain. It feels 
like err... you can tell its something sharp but its not painful as such over the 
overall area.
SECOND APPLICATION:
P8: ok, yer, that again feels similar to the first. Umm, pressing a bit more, err, 
it feels a little bit sharper, and you can tell there is something going into the 
skin but it’s not a sharp pain, but you can feel something. Umm, similar to the 
first but a little bit more intense. Umm, but I wouldn’t call it pain.
t
THIRD APPLICATION 
P8: Yes that’s a needle!
p8: ok, yep, it felt like a needle. Very different, can tell something pressing on 
the skin and going in, and then coming out as well. Umm, it feels like the 
injections you get from the nurse. Umm, again it is, there is an increase in 
pressure as it pierces the skin and then its not so bad. But you can definitely 
feel in terms of the other two umm, its far more intense, umm,
FINAL COMMENTS:
Dai: and the final thing is the box for comments you have on the 3 application. 
Perhaps the differences in between them.
P8: differences in between them... well the 3rd application you could tell was 
quite different to the other two, umm, and it did feel like pain a needle if I am 
honest. Umm, so I could feel it going in. with regards to comparing that to the 
other 2 applicators. Umm, yer you felt very different to, the application 2 felt 
more, umm, you could feel it more. If that’s of any help
P8: yer you could tell that more pressure was being applied, umm, and you 
could feel. I suppose the only way of describing it is if you get like err, like 
some leaves and they’ve got little prickly things on the back and you are 
pressing on them. Like a nettle leaf but without the actual sting in it. So you 
can feel that its gone in, it feels a bit like that so the more you press on it the 
more prickly but again it doesn’t feel painful. You can sense that are the 
pricks there... umm, that’s more for the first one. But yer, 3 felt far more sort 
of penetrating than the other 2.
APPENDIX X
Summarised and tabulated data from 
all the collection methods for each
participant
Data for Participant 1
Application order:
Device 1 Device 2 Device 3
280pm Hypodermic 180pm
VAS:
Needle VAS /
Device cm
180pm 0.95
280pm 0.14
Hypodermic 0.25
Sensation words:
180pm 280pm Hypodermic
Mild Moderate Mild Moderate Mild Moderate
Stabbing ✓ ✓
Sharp ✓ ✓
Aching ✓
Heavy ✓ ✓
Tender ✓ • s
Pressing ✓ ✓
Pricking s
180pm 280pm Hypodermic
0 No pain V
1 Mild ✓
2 Discomforting ✓
3 Distressing
4 Horrible
5 Excruciating
Increasing order of Painful/ 
uncomfortable
(deduced from comments)
Least Middle Most
280pm 180pm hypodermic
Placebo 180pm 280pm Hypodermic
“Were there any additional 
comments you wanted to 
make in relation to the three 
devices or what ju st 
happened?"
"No can’t really feel 
anything. There was a 
feeling of pressing 
wax in. 1 feel 
pressure, pressure 
and cold.”
"There’s pressure, slightly 
sharp feeling, umm, much 
like the first one (280), a 
little bit more uncomfortable 
and a greater feeling of 
pressure. In fact some dull 
pain this time. Umm, again 
it’s quite mild, now pressure 
relief, release and now it’s 
gone.”
[comment on VAS]: "Again 
not a huge amount of pain 
so (moves VAS meter), 
much like the second one 
(hypodermic) but err more 
than the first one (280)... 
but it’s a different type of 
pain to the second one 
(hypodermic). The second 
one (hypodermic) was quite 
sharp type of pain, that was 
more of a dull pressure 
pain."
Fine, I can just feel 
pressure, erm stronger 
than last time (placebo), 
no particular discomfort, 
perhaps getting more so 
like a bruise now, like a 
dull pressure. And now 
its coming, leaving. 
Slight stinging now, but 
now it’s gone."
[comment on VAS]: "It 
would be minimal, no 
real pain."
"Sharp pain, more 
uncomfortable than 
last time (280). 
Feels err like a 
normal injection, 
so a sharp pain 
going in and 
leaving and now 
it's gone. Far less 
pressure than last 
time (280)."
"Erm, the first one (280) was 
the easiest to tolerate. Erm 
there is more a feeling of 
pressure, more like 
somebody’s just pushing onto 
the skin without actually 
breaking the skin. Umm the 
second one (hypodermic) felt 
like a sharp needle application, 
so sort of you know a sub cut 
injection. Umm it was sharp, 
and as as uncomfortable as 
subcut injections normally are. 
Umm not crazily discomforting. 
The last (180) umm application 
felt heavier and more pressure. 
Same kind of feeling as the first 
one (280), umm with perhaps 
just err bit more of err err 
pressure pain in the middle, 
perhaps just a sharp in the 
middle. So like the first one 
(280) but it felt like perhaps its 
pushing a bit deeper."
Data for Participant 2
Device 1 Device 2 Device 3
Hypodermic 280pm 180pm
VAS:
Needle VAS/
Device cm
180|im 0.6
280pm 0
Hypodermic 0.64
Sensation words:
180|im a{80pm Hypodermic
Mild Moderate Mild Moderate Mild
Stabbing ✓ V
Sharp ✓ s
Heavy ✓ V
Pressing ✓ ✓ ✓
Pricking ✓ ✓
Cold ✓
180pm 280pm Hypodermic
0 No pain ✓
1 Mild ✓
2 Discomforting ✓
3 Distressing
4 Horrible
6 Excruciating
Increasing order of Painful/ 
uncomforable
(deduced from comments)
Least Middle Most
280pm 180pm hypodermic
Transcription of audio-recorded data:
Placebo 180pm 280pm Hypodermic
‘W ere there any additional 
comments you wanted to 
make in relation to the three 
devices or what just 
happened?"
"Um, 1 can’t really 
feel a lot, 1 feel just 
a bit of pressure on 
the skin."
"That one feels cold and 
pressing. Felt slightly 
sharp, that one does."
"It feels more like 
pressing, but there is no 
sharp pain at the moment. 
Can’t feel anything at all 
now."... "I would say there 
isn’t any pain."
"Felt er like a sharp 
scratch. I can’t feel 
anything else."
[comment on 
PRESSING]: "Yep, but 
I think that was before 
the application."
"The first one (hypodermic) was 
the normal needle, and the 
second one (280) was the least 
painful, or anything like that."
Data for Participant 3
Application order:
Device 1 Device 2 Device 3
Hypodermic 180pm 280pm
VAS:
Needle VAS/
Device cm
180pm 0
280pm 0
Hypodermic 1.14
Sensation words:
180pm 280pm Hypodermic
Mild Moderate Mild Moderate Mild Moderate
Throbbing ✓
Shooting ✓
Stabbing ✓
Sharp ✓
Hot-burning ✓
Aching • ✓
Heavy ✓ ✓
Tender
Splitting ✓
Punishing-
cruel
V
Pressing ✓ ✓ ✓
Pricking ✓
Cold
180pm 280pm Hypodermic
0 No pain ✓ ✓
1 Mild
2 Discomforting ✓
3 Distressing
4 Horrible
5 Excruciating
Increasing order of Painful/ uncomfortable
(deduced from comments)
Least Middle Most
180pm & 280pm - hypodermic
Transcription of audio-recorded data:
Placebo 180|im 280tim Hypodermic
"Were tbere any additional 
comments you wantad fo make In 
rotation to tha thraa davhaa or 
what Juat happanad?"
"I'm just feeling a slight 
pressure."
"Feel a slight pressure, 
continued pressure. There is 
no other sensation."
"Pressure." "Just a slight prick. Maybe, 
a slight decrease. 
Sensation, obviously of the 
needle going through."
"I thought the first (hypodermic) was 
hypodermic needle. Erm when it 
entered the skin there was, there 
wasn't so much pressing, but there 
was more of err, there was a slight 
pain and it continued and umm that 
lasted until, until it was removed. It 
was quite cold as well. Umm in terms 
of the, the second (180) and third 
(280) applications were similar. Umm 
there was no pain at all, umm it was 
just pressing, but I wouldn’t say it was 
a pain sensation. There was just a 
sensation of pressing down on the 
skin. So the last two (180, 280) were 
the most comfortable out of the 
three."
Data for Participant 4
Device 1 Device 2 Device 3
280pm Hypodermic 180pm
VAS:
Needle VAS/
Device cm
180|im 0
280pm 0
Hypodermic 0.11
Sensation words:
180pm 280pm Hypodermic
Mild Moderate Mild Moderate Mild
Stabbing ✓
Sharp ✓ ✓
Heavy ✓
Pressing ✓ ✓
Pricking ✓ ✓ ✓
Cold
180pm 280pm Hypodermic
0 No pain ✓ ✓
1 Mild
2 Discomforting ✓
3 Distressing
4 Horrible
5 Excruciating
Increasing order of Painful/ 
uncomfortable
(deduced from comments)
Least Middle Most
180pm 280pm hypodermic
Transcription of audio-recorded data:
Placebo 180pm 280pm Hypoderm ic
“Were there any additional 
comments you wanted to make in 
relation to the three devices or 
what just happened?”
"A very light prick, but 
no pain whatsoever"
"Umm, that was, it just felt like a 
big press, it just felt like a big 
press. And just new the end of 
it, I think as you were 
withdrawing it I felt it, a little 
prick but it was quite 
comfortable overall."
(comment on VAS]: "I would 
say in terms of pain it would be 
probably nearer what the first 
one (280) was Oh actually 
even less than the first one 
(280), so virtually no pain."
[comment on HEAVY]: "A little 
heavy, a little heavy in terms of 
the press, 1 mean is that what 
heavy means? 1 would say 0 to
1."
[comment on PRICKING]: 
"There was no pricking but I felt 
pricking at the end when he 
was taking it out. So I would 
say, you know, between 0 and 
1 . . .  felt it while he was 
withdrawing the application."
"It's umm, very tiny prick, err, 
again not painful at all. Just 
barely felt It."
(comment on SHARP]: "No, but 
I would probably classify it as 
none, its probably not mild, so 
in between."
[comments on PRICKING & 
PRESSING]: "A bit. in the 
middle (of none and mild)."
"Ok, its quite, I felt that far 
more than the first one 
(280). It was a sharp prick 
this time, and a bit more 
painful than the first one."
[comment on VAS]: "It’s a 
bit more than the other 
one."
[comments on STABBING 
& SHARP]: "Between 0 and 
1 for stabbing and sharp"
"Overall no pain, if only injections 
were like that [laughs]."... "Out of 
those three I probably thought the 
second (hypodermic) was the most 
uncomfortable. Umm third one (180) 
perhaps the most comfortable Err, 
err, I barely felt the first one (280). But 
I did feel a tiny pricking sensation (for 
the 280), so if I was to. Out of all the 
three I would probably prefer the third 
one (180) for an injection. Umm, apart 
from that they were all pretty minimal 
in terms of pain, or you know, umm, 
except second one (hypodermic) is 
probably highest in terms of pain, but 
they were all pretty minimal. I would 
prefer all three, I mean if I was given 
a choice its no problem."... "Err, I felt 
no the side effects apart from the odd 
press in the third one (180) and 
prickly sensations at times but that’s 
it."
Data for Participant 5
Application order:
Device 1 Device 2 Device 3
180pm Hypodermic 280pm
VAS:
Needle VAS/
Device cm
180pm 2.3
280pm 1
Hypodermic 2.3
Sensation words:
180pm 280pm Hypodermic
Mild Moderate Mild Moderate Mild Moderate
Shooting ✓ V
Stabbing ✓ ✓ s
Sharp ✓ ✓ ✓
Tender ✓
Fearful ✓
Pressing ✓ ✓ ✓
Pricking ✓ ✓ ✓
180pm 280pm Hypodermic
0 No pain
1 Mild ✓ ✓
2 Discomforting ✓
3 Distressing
4 Horrible
5 Excruciating
Increasing order of Painful/ 
uncomfortable
(deduced from comments)
Least Middle Most
180pm
&
280pm
- hypodermic
Transcription of audio-recorded data:
Placebo 180pm 280|im Hypodermic
mfere t h f  any s d d W o n s I 
comments y o u  wanted to make In  
relation to the three dev#cos o r  
w h s t J u s t happened?”
"Just a little pricking 
sensation, but its 
fine"..."No, not pain, but 
1 could feel it going in, 
but not painful, no."
"Ok, I can feel something 
there, but I didn’t really see it 
go in, I didn’t really feel much, 
didn’t hurt, it’s a bit erm, yer I 
can feel it"..."prickling"..."I 
didn’t really feel anything"... 
"I suppose it didn’t, the thing 
is it didn’t hurt when it 
entered, but when the doctor 
put it in and started shaking it 
hurt more."
"Err, its ok, more or less like the 
first one (180). Hurt much less 
than the second one 
(hypodermic). I can feel it, 
sharp, but it didn’t hurt as much 
as the last one. Very similar to 
the first one (180)."
"Much sharper, ARGHH 
That is much sharper"... 
"Can feel it much more"
"The second one (hypodermic) was 
the most painful, I could feel it the 
most Umm, the third one (280) I 
didn’t feel as much, but maybe that’s 
because I had the first 2 before. So 
maybe it didn’t 'cause I’ve had the 
first 2 I didn’t feel it, but the second 
one (hypodermic), oh, definitely the 
most painful. And I felt most were 
stabbing and it prickled it a bit**
Data for Participant 6
Device 1 Device 2 Device 3
280pm Hypodermic 180pm
VAS:
Needle VAS /
Device cm
180pm 1.44
280pm 0
Hypodermic 2.17
Sansation words:
180pm 280pm Hypodermic
Mild Moderate Mild Mild
Throbbing ✓
Shooting ✓
Stabbing ✓
Heavy ✓ v'
Pressing ✓ ✓ ✓
Pricking ✓
180pm 280pm Hypodermic
0 No pain ✓
1 Mild V
2 Discomforting ✓
3 Distressing
4 Horrible
5 Excruciating
Increasing order of Painful/ 
uncomfortable
(deduced from comments)
Least Middle Most
280pm 180pm hypodermic
Transcription of audio-recorded data:
Placebo 180pm 280pm Hypodermic
"Were 0m s any additional 
comments you wantad to metre In 
rotation to tha thraa davicaa or 
whatjuat happanad?"
[nothing audible] "There's quite firm pressing 
down. Feel it going in. More 
discomfort than the first (280) 
and second one 
(hypodermic)."
"Feels as if there is something 
being pressed down. He's 
taken his hand off."
"Now its quite sharp, can 
feel something going in, 
inside. Yer it's really 
painful."
"Erm, you could tell quite easily the 
second one (hypodermic) was the 
needle. That was definitely more 
uncomfortable than the other two. 
You could actually feel it in terms of it 
going into you. Erm, third one (180) 
felt as if it was being pressed down 
harder, er, and the first one (280) was 
like someone holding onto your arm."
Data for Participant 7
Application order:
Device 1 Device 2 Device 3
180pm 280pm Hypodermic
VAS:
Needle VAS /
Device cm
180pm 0.21
280pm 0.14
Hypodermic 0.28
Sensation words:
180pm *!80pm Hypodermic
Mild Moderate Mild Moderate Mild Moderate
Sharp ✓ ✓ V
Heavy ✓
Pressing V V ✓
Pricking ✓ • ✓ ✓
Overall Evaluative Pain Intensity:
180pm 280pm Hypodermic
0 No pain ✓ ✓
1 Mild ✓
2 Discomforting
3 Distressing
4 Horrible
5 Excruciating
Increasing order of Painful/ 
uncomfortable
(deduced from comments)
Least Middle Most
180pm
&
280pm
- hypodermic
Transcription of audio-recorded data:
Placebo 180pm 280pm Hypodermic
"Were there any additional 
comments you wanted to make in 
relation to the three devices or 
what just happened?"
"It feels, loads of 
pressure, feels circular 
and 1 can feel an edge 
pressing in more on 
one side. Its getting 
lighter now, umm just 
feels a tickle now."
"Ok, I can feel heavy 
pressure pushing down, 
umm, slightly sharp towards 
the centre, but err, not 
excessively painful, now its 
pulling backwards and its 
gone."
[comment on VAS): "It was 
very little at all."
[comment on HEAVY] 
"Moderate, that was the 
overriding sensation"
"Ok, pressure again, less sharp 
pain, ok there is more sharp 
pain now. Ok, can feel it 
pushing down, it slightly gripped 
my skin and then came out."... 
[during withdrawing of device]: 
no.
[comment on VAS]: "Very little 
again, probably about the same 
as last time (180)."
[comment on HEAVY]: "A mild 
heavy, there wasn’t quite such 
pressure as last time (180)."
[comment on PRESSING]: 
"Umm, felt quite similar to last 
time (180), so I would say 
moderate pressing, that was 
the overriding feeling."
"Yes I can feel that, that's 
like a nipping feeling on the 
skin. Umm it's less now but 
it was worse to start with 
and it’s gone."
[comments on VAS]: 'That 
was slightly sharper to start
with."...
[comments on HEAVY]: I 
didn't feel the heaviness 
that time."
"Umm, I think the first two (180, 280) 
felt fine because pressure doesn’t feel 
as bad as this sharp. Well I suppose 
you would it as a pain, a sharp pain 
on the third one (hypodermic) like 
your skin’s being nipped. But I think 
the third (hypodermic) was the worst. 
The first two (180, 280) were fine and 
not a lot of difference between the 
two."
Data for Participant 8
Device 1 Device 2 Device 3
280pm 180pm Hypodermic
VAS:
Needle VAS/
Device cm
180|im 0.08
280pm 0.01
Hypodermic 0.74
Sensation words:
180|im 280pm Hypodermic
Mild Mild Moderate Mild Moderate
Stabbing ✓
Sharp ✓ ✓ ✓
Tender ✓
Pressing ✓ ✓ ✓
Pricking ✓ V ✓
180pm 280pm Hypodermic
0 No pain ✓ ✓
1 Mild
2 Discomforting ✓
3 Distressing
4 Horrible
5 Excruciating
Increasing order of Painful/ 
uncomfortable
(deduced from comments)
Least Middle Most
280pm 180pm hypodermic
Transcription of audio-recorded data:
Placabo 180|im 280pm Hypodermic
"Mfare there any ecftiftfo/w/ commute you 
wmtfd to mmke in relation to die three 
devices or what Just happened?"
"Yer, umm, 1 can feel 
this, umm, endo- 
pressure, like someone 
is pressing against me 
with perhaps a rough 
fingertip. And that’s 
about it now."
"ok, yer, that again feels 
similar to the first (280). 
Umm, pressing a bit 
more, err, it feels a little 
bit sharper, and you can 
tell there is something 
going into the skin but 
if s not a sharp pain, but 
you can feel something. 
Umm, similar to the first 
(280) but a little bit more 
intense. Umm, but I 
wouldn’t call it pain."
"Again it feels like, err, 
fingertip. Umm, a bit of 
pressure, nothing 
else."..."Its not really 
pain, there is a 
sensation there but not 
really pain. It feels like 
err... you can tell its 
something sharp but its 
not painful as such over 
the overall area.”
"Yes, thafs a needier... "Ok, 
yep, it felt like a needle. Very 
different can tell something 
pressing on the skin and going 
in, and then coming out as 
well. Umm, it feels like the 
injections you get from the 
nurse. Umm, again it is, there 
is an increase in pressure as it 
pierces the skin and then its 
not so bad. But you can 
definitely feel in terms of the 
other two umm, it's far more 
intense, umm."
"Differences in between them. Well the third 
application (hypodermic) you could tell was 
quite different to the other two, umm, and it did 
feel like pain a needle if I am honest Umm, so I 
could feel it going in. with regards to comparing 
that to the other two applicators. Umm, yer you 
felt very different to, the application two (180) 
felt more, umm, you could feel it more. If thafs 
of any help"... "yer you could tell that more 
pressure was being applied, umm, and you 
could feel. I suppose the only way of describing 
it is if you get like err, like some leaves and 
they’ve got little prickly things on the back and 
you are pressing on them. Like a nettle leaf but 
without the actual sting in it. So you can fed 
that its gone in, it feels a bit like that so the 
more you press on it the more prickly but again 
it doesn’t feel painful. You can sense that are 
the pricks there. Umm, thafs more for the first 
one. But yer, three (hypodermic) felt for more 
sort of penetrating than the other two." I
Data for Participant 9
Application order:
Device 1 Device 2 Device 3
180pm 280pm Hypodermic
VAS:
Needle VAS /
Device cm
180pm 1.08
280pm 0.88
Hypodermic 2.23
Sensation words:
180pm 280pm Hypodermic
Mild Mild Mild Moderate
Shooting ✓
Stabbing ✓ V
Sharp ✓ V
Cramping ✓ V
Gnawing ✓
Hot-burning s
Aching ✓ V
Heavy s s
Tender V ✓
Splitting s s
Sickening ✓
Fearful ✓ ✓
Punishing-
cruel
Pressing ✓ ✓
Pricking s
180pm 280pm Hypodermic
0 No pain
1 Mild ✓ ✓
2 Discomforting ✓
3 Distressing
4 Horrible
5 Excruciating
Increasing order of Painful/ 
uncomfortable
(deduced from comments)
Least Middle Most
180pm & 
280pm
- hypodermic
Transcription of audio-recorded data:
Placebo 180pm 280pm Hypoderm ic
“Were there any additional 
comments you wanted to make in 
relation to the three devices or 
what just happened?"
"Its just like something 
on my skin."
"I feel its er, er not clear, it's 
like something scratching on 
the area."...
[comment on FEARFUL] 
"Because I expect it is going 
to cause me a pain, I don’t 
know whether ( I ancitipate 
it)."..."yer, but actually when 
the device was applied, but 
before that was feeling a bit 
fearful."
"No I think it feel quite similar to 
the previous one (180)."...
[comment on associated pain]: 
"No, no, no."
"Sharp and pain." «N o  comments given by 
participants»
Data for Participant 10
Application order:
Device 1 Device 2 Device 3
180pm Hypodermic 280pm
VAS:
Needle VAS/
Device cm
180pm 0.23
280pm 0.46
Hypodermic 0.92
Sensation words:
180pm 280pm Hypodermic
Moderate Moderate Mild
Stabbing ✓ ✓
Sharp ✓
Pressing ✓ ✓
Pricking ✓
Overall Evaluative Pain Intensity:
180pm 280pm Hypodermic
0 No pain ✓ ✓
1 Mild s
2 Discomforting
3 Distressing
4 Horrible
5 Excruciating
Increasing order of Painful/ 
uncomfortable
(deduced from comments)
Least Middle Most
180pm 280pm hypodermic
Transcription of audio-recorded data:
Placebo 180pm 280pm Hypoderm ic
“Were there any additional 
comments you wanted to make in 
relation to the three devices or 
what just happened?"
"Umm literally just feel 
pressure."
"Alright, quite a bit of 
pressure, quite a lot of 
pressure really. Slight pain 
and a lot of pressure."
[comment of VAS]: “Hardly 
any really"
[comment on Evaluative 
Overall Pain]: “It was just mild 
pain, there wasn't pain as in 
sharp pain, but because there 
was pressure." ...“mild 
sensation”... “I think it was 
more of a sensation, it wasn't 
really a pain."
"Quite a lot of pressure, not 
pain, but its [pause] no pain.
[comment on VAS]: "Same as 
the first one (180) really."
"feel a slight pressure and a 
slight pain."
[comment on VAS]: "slightly 
more than the first one 
(180)"
"The second one (hypodermic) was 
painful, then slightly painful. The first 
(180) and the last one (280), they 
were similar. Couldn’t feel any pain, 
could feel sensation and a lot, a lot of 
pressure. There was probably actually 
slightly more pressure on the last one 
(280)."
Data for Participant 11
Device 1 Device 2 Device 3
Hypodermic 180pm 280pm
VAS:
Needle VAS/
Device cm
180pm 0
280pm 0
Hypodermic 2.65
Sensation words:
180pm 280pm Hypodermic
Mild Moderate Mild Mild
Stabbing ✓
Sharp ✓
Hot-
burning *
✓
Heavy ✓
Pressing ✓ s
180pm 280pm Hypodermic
0 No pain ✓ ✓
1 Mild
2 Discomforting ✓
3 Distressing
4 Horrible
5 Excruciating
Increasing order of Painful/ 
uncomfortable
(deduced from comments)
Least Middle Most
180pm 280pm hypodermic
Transcription of audio-recorded data:
Placebo 180pm 280pm Hypodermic
"Were there any additional 
comments you wanted to make In 
relation to the three devices or 
what Just happened?"
«  No comment from 
participant audiabie on 
recording»
"Umm pressing, umm, umm 
pressure.”
"Umm, sharp with a bit, with a 
lot of pressing."
"Yer, err feel kind a like a 
sting."
"First one (hypodermic) was ready 
sharp. The second one (180) was 
more intense pressing. The third one 
(280) was like a mixture between 
both."
Data for Participant 12
Application order:
Device 1 Device 2 Device 3
280pm 180pm Hypodermic
VAS:
Needle VAS /
Device cm
180pm 0.21
280pm 0
Hypodermic 1.69
Sensation words:
180pm 280pm Hypodermic
Mild Mild Mild Moderate
Shooting ✓
Sharp ✓ ✓
Tender ✓
Pressing ✓ s
Pricking ✓ s
180pm 280pm Hypodermic
0 No pain s
1 Mild ✓
2 Discomforting ✓
3 Distressing
4 Horrible
5 Excruciating
Increasing order of Painful/ 
uncomfortable
(deduced from comments)
Least Middle Most
180pm
&
280pm
- hypodermic
Transcription of audio-recorded data:
Placebo 180pm 280pm Hypodermic
“ W e r e  t h e r e  a n y  a d d i t i o n a l  
c o m m e n t s  y o u  w a n t e d  t o  m a k e  i n  
r e l a t i o n  t o  t h e  t h r e e  d e v i c e s  o r  
w h a t  j u s t  h a p p e n e d ? "
"1 can feel a very light 
pressure, umm, on 
my right buttock. 
That’s pretty much 
the only sensation 
really"
"Umm, I’m sorry, umm, ok, 
same sort of, same level of err 
pressure as the last time (280). 
Err, I wouldn’t call it pain, but I 
did feel a slight, I did feel 
something err go into my skin 
but not pain More sort of, don’t 
really know the word to 
describe it really, sort of mild 
discomfort, but."
[comment on SHARP): "I would 
say mild sharp, and umm, 0.5 
for this, because I did feel 
sharp but it wasn’t sort of."
[comment on Overall Evaluative 
Pain): "Mild pain, again it was 
more than the first one (280) 
but you can spot the a mild 
pain So I don’t know."... 
[suggested between none and 
mild): "Yer"
"yer, I can feel a heavier, 
heavier touch, feels as if there 
is something in the centre and 
sort of like a point in the centre 
of the circle. No, no pain at all. 
Just a slightly heavier touch."
"Ok I can feel, ok now I can 
actually feel err what I 
would describe as a pain, 
umm very mild, umm felt 
some needle going into the 
skin. Shucks, slight err 
shooting as the needle sort 
of punctured the skin, umm 
but quite quite, not a, not a 
major pain, but a pain all 
the same."... "Umm yer I 
knew it was there I could 
sort of, I could sense that a 
needle was going in that 
time."
"Err, my least favourite was the last 
one (hypodermic), umm which well 
obviously I didn’t see but I am pretty 
confident that’s the standard sort of 
hypodermic needle, umm. Yer that 
was my least favourite cause that felt, 
that was quite, if I had a choice out of 
the three I would definitely go for one 
of the first two (280, 180). Umm, err, I 
can’t really remember which one out 
of the first two was the least actually, 
umm but I think they were pretty, you 
know they were quite close by. Umm, 
yer so the first two (280, 180) were 
better. Third one (hypodermic), yer, 
uncomfortable but not intolerable, but 
sort of out, out a preference I would 
go for either of the first two (280, 
180)."
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Clinical administration o f microneedles: skin puncture, pain 
and sensation
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Abstract Injections using hypodermic needles cause pain, 
discomfort, localised trauma and apprehension. Additional­
ly, careful use and disposal of needles is required to avoid 
transmission of blood-borne pathogens. As an alternative, 
microneedles can facilitate drug delivery without signifi­
cantly impacting on pain receptors or blood vessels that 
reside beneath the skin outer layers. In this study we aim to 
determine the pain and sensory response to the application 
of wet-etch silicon microneedles, when used in such a way 
as to reliably penetrate skin, and provide a preliminary 
indication of how skin responds to microneedle injury with 
time. Twelve subjects received single-blinded insertions of 
a 25-G hypodermic needle and two microneedle arrays (36 
needles of 180 and 280 pm height). The optimal method for 
microneedle application was determined in a pilot study. 
Pain intensity was scored using a visual analogue scale 
(VAS) and sensory perception determined using an adapted 
McGill Pain Questionnaire Short Form. Skin penetration 
was determined by external staining and measurement of 
trans-epidermal water loss (TEWL). Mean VAS scores, 
verbal descriptions and questionnaire responses showed
M. I. Haq • E. Smith • D. N. John • J. C. Birchall (L2)
Welsh School O f Pharmacy, Cardiff University,
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Cardiff C F10 3NB, UK 
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Ciwent Healthcare NHS Trust, Royal Gwent Hospital,
Cardiff Road,
Newport NP20 2UB, UK
A. Morrissey
Biomedical Microsystems Team, Tyndall National Institute, 
Prospect Row,
Cork, Ireland
that the 180 and 280 pm microneedles caused significantly 
less pain and discomforting sensation in participants than 
the hypodermic needle. Methylene blue staining and TEWL 
analysis confirmed that microchannels were formed in the 
skin following microneedle application. Evidence of micro- 
channel repair and resealing was apparent at 8-24 h post­
application. In summary, this study shows that pyramidal 
wet-etch microneedles can penetrate human skin with 
minimal pain and sensory discomfort, creating transient 
pathways for potential drug, vaccine and DNA delivery.
Keywords Microneedle • Pain • Sensation •
Visual analogue scale • Clinical trial
1 Introduction
Over 15 billion injections are given worldwide each year, 
with at least 40 million curative or therapeutic injections 
being administered globally each day (WHO 1999, 2004). 
With only 5% of injections being used in prophylactic 
immunisations, the vast majority are prescribed for thera­
peutic medical interventions. Whilst injections using hypo­
dermic needles are reliable and effective, they cause pain 
and discomfort and a considerable degree of apprehension 
in young and vulnerable patient groups. Indeed, patients 
suffering from needle-phobia, or “belonephobia”, common­
ly avoid seeking medical and dental assistance due to their 
fear of injections (Kleinknecht 1994; Fredrikson et al. 1996; 
Marks 1988; Ost 1992; Milgrom et al. 1997; Nir et al. 
2003). Needle use also carries the inherent risk of 
transmission of blood-bome pathogens from patient to 
patient where needles are re-used, or from patient to health 
care worker. In some countries the likelihood of cross 
infection with needles is further exaggerated where insuf-
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ficient resources are available for consistent and effective 
disposal and where needle re-use may be unavoidable due 
to economic or supply constraints or necessity. In particular, 
the use o f needles and syringes for delivering vaccines 
creates key challenges for immunisation programmes in 
developing countries including stability, transport and 
storage o f the vaccine in liquid form, the requirement for 
trained clinicians to administer injections and sharps 
disposal. Other potential disadvantages o f injections include 
hypersensitivity, lipohypertrophy, bruising and bleeding at 
the site o f administration. It is also debatable whether 
localised injections are refined enough to deliver the 
medicament or antigen consistently to the most appropriate 
site to exert maximum effect. Clearly, conventional injec­
tion practices, whilst effective, are crude and invasive.
Transdermal drug delivery (TDD) is a proven patient 
choice, providing the potential for improved user conve­
nience and compliance and controlled release o f medica­
ment for enhanced duration o f action and reduced side 
effects (Hutin et al. 2003; Barry 2001). As the skin plays a 
definitive role as a protective barrier however, only a very 
limited number o f drug candidates are able to penetrate 
through the skin and therefore TDD is currently not an 
option for most applications. To this end, various strategies 
for facilitating the transcutaneous delivery o f a larger range 
o f therapeutics have been developed. These include electro­
poration, ultrasound, thermal ablation, iontophoresis and 
skin bombardment (Barry 2001; Coulman et al. 2006a; 
Asbill et al. 2000; Denet et al. 2004; Dreher et al. 2005). 
Whilst demonstrating proof-of-concept, these methods all 
require complex and relatively expensive equipment and 
have yet to make a significant clinical impact.
The last 10 years has seen the development o f minimally 
invasive needle devices, microneedles, that provide a new 
method for delivering medicaments and vaccines into and 
through skin (Coulman et al. 2006a; Henry et al. 1998; 
McAllister et al. 2000; Prausnitz 2001; Birchall et al. 2006). 
Microneedles are designed specifically to penetrate the 
outermost skin barrier layer, the stratum comeum (SC), 
creating transient pathways for transcutaneous delivery. It is 
purported that microneedles can facilitate drug delivery 
through SC interruption without necessarily stimulating the 
pain receptors or blood vessels that reside beneath the skin 
outer layers (Henry et al. 1998; McAllister et al. 2000; 
Kaushik et al. 2001). Kaushik et al. (2001) measured pain 
response to an array o f 400 microneedles o f approximate­
ly 150 pm length (Kaushik et al. 2001). The authors 
showed that pain response following microneedle appli­
cation was statistically indistinguishable from application 
o f a smooth surface and statistically inferior to pain 
response following insertion o f a 26-gauge hypodermic 
needle. In this study pain was measured using a visual 
analogue scale, which is an effic ient, reliable and
validated tool for scoring subject pain, but provides 
limited information on sensation or overall assessment o f 
the human perception o f microneedle application. Impor­
tantly, this study did not attempt to simultaneously 
demonstrate both microneedle functionality and pain 
response as there was no in vivo assessment during the 
study to verify skin puncture due to microneedles.
Sivamani et al. (2005) also assessed pain when compar­
ing in vivo human injections o f 1 pi methyl nicotinate using 
200 pm length hollow microneedle arrays to topical 
application. The data revealed increased blood flux post 
application o f microneedles whilst comments from the 
volunteers describe the application o f microneedles as a 
feeling o f “ pressure but no pain”  (Sivamani et al. 2005). 
Shirkhanzadeh (2005) reported that microneedles coated 
with porous calcium phosphate would appear to be well 
tolerated in human subjects although pain scoring was not 
performed (Shirkhanzadeh 2005). Miyano et al. (2005) 
reported that detachable, biodegradable microneedles o f 
500 pm length manufactured from maltose do not cause 
any pain on skin insertion (Miyano et al. 2005). Further 
reports suggest that microneedles do not cause any 
significant pain when used for extraction o f interstitial fluid 
or blood for glucose monitoring (Smart and Subramanian 
2000; Wang et al. 2005).
Pain is subjective and has several dimensions and 
therefore, is hard to clinically measure or quantify. Any 
measurements o f pain are dependent on how a person 
views and communicates the pain they are feeling and this 
is individual to them. A reliable device for assessing pain 
w ill be able to measure pain consistently without being 
affected by minor changes in environment, administration 
or circumstances, yet would identify i f  the experienced 
pain was to change. One such device is the McGill Pain 
Questionnaire (MPQ) which contains a visual analogue 
scale (VAS) to measure pain intensity, certain key 
descriptor words and an evaluative index using key words 
such as mild, discomforting and excruciating (Melzack 
1975). The MPQ measures dimensions o f pain quality by 
including a set o f descriptor adjectives, an intensity scale 
and pain drawing. The MPQ is one o f the most widely 
used o f all pain measurement tools, it has been shown to be 
h ighly reliable, is able to measure multidimensional 
aspects o f  pain and provides both quantitative and 
qualitative data (Kahl 2005). It is also important however, 
not to use a measurement tool that is overly time 
consuming to administer, making it impractical to employ 
in a clinical setting. One o f the disadvantages o f the MPQ 
is that it takes at least ten minutes to administer, which in 
some studies is not viable. To overcome this, Melzack 
developed a short-form version (MPQ-SF), which uses key 
adjectives from the longer MPQ (Melzack 1987; Collins et 
al. 1997). As shown by Melzack and Katz (1994), the
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MPQ-SF provides a reliable and valid method for assessing 
the qualitative nature o f an individual’s pain experience 
(Melzack and Katz 1994).
In this study we aim to utilise these tools to determine 
whether the wet-etch silicon microneedles we have previ­
ously used in our ex vivo studies (Pearton et al. 2008; 
Birchall et al. 2005; Coulman et al. 2006b) elicit pain on 
application to human volunteers. Uniquely, we w ill simul­
taneously confirm that the solid microneedles have been 
applied appropriately for clinical use, i.e. that they have 
been used in such a way as to reliably penetrate the stratum 
comeum. Our results also provide distinctive data for 
sensory perception on microneedle application and a 
primary indication o f how skin responds to microneedle 
injury with time. We include details o f a preliminary study 
that was performed to confirm that the data obtained in the 
clinical study relates to pain, sensation and injury arising 
from the microneedles themselves rather than the micro- 
needle applicator.
2 M ateria ls  and methods
2.1 Materials
Methylene blue dye was from Fisher Scientific UK, 
Loughborough, UK. Dulbecco’s modified Eagle’s medium 
(DMEM; in 25 mmol 1 1 HEPES) and fetal bovine serum 
were from Invitrogen Ltd, Paisley, UK.
The microneedle arrays used in this study were provided 
by The Tyndall National Institute, Cork, Ireland. These 
platinum-coated “wet-etch”  manufactured silicon micro­
needles have been shown to be o f appropriate dimensions 
to create microconduits, approximately 50 pm in diameter, 
extending through the stratum comeum (SC) and viable
Fig. 1 Each of the 36 pyramidal 180 and 280 pm length microneedle 
arrays were characterized by SEM. Each array was inspected for 
damage (left) and each needle clearly observed for defects in its
epidermis (Wilke et al. 2005). Wet etching using potassium 
hydroxide (KOH) provides a method of mass production 
with lower fabrication costs than dry etching (McAllister et 
al. 2000; Birchall et al. 2005; Wilke et al. 2005). The 
process starts with a standard silicon wafer which is coated 
with silicon nitride on a silicon oxide layer. Square shape 
patterns are transferred into the masking double layer by 
standard photolithography. After lithography, the patterned 
silicon wafer is etched using a 29% KOH solution at a 
temperature o f 79°C. The needle formation is based on 
convex-comer undercut. The silicon wafers are subsequent­
ly coated with a thin (0.3 pm) layer o f platinum. In this 
study the microneedle arrays comprised 36 pyramidal 
shaped microneedles o f either 280 or 180 pm length with 
a base diameter o f approximately 180 pm. The needle tips 
can be less than 1 pm wide. The microneedle arrays were 
characterised and checked for damage prior to use in any 
procedure using scanning electron microscopy (SEM; 
Fig. 1).
Aluminium applicator rods used in preliminary studies 
were supplied by Professor David Barrow at the Cardiff 
School o f Engineering.
3 M ethods
3.1 Preliminary study on microneedle application method
3.1.1 Design o f microneedle applicators
Seven very simple and basic microneedle applicator designs 
were considered. The applicator designs were:
(a) Inverted 2 ml plastic syringe with the plunger surface 
heated and smoothed to remove any protrusions
structure (right). The left image shows a complete 280 pm micro­
needle array, and the right image is a single magnified 180 pm 
microneedle
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(b) Cylindrical aluminum rod with soft rubber (3*2 mm) 
cushion
(c) Cylindrical aluminum rod with an elastic band rubber 
(4* 1 mm) cushion
(d) Cylindrical aluminum rod with hard rubber (2x 1 mm) 
cushion
(e) Cylindrical aluminum rod with foam (5x4 mm) 
cushion
(f) Cylindrical aluminum rod with rubber (6x2 mm) 
cushion and foam (6x9 mm) mounting on the 
application face
(g) Cylindrical aluminum rod with foam (6x9 mm) 
mounting on the application face
These designs are shown in Fig. 2.
3.1.2 Ethical and consent approval
For the collection and use of excised human skin ethical 
approval was obtained from the South East Wales Local 
Research Ethics Committee. Skin samples were obtained 
from redundant skin in mastectomy or breast reduction 
specimens from women who had given their informed 
consented.
3.1.3 Study design fo r pain assessment
Participants (n=13) were recruited after obtaining written 
informed consent to have different applicators applied to 
the inside o f their forearms. Initially, as a control, 
participants received a single application of unmodified 
cylindrical and square aluminium rods. Subsequently, the 
modified applicators were applied single-blind and rando­
mised to either left or right forearm. The pressure of 
application was kept consistent for each applicator. After 
the application a simple pain questionnaire was administered. 
Recovery time o f at least 1 h was provided between 
applications, in case previous applications had increased the 
sensitivity o f the forearm. Verbal descriptions of the application 
from the volunteers were recorded during the application 
process and transcribed verbatim.
3.1.4 Ex vivo testing o f applicators
Full-thickness human breast skin was obtained from 
mastectomy or breast reduction. Skin was collected from 
a variety o f donors ranging from 45 to 65 years of age. The 
skin was frozen at -20°C and defrosted for 2 h before use. 
The two least painful applicators, as determined from
Fig. 2 Seven simple micronee­
dle applicators designs, (a) 
Inverted 2 ml plastic syringe 
with the plunger surface heated 
and smoothed to remove any 
protrusions, (b) Cylindrical alu­
minum rod with soft rubber (3 x 
2 mm) cushion, (c) Cylindrical 
aluminum rod with an elastic 
band rubber (4* 1 mm) cushion, 
(d) Cylindrical aluminum rod 
with hard rubber (2 x 1 mm) 
cushion, (e) Cylindrical alumi­
num rod with foam (54 mm) 
cushion, (f) Cylindrical alumi­
num rod with rubber (6 x 2 mm) 
cushion and foam (6x 9 mm) 
mounting on the application 
face, (g) Cylindrical aluminum 
rod with foam (6x9 mm) 
mounting on the application face
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subject pain questionnaire, were tested ex vivo for skin 
puncturing efficiency. Araldite adhesive was applied to the 
top o f the applicators and a microneedle array (in this case 
49 microneedles o f 250 p.m length) bonded in a central 
position. Three different skin application techniques were 
tested:
1. Applying the applicator in a single rolling motion, 
whereby the applicator is placed at an angle o f 
approximately 45° to the skin surface and rotated 
firmly forward through an angle o f 90°, finishing at 
approximately 135°
2. Pushing the applicator vertically onto the skin, gently 
rotating the applicator for 10 s before removal
3. Punching the applicator vertically onto the skin with 
force, holding down for 10 s and then lifting o ff
Following application skin samples were treated topical­
ly with 10% methylene blue dye solution for 5 min before 
the excess dye was wiped from the skin surface. The 
samples were viewed under a light microscope.
3.2 Clinical study on microneedle pain, perception and skin 
puncturing
3.2.1 Ethical and consent approval
Ethical approval for this study was obtained from the South 
East Wales Local Research Ethics Committee. Written 
informed consent was obtained from healthy volunteers in 
adherence with the principles of the Declaration of Helsinki.
3.2.2 Study design
Participants («=12) received single-blind applications o f 
two types o f microneedle array (36 pyramidal microneedles 
o f either 180 or 280 pm height) and a 25-gauge 
subcutaneous hypodermic needle, injected at an angle 
appropriate for sub-cutaneous injection. Figure 3 shows 
the hypodermic needle in scale with one o f the microneedle 
arrays. Each o f these three applications were given to each 
buttock. The buttock was used as 6 mm skin biopsies were 
subsequently taken for further study. Applications o f needle 
devices on one buttock were used to assess pain, perception 
and skin puncturing whereby the assessor was also blinded 
to the application device being administered. The second 
application was used to assess transepidermal water loss 
(TEWL) from the skin.
Following application to the human subjects each 
microneedle array was carefully examined by SEM for 
morphological changes. We observed no structural damage 
to any o f the arrays or to any individual microneedles. The 
puncture sites on each patient were also carefully examined
Fig. 3 The 25-G hypodermic needle used in this study placed next to 
36 pyramidal microneedles on the 280 pm microneedle array (Bar= 
1 cm)
by dermatoscopy post-application and no microneedle or 
microneedle array artefacts were visible.
3.2.3 VAS and sensation questionnaire
The pain intensity rating was taken immediately after 
application o f each needle using an electronic sliding VAS 
whereby the participant moved a slider along a 10 cm slide 
where one end represented “No Pain=0 cm” and the other 
end the “ Worst Pain Imaginable=10 cm. The slider was set 
to 0 cm at prior to each reading. The device does not disclose 
to the participant their rating, although a digital display 
viewed only by the assessor shows the rating for recording.
The perception questionnaire is based on the McGill 
Pain Questionnaire Short Form (MPQ-SF). It contains the 
four main assessment points o f the MPQ-SF and three 
additional words (pressing, pricking and cold) taken from 
the long form MPQ, which unpublished research within our
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Table 1 Summary of oral comments recorded during and immediately post-application of prototype applicator designs 
Applicator Summary of transcribed comments
A Does not feel sharp on the skin. Pressure can be felt but no pain. Could offer advantage over both original applicators
B Causes less sharpness than the square applicator but feels very similar to the round applicator. Therefore, although it
offers advantage over the square applicator it is probably not significantly better than the round applicator 
C Similar to applicator B, causes less sharpness than the square applicator but feels very similar to the round applicator. Therefore,
although it offers advantage over the square applicator it is probably not significantly better than the round applicator 
D Feels the same as the round applicator therefore would offer no advantage over it
E Feels soft on the skin. Causes no pain or does not feel sharp. Could offer advantage over both original applicators
F Cannot really feel the applicator on the skin. Causes no pain. Could offer advantage over both original applicators
G Similar to applicator F, causes no pain and could offer advantage over both original applicators
group have shown to be o f specific relevance in this study. 
The formatting and presentation o f the MPQ-SF was 
designed to ensure reliability and validity o f the data 
collected. To prevent leading of the participants the “ Pain 
Rating Index" o f descriptor words was relabelled the 
“ Sensation Rating Index" as this provided a truer context 
o f what was felt during device application.
3.2.4 Transepidermal water loss (TEWL)
TEWL was measured to determine the level o f disruption to 
skin barrier function following application o f the hypoder­
mic needle and microneedle arrays. A Tewameter TM 210 
(Courage and Khazaka Electronic GmbH, Koln, Germany) 
was used to measure TEWL at a control site as well as the 
three sites pre- and post-application of needle devices. The 
TEWL probe is a delicate measuring device, and was 
protected from shock, dirt, manual contact and liquids, 
using a cap when not in use. Before TEWL measurement 
each participant rested for 15 min to acclimatise to the 
ambient room temperature and relative humidity, which 
were maintained at 22°C and 45±5%, respectively. TEWL 
measurements were taken by carefully resting the TEWL 
probe horizontally on the application site, with the probe 
head vertical and perpendicular to the skin. The probe was 
held in place using a clamp stand to prevent any 
interferences arising from hand movement or heating o f 
the probe by the assessor. Once the participant was 
comfortable, a reading was taken over 3 mins. The 
presented values represent the mean TEWL reading for 
the 20 s prior to stopping the measurement. I f  there were 
any uncharacteristic spikes during this period a more 
representative 20 s reading was used. TEWL readings were 
taken 1, 4, 8 and 24 h after the needle applications.
3.2.5 Dermatoscope ami skin staining
Evidence of skin puncturing and microchannel healing and re­
sealing was provided using an external stain. The 12 
participants were randomised into four groups o f three 
participants. At either 1 (group 1), 4 (group 2), 8 (group 3) or
24 (group 4) h after application of the needles 20 p.1 of 
methylene blue stain was applied to the needle treated skin 
surface. The stain was left in place for 10 min before excess 
stain was removed using ethanol wipes. The sites was then 
visually assessed through the dermatoscope and a photographic 
image recorded (Canon IXUS 500 digital camera; Canon, UK).
3.2.6 Statistical analysis o f results
Non-parametric Wilcoxon signed rank test was performed 
using Prism GraphPad. Statistical significance was shown 
when p<0.05 and applied to both the VAS and TEWL data.
4 Results
4.1 Preliminary study on microneedle application method
The method o f application o f microneedles w ill be key to 
efficient and painless penetration through the skin barrier
Fig. 4 Methylene blue staining of ex vivo human skin. A 49 
microneedle array of 250 p.m microneedle length was mounted onto 
the inverted syringe applicator and applied to human skin. The 
presence of blue staining confirms successful interruption of the 
stratum comeum barrier
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Fig. 5 Microneedle arrays of 
180 and 280 pm length 
mounted onto inverted syringe 
applicators
/ /
layer. A preliminary study assessed pain response and 
puncturing efficacy of different applicator designs prior to 
the clinical study. Seven potential basic applicator designs 
(Fig. 2) were investigated. A summary of oral comments 
post-application o f the applicators are presented in Table 1.
As shown in Table 1, some of the applicator designs 
were less painful on administration than the applicators 
commonly used in laboratory studies, i.e. cylindrical and 
square-end metal rods. Figure 4 confirms that one o f these 
applicator designs, i.e. the inverted syringe (A), was able to 
efficiently penetrate human skin when mounted with a 
microneedle array. Similar results were obtained with the 
foam applicator (E). Whilst Table 1 suggests that designs F 
and G are also suitable from a pain perspective, the ex vivo 
skin tests revealed that these applicators were not as 
efficient as penetrating human skin due to the cushioning 
effect o f the rubber and/or foam mounting. Ex vivo testing 
also showed that the first method of application was shown 
to be optimal for applying the microneedles, i.e. applying 
the applicator in a single rolling motion.
Based on this simple pilot study the foam applicator and 
the syringe applicator were shown to be most appropriate 
for use in the clinical study. As the syringe applicators are 
easier and less costly to obtain and are supplied sterile, 
these applicators were selected for application o f micro­
needles to human volunteers (Fig. 5).
4.2 Clinical study on microneedle pain, sensation and skin 
puncturing
The 12 subject clinical study firstly aimed to test the pain 
response against single-blinded application o f microneedle 
arrays o f two different microneedle heights (mounted on the 
reverse o f a syringe barrel) and a hypodermic needle. The 
mean VAS pain scores following application o f each 
'needle' treatment show that the 180 and 280 pm micro­
needles caused significantly less pain (p =0.027 and p =
0.0005 respectively) in participants than the hypodermic 
needle [Fig. 6(a)]. The 280 pm microncedles were 
perceived to be significantly less painful than the 180 pm 
microneedles (/?=0.039). Individualised data in Fig. 6(b)
further show that the hypodermic needle was always more 
painful than either microneedle device whilst 11 o f the 12 
participants found the 180 pm microneedles to be more 
painful than the 280 pm microneedles.
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Fig. 6 (a) Overall mean±SD for VAS pain scores following 
application of a 180 pm microneedle array (180), a 280 pm micro­
needle array (280) and a 25-G hypodermic needle (Hypodermic), (b) 
Individual participant VAS scores following application of a 180 pm 
microneedle array (circle), a 280 pm microneedle array (cross) and a 
25-G hypodermic needle (triangle)
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Table 2 Ranking of reports of 
pain and discomfort following 
device applications
Ranking deduced from audio- 
recorded comments made by 
participants both during and 
after the application of each 
device
Comparative pain/discomfort from participant oral descriptions 
following application of three needle devices
Participant (order of application) Least
Pain/discomfort
Middle
Pain/discomfort
Most
Pain/discomfort
1 (280/hypo/180) 280 180 Hypo
2 (hypo/280/180) 280 180 Hypo
3 (hypo/180/280) 180/280 Hypo
4 (280/hypo/180) 180 280 Hypo
5 (180/hypo/280) 280 180 Hypo
6 (280/hypo/180) 280 180 Hypo
7 (180/280/hypo) 180/280 Hypo
8 (280/180/hypo) 280 180 Hypo
9 (180/280/hypo) 180/280 Hypo
10 (180/hypo/280) 180 280 Hypo
11 (hypo/180/280) - 180/280 Hypo
12 (280/180/hypo) 180/280 Hypo
Oral comments confirmed that every participant found 
the hypodermic to be the most painful and uncomfortable 
of the three applications. Five of the 12 participants felt that 
treatment with the 180 pm microneedle array was slightly 
more discomforting than the application o f the 280 pm 
microneedle array as clearly explained by participant 6:
“ Third one (180) felt as i f  it was being pressed down 
harder” , “ The first one (280) was like someone holding 
onto your arm” . The hypodermic needle was immediately 
highlighted as the most painful and uncomfortable, as 
explained by participant 5: “ definitely the most painful” . 
Table 2 summarises the level o f pain/discomfort felt by
Cold 
Pricking 
Pressing 
Punishing-cruel 
Fearful 
Sickening 
Tiring-exhausting 
Splitting 
T ender 
Heavy 
Aching 
Hot-buming 
Gnawing 
Cramping 
Sharp 
Stabbing 
Shooting 
Throbbing
0%
Microneedle Array
180 micron 280 micron
Hypodermic Needle 
25-gauge
100% 0% 100% 0% 100%
Fig. 7 Sensory evaluation following needle application. Each 
participant was asked to complete an adapted SF-MPQ to rate the 
sensations experienced during application of the 180 pm length and
280 pm length microneedle arrays and 25-G hypodermic needle. 
These data show the percentage of participants who rated each 
sensation occurring as mild (empty square) or moderate {filled square)
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each participant following each needle application. The 
order o f needle application, from the randomisation 
schedule, did not affect the participants’ description o f 
differences in pain and discomfort.
In addition to perceived pain this study further explored 
the sensation following microneedle and hypodermic 
needle treatment. Collated responses to the sensation 
questionnaire are shown in Fig. 7. Overall a greater number, 
variety and severity o f sensations were experienced when 
participants were treated with the hypodermic needle when 
compared with either microneedle array. Participants felt 
greater “sharp’ and “stabbing’ sensations when the hypo­
dermic needle was applied and more ‘pressing’ and ‘heavy’ 
sensations when the microneedles were applied.
Allied to pain and sensory response an important arm of 
this study was to demonstrate that the microneedle arrays 
had been applied in such a way as to penetrate the skin. 
This allows for meaningful comparison of pain response 
using an application procedure that is relevant, that is, using 
an application method and pressure that is shown to work
in human skin. Monitoring the presence o f skin punctures 
also provides a preliminary indication o f skin healing 
following microneedle insult. The application sites of the 
two different microneedle array designs and the hypoder­
mic needle used in pain and sensory measurements were 
subsequently stained using an external application of 
methylene blue dye. The stain was applied to the skin 
surface at 1 hr, 4 hrs, 8 hrs or 24 hrs after initial ‘needle’ 
application. Methylene blue staining clearly showed that 
microchannels are formed in the skin following application 
o f the microneedles (Fig. 8). A larger puncture mark is 
observed when a 25-G hypodermic needle is applied and in 
this case, unlike microneedle treated skin, bleeding and 
erythema is also apparent. Whereas methylene blue staining 
plainly shows that the hypodermic injury is still amenable 
to staining at 24 h, evidence of microchannel repair and 
resealing following microneedle application is apparent at 
8-24 h post-application. Generally the 280 pm length 
microneedle array was more effective at skin penetration 
than the 180 pm length microneedle array with a mean of
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Fig. 8 Skin puncture marks for each needle device as observed with (180) 180 p.m microneedle array, (280) 280 pm microneedle array,
time following methylene blue staining. The blue dye was externally (Hypodermic) 25-G hypodermic needle
applied to the sites of puncture at I, 4, 8 and 24 h after needle use.
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96% o f the individual pyramidal needles puncturing the 
skin in participants (shown at 1 h staining) compared to a 
mean o f 50% for the 180 p.m length microneedle array.
Water loss from the skin is restricted by the SC layer. 
Transepidermal water loss (TEWL) measurement is a 
standardised method o f determining changes in skin barrier 
properties, being frequently used in the cosmetics and 
dermatology industry (Treffel et al. 1994; Rosado et al. 
2005; Aramaki et al. 2002; Schwindt et al. 1998). High 
TEWL values correspond to damaged skin whilst low 
TEWL correlate to healthy undamaged skin. The measure­
ment o f TEW L in this study was used to provide 
information concerning the compromised integrity o f skin 
epidermis following application o f the microneedle and 
hypodermic needle treatments.
Following skin puncture for pain, sensory and staining 
analysis, each participant received a second application o f 
each o f the 180 and 280 pjn microneedle arrays and the 25- 
G hypodermic needle. TEWL was measured immediately 
after application and at three further intervals over a period 
o f 24 h. In accordance with the external staining data, 
TEWL measurements further demonstrated perbation o f the 
SC barrier following needle treatments with water loss 
increasing post application o f each device (Eig. 9). Mean 
TEWL increased significantly (F><0.05) immediately post­
application for all applications: from 5.1 (SD=3.8) to 8.8 
(SD=5.4) g H20  m 2 h~‘ for the hypodermic needle; from 
5.9 (SD=4.0) to 7.9 (SD=2.8) for 180 pm microneedles; 
and from 5.7 (SD=3.4) to 10.3 (SD=13.0) for the 280 pm 
microneedle array. In each case skin water loss recovered to 
baseline within 24 h with their being no significance (P >  
0.05) for any device when compared to control.
Figure 10 allows comparison o f the percentage o f 
puncture marks observed via methylene blue staining in 
microneedle treated skin with the TEWL readings at 
various timepoints. It is evident that as the number o f 
distinct puncture marks reduces over the 24 h period the 
TEWL values normalise accordingly.
5 Discussion
In total seven designs o f applicators were pre-tested, 
without any microneedles mounted, to ensure that the 
applicator itself would not bias the pain response data in the 
subsequent clinical study. Further, laboratory tests were 
performed to ensure that selected designs, once mounted
I, 8 and 24 h post-application of (a) 25-G hypodermic needle 
(triangle), (b) 180 pm microneedle array (cross) and (c) 280 pm 
microneedle array (circle), each compared to control (square)
with microneedle arrays, were able to puncture excised 
human skin. Our results showed that the simplest applicator 
design, i.e. the reverse end o f a 2 ml plastic syringe, was the 
most appropriate for use in the clinical study from pain, 
accessibility, ease o f use and skin penetration perspectives. 
Ex vivo testing also showed that the pyramidal micro-
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needles penetrated skin more effectively and reproducibly if 
applied in a single rolling motion rather than by downward 
vertical pressure. This indicates that these arrays pierce skin 
more efficiently when the force is distributed over one row 
at a time, rather than over the whole array. This is not 
surprising given the likely ‘bed-of-nails’ effect resulting 
from vertical application and the fact that similarly 
dimensioned microneedles mounted onto a cylindrical drum 
have been shown to effectively penetrate outer skin layers 
for cosmetic and medical applications (Dermaroller SARL, 
France).
A 12 subject human clinical study was used to explore 
whether clinically untested wet-etch silicon microneedles 
elicit pain when used in such a way as to reliably penetrate 
the stratum comeum, and compare microneedle pain 
response with that following insertion of a 25-G small 
hypodermic needle. VAS scores showed the hypodermic 
needle to be significantly more painful on insertion than 
either 180 or 280 pm microneedle arrays. This was further 
substantiated by descriptive comments and a sensation 
assessment from each participant. The fact that the 
participants scored and described the 180 pm microneedles 
to be more painful than the 280 pm microneedles may 
initially appear to be contradictory. This result is however 
perfectly understandable when you consider how the 
microneedles were used in this study. Uniquely, this study 
focuses on the experienced pain response to microneedle 
use when they are applied in such a way as to ensure 
sufficient penetration of the skin outer layer to facilitate 
drug delivery. The amount of application force required to 
provide reliable skin penetration is analogous with the force 
used to massage an aching muscle. Prior to applying the 
microneedle designs to human volunteers we have per­
formed a large number of ex vivo studies using human skin, 
obtained from surgical procedures under ethical approval
and informed patient consent. These studies have clearly 
shown that smaller microneedles (i.e. 180 pm in height) 
need to be more firmly applied to skin than larger 
microneedles (280 pm in height) to ensure comparable 
skin penetration. The clinician in our clinical study was 
therefore trained to apply the microneedle arrays to human 
skin, using more force with the 180 pm microneedle array. 
The oral commentaries from participants support the VAS 
data by highlighting key words and analogies given by the 
participants relating to pain response.
The sensory questionnaire further probed the perception 
of the participants to microneedle and hypodermic needle 
treatment. The microneedle applications were commonly 
perceived as being ‘pressing’ and ‘heavy’ with the 
hypodermic needle application perceived as more ‘sharp’ 
and ‘pricking’. These data relate to surface area and ease of 
needle puncture. Microneedles spread over a larger surface 
area may require more force of penetration than an 
individual sharp hypodermic needle. Sensory responses 
suggest that further developments in microneedle array 
design, microneedle applicator morphology and clinical 
application technique that reduce the force required to 
ensure penetration of the SC would be beneficial. Impor­
tantly however, this study confirms that the pain and 
sensation felt from application of the wet-etch pyramidal 
microneedle devices were relatively similar, and in each 
case significantly lower than for the hypodermic needle. 
The verbal comments from the participants correlate with 
the pain questionnaire results with participants stating that 
application of the hypodermic was sharper and more 
pricking than either of the microneedle designs.
As previously mentioned, we thought it important to 
demonstrate that the pain and sensory response data would 
be relevant to clinical application of the microneedles. 
Therefore, the functionality of the microneedles, at least
Fig. 10 TEWL measurements 
for 180 pm (cross) and 280 pm 
(circle) microneedle arrays 
compared against the percentage 
of puncture marks observed by 
external staining (out of 36) 
following application of the 
180 pm (while bars) and 
280 pm (black bars) micronee­
dle arrays
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from a skin penetration perspective if not a drug delivery 
viewpoint, was monitored. Following application of the 
microneedle arrays, skin puncture marks could be identified 
by staining with a topically applied solution of methylene 
blue dye. The intensity of puncture staining reduced with 
time after microneedle application indicating temporal 
sealing of the transient skin microchannels over the 24 h 
study period.
Trans-epidermal water loss (TEWL) measurements were 
used as an additional indicator of skin barrier disruption. It 
is acknowledged that TEWL is an extremely sensitive 
measurement of skin permeability and as the microneedle 
punctures are less than 100 pm at their widest and 280 pm 
at their theoretical deepest, it is likely that TEWL is 
affected by the participant's movements, diet and atmo­
sphere over the 24 h study period, despite taking rigorous 
precautions at the time of measurement. Nevertheless, 
TEWL data correlated with the skin staining experiments 
in that an increase in TEWL is observed immediately after 
microneedle puncture and this increase diminishes to 
baseline over the 24 h study period. The TEWL values 
also reflect the relative efficiency of skin puncture with 
larger differences in TEWL observed when using 280 pm 
microneedles compared with 180 pm microneedles.
6 Conclusions
We have shown that pyramidal microneedles fabricated 
using low-cost wet-etching processes can penetrate human 
skin, providing transient microconduits for transcutaneous 
drug delivery, with minimal pain and discomfort. Our data 
suggest that the size of the microneedle must be optimised 
to ensure consistent skin penetration without excessive 
application force. The transient nature of skin disruption 
following application of microneedles was demonstrated 
with preliminary indications of microchannel healing and 
repair within the 24 h study period. More extensive studies 
investigating these skin repair responses at a cellular level 
are underway.
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